US20050023155A1 - Protein and peptide sensors using electrical detection methods - Google Patents
Protein and peptide sensors using electrical detection methods Download PDFInfo
- Publication number
- US20050023155A1 US20050023155A1 US10/203,874 US20387403A US2005023155A1 US 20050023155 A1 US20050023155 A1 US 20050023155A1 US 20387403 A US20387403 A US 20387403A US 2005023155 A1 US2005023155 A1 US 2005023155A1
- Authority
- US
- United States
- Prior art keywords
- molecules
- microelectrodes
- electrical signal
- protein
- immobilized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 79
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 79
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 54
- 238000001514 detection method Methods 0.000 title claims abstract description 43
- 239000000523 sample Substances 0.000 claims abstract description 155
- 238000000034 method Methods 0.000 claims abstract description 102
- 230000004001 molecular interaction Effects 0.000 claims abstract description 32
- 125000005647 linker group Chemical group 0.000 claims description 59
- 239000000758 substrate Substances 0.000 claims description 57
- 238000009739 binding Methods 0.000 claims description 53
- 230000027455 binding Effects 0.000 claims description 51
- -1 polythiphene Polymers 0.000 claims description 39
- 239000000499 gel Substances 0.000 claims description 29
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 25
- 229920002401 polyacrylamide Polymers 0.000 claims description 23
- 150000007523 nucleic acids Chemical class 0.000 claims description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 22
- 229910052751 metal Inorganic materials 0.000 claims description 21
- 239000002184 metal Substances 0.000 claims description 21
- 108020004707 nucleic acids Proteins 0.000 claims description 20
- 102000039446 nucleic acids Human genes 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 18
- 239000011521 glass Substances 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 16
- 239000004020 conductor Substances 0.000 claims description 15
- 108091034117 Oligonucleotide Proteins 0.000 claims description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 13
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 13
- 239000000919 ceramic Substances 0.000 claims description 13
- 239000010949 copper Substances 0.000 claims description 13
- 229910052709 silver Inorganic materials 0.000 claims description 13
- 239000004332 silver Substances 0.000 claims description 13
- 229910052723 transition metal Inorganic materials 0.000 claims description 13
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 12
- 229910052802 copper Inorganic materials 0.000 claims description 12
- 229910052697 platinum Inorganic materials 0.000 claims description 12
- 150000003624 transition metals Chemical class 0.000 claims description 12
- 238000004832 voltammetry Methods 0.000 claims description 12
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 239000010703 silicon Substances 0.000 claims description 9
- 229910052710 silicon Inorganic materials 0.000 claims description 9
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 8
- 229920001577 copolymer Polymers 0.000 claims description 8
- 239000008151 electrolyte solution Substances 0.000 claims description 8
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 8
- 229910052737 gold Inorganic materials 0.000 claims description 8
- 239000010931 gold Substances 0.000 claims description 8
- 229920003023 plastic Polymers 0.000 claims description 8
- 239000004033 plastic Substances 0.000 claims description 8
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 7
- 108010090804 Streptavidin Proteins 0.000 claims description 7
- 239000011159 matrix material Substances 0.000 claims description 7
- 238000005259 measurement Methods 0.000 claims description 7
- 239000010936 titanium Substances 0.000 claims description 7
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 6
- 229910044991 metal oxide Inorganic materials 0.000 claims description 6
- 150000004706 metal oxides Chemical class 0.000 claims description 6
- 229910052719 titanium Inorganic materials 0.000 claims description 6
- 108091023037 Aptamer Proteins 0.000 claims description 5
- 229910052581 Si3N4 Inorganic materials 0.000 claims description 5
- 229910002804 graphite Inorganic materials 0.000 claims description 5
- 239000010439 graphite Substances 0.000 claims description 5
- 150000004767 nitrides Chemical class 0.000 claims description 5
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 claims description 5
- 230000001052 transient effect Effects 0.000 claims description 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical group O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical group O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 239000011651 chromium Substances 0.000 claims description 4
- 229920000547 conjugated polymer Polymers 0.000 claims description 4
- BVQAWSJMUYMNQN-UHFFFAOYSA-N dipyridophenazine Chemical compound C1=CC=C2C3=NC4=CC=CC=C4N=C3C3=CC=CN=C3C2=N1 BVQAWSJMUYMNQN-UHFFFAOYSA-N 0.000 claims description 4
- 229920001971 elastomer Polymers 0.000 claims description 4
- 239000004744 fabric Substances 0.000 claims description 4
- 229930014626 natural product Natural products 0.000 claims description 4
- 229910052762 osmium Inorganic materials 0.000 claims description 4
- 238000002823 phage display Methods 0.000 claims description 4
- 125000006853 reporter group Chemical group 0.000 claims description 4
- 239000005060 rubber Substances 0.000 claims description 4
- 229910052707 ruthenium Inorganic materials 0.000 claims description 4
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 3
- 108010067902 Peptide Library Proteins 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 3
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical group C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 claims description 3
- 239000011543 agarose gel Substances 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 3
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Chemical group C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims description 3
- 229910052804 chromium Inorganic materials 0.000 claims description 3
- 229910017052 cobalt Inorganic materials 0.000 claims description 3
- 239000010941 cobalt Substances 0.000 claims description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 3
- 238000002484 cyclic voltammetry Methods 0.000 claims description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical group [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 claims description 3
- 229960005542 ethidium bromide Drugs 0.000 claims description 3
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical group [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 claims description 3
- 238000001566 impedance spectroscopy Methods 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 238000000691 measurement method Methods 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 229910052759 nickel Inorganic materials 0.000 claims description 3
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920000128 polypyrrole Polymers 0.000 claims description 3
- 238000000083 pulse voltammetry Methods 0.000 claims description 3
- 238000004365 square wave voltammetry Methods 0.000 claims description 3
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims description 2
- 229940005561 1,4-benzoquinone Drugs 0.000 claims description 2
- CJAOGUFAAWZWNI-UHFFFAOYSA-N 1-n,1-n,4-n,4-n-tetramethylbenzene-1,4-diamine Chemical compound CN(C)C1=CC=C(N(C)C)C=C1 CJAOGUFAAWZWNI-UHFFFAOYSA-N 0.000 claims description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 claims description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Chemical group C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 claims description 2
- 108700012813 7-aminoactinomycin D Proteins 0.000 claims description 2
- XJGFWWJLMVZSIG-UHFFFAOYSA-N 9-aminoacridine Chemical group C1=CC=C2C(N)=C(C=CC=C3)C3=NC2=C1 XJGFWWJLMVZSIG-UHFFFAOYSA-N 0.000 claims description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N Azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Natural products C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004099 Chlortetracycline Substances 0.000 claims description 2
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Chemical group CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims description 2
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical group C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 claims description 2
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical group O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 claims description 2
- 229920000265 Polyparaphenylene Polymers 0.000 claims description 2
- 229910021607 Silver chloride Inorganic materials 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical group O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 claims description 2
- 229960004176 aclarubicin Drugs 0.000 claims description 2
- 229960001441 aminoacridine Drugs 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 claims description 2
- 229960004475 chlortetracycline Drugs 0.000 claims description 2
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 claims description 2
- 235000019365 chlortetracycline Nutrition 0.000 claims description 2
- ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical group O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229960004023 minocycline Drugs 0.000 claims description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 2
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001221 pirarubicin Drugs 0.000 claims description 2
- 229960003171 plicamycin Drugs 0.000 claims description 2
- 229920000767 polyaniline Polymers 0.000 claims description 2
- 229920001088 polycarbazole Polymers 0.000 claims description 2
- 229920002098 polyfluorene Polymers 0.000 claims description 2
- 229920000414 polyfuran Polymers 0.000 claims description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 2
- 229960001225 rifampicin Drugs 0.000 claims description 2
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- FHCPAXDKURNIOZ-UHFFFAOYSA-N tetrathiafulvalene Chemical compound S1C=CSC1=C1SC=CS1 FHCPAXDKURNIOZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 239000011810 insulating material Substances 0.000 claims 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910001428 transition metal ion Inorganic materials 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 53
- 239000003446 ligand Substances 0.000 description 50
- 239000000463 material Substances 0.000 description 39
- 239000000017 hydrogel Substances 0.000 description 26
- 239000000853 adhesive Substances 0.000 description 19
- 230000001070 adhesive effect Effects 0.000 description 19
- 239000000427 antigen Substances 0.000 description 19
- 102000036639 antigens Human genes 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 239000012491 analyte Substances 0.000 description 16
- 238000005245 sintering Methods 0.000 description 16
- 230000003993 interaction Effects 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 239000012530 fluid Substances 0.000 description 13
- 238000010304 firing Methods 0.000 description 12
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 230000006037 cell lysis Effects 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000003491 array Methods 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 230000009870 specific binding Effects 0.000 description 10
- 230000037361 pathway Effects 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 125000002524 organometallic group Chemical group 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 230000027756 respiratory electron transport chain Effects 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000000835 electrochemical detection Methods 0.000 description 7
- 229940021013 electrolyte solution Drugs 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000006116 polymerization reaction Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 102100031156 Prohibitin-2 Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000003475 lamination Methods 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 238000000018 DNA microarray Methods 0.000 description 5
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 5
- 108010009583 Transforming Growth Factors Proteins 0.000 description 5
- 102000009618 Transforming Growth Factors Human genes 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 102000011923 Thyrotropin Human genes 0.000 description 4
- 108010061174 Thyrotropin Proteins 0.000 description 4
- 239000000370 acceptor Substances 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005530 etching Methods 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 239000010954 inorganic particle Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 229910052721 tungsten Inorganic materials 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000289669 Erinaceus europaeus Species 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 3
- 239000002241 glass-ceramic Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 239000000976 ink Substances 0.000 description 3
- 239000012212 insulator Substances 0.000 description 3
- 150000001247 metal acetylides Chemical class 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 239000013110 organic ligand Substances 0.000 description 3
- 239000011368 organic material Substances 0.000 description 3
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 150000004032 porphyrins Chemical class 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 229910052702 rhenium Inorganic materials 0.000 description 3
- 239000010948 rhodium Substances 0.000 description 3
- 238000007650 screen-printing Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000004528 spin coating Methods 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 3
- 239000010937 tungsten Substances 0.000 description 3
- MDAXKAUIABOHTD-UHFFFAOYSA-N 1,4,8,11-tetraazacyclotetradecane Chemical compound C1CNCCNCCCNCCNC1 MDAXKAUIABOHTD-UHFFFAOYSA-N 0.000 description 2
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 102100036154 Platelet basic protein Human genes 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 102000004879 Racemases and epimerases Human genes 0.000 description 2
- 108090001066 Racemases and epimerases Proteins 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- HXGDTGSAIMULJN-UHFFFAOYSA-N acenaphthylene Chemical compound C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 2
- 229920006397 acrylic thermoplastic Polymers 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229910010293 ceramic material Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 108010035886 connective tissue-activating peptide Proteins 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- VPUGDVKSAQVFFS-UHFFFAOYSA-N coronene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3)C4=C4C3=CC=C(C=C3)C4=C2C3=C1 VPUGDVKSAQVFFS-UHFFFAOYSA-N 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000032798 delamination Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 2
- 238000009713 electroplating Methods 0.000 description 2
- 238000004049 embossing Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000011152 fibreglass Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000002847 impedance measurement Methods 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229910052741 iridium Inorganic materials 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 150000002736 metal compounds Chemical class 0.000 description 2
- 239000002923 metal particle Substances 0.000 description 2
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 2
- 229960000907 methylthioninium chloride Drugs 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 150000002902 organometallic compounds Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 150000005041 phenanthrolines Chemical class 0.000 description 2
- 150000003003 phosphines Chemical class 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 2
- 229910052703 rhodium Inorganic materials 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229910052713 technetium Inorganic materials 0.000 description 2
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- 229910018861 (C5H5)2Fe Inorganic materials 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- JFJNVIPVOCESGZ-UHFFFAOYSA-N 2,3-dipyridin-2-ylpyridine Chemical class N1=CC=CC=C1C1=CC=CN=C1C1=CC=CC=N1 JFJNVIPVOCESGZ-UHFFFAOYSA-N 0.000 description 1
- CCBICDLNWJRFPO-UHFFFAOYSA-N 2,6-dichloroindophenol Chemical compound C1=CC(O)=CC=C1N=C1C=C(Cl)C(=O)C(Cl)=C1 CCBICDLNWJRFPO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- JIVLDFFWTQYGSR-UHFFFAOYSA-N 4,7-dimethyl-[1,10]phenanthroline Chemical compound C1=CC2=C(C)C=CN=C2C2=C1C(C)=CC=N2 JIVLDFFWTQYGSR-UHFFFAOYSA-N 0.000 description 1
- NMTUJCMONVTLHN-UHFFFAOYSA-N 7-ethyl-10-methylbenzo[a]phenazin-7-ium-5-amine;chloride Chemical compound [Cl-].C1=C(N)C2=CC=CC=C2C2=C1[N+](CC)=C(C=CC(C)=C1)C1=N2 NMTUJCMONVTLHN-UHFFFAOYSA-N 0.000 description 1
- LUBXLGUQZVKOFP-UHFFFAOYSA-N 9-phenylanthracene Chemical compound C1=CC=CC=C1C1=C(C=CC=C2)C2=CC2=CC=CC=C12 LUBXLGUQZVKOFP-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 241001120493 Arene Species 0.000 description 1
- JBRZTFJDHDCESZ-UHFFFAOYSA-N AsGa Chemical compound [As]#[Ga] JBRZTFJDHDCESZ-UHFFFAOYSA-N 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 1
- 102100036509 Erythropoietin receptor Human genes 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 108010054265 Factor VIIa Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 1
- 101710114816 Gene 41 protein Proteins 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 1
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010010369 HIV Protease Proteins 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000777471 Homo sapiens C-C motif chemokine 4 Proteins 0.000 description 1
- 101000896959 Homo sapiens C-C motif chemokine 4-like Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 1
- 101000950847 Homo sapiens Macrophage migration inhibitory factor Proteins 0.000 description 1
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- GPXJNWSHGFTCBW-UHFFFAOYSA-N Indium phosphide Chemical compound [In]#P GPXJNWSHGFTCBW-UHFFFAOYSA-N 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102100039064 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- 102100039897 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000005385 Intramolecular Transferases Human genes 0.000 description 1
- 108010031311 Intramolecular Transferases Proteins 0.000 description 1
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- JSAWYMYUJKVZGE-UHFFFAOYSA-N Oc1c([nH]c2c(cc(cc12)S(O)(=O)=O)S(O)(=O)=O)C1=Nc2c(cc(cc2S(O)(=O)=O)S(O)(=O)=O)C1=O Chemical compound Oc1c([nH]c2c(cc(cc12)S(O)(=O)=O)S(O)(=O)=O)C1=Nc2c(cc(cc2S(O)(=O)=O)S(O)(=O)=O)C1=O JSAWYMYUJKVZGE-UHFFFAOYSA-N 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910002656 O–Si–O Inorganic materials 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 102000000395 SH3 domains Human genes 0.000 description 1
- 108050008861 SH3 domains Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 241000718007 Taenionema palladium Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 229910001093 Zr alloy Inorganic materials 0.000 description 1
- IVNALXNJOCZGMK-UHFFFAOYSA-M [4-[4-(dimethylamino)phenyl]iminocyclohexa-2,5-dien-1-ylidene]-dimethylazanium;chloride Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1N=C1C=CC(=[N+](C)C)C=C1 IVNALXNJOCZGMK-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- CWRYPZZKDGJXCA-UHFFFAOYSA-N acenaphthalene Natural products C1=CC(CC2)=C3C2=CC=CC3=C1 CWRYPZZKDGJXCA-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- QZPSXPBJTPJTSZ-UHFFFAOYSA-N aqua regia Chemical compound Cl.O[N+]([O-])=O QZPSXPBJTPJTSZ-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- IWCQVOVBDXJJDF-UHFFFAOYSA-N benzene;chromium;cyclohexane Chemical compound [Cr].[CH-]1[CH-][CH-][CH-][CH-][CH-]1.C1=CC=CC=C1 IWCQVOVBDXJJDF-UHFFFAOYSA-N 0.000 description 1
- ZDZHCHYQNPQSGG-UHFFFAOYSA-N binaphthyl group Chemical group C1(=CC=CC2=CC=CC=C12)C1=CC=CC2=CC=CC=C12 ZDZHCHYQNPQSGG-UHFFFAOYSA-N 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 108010089934 carbohydrase Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000005229 chemical vapour deposition Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010344 co-firing Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006854 communication Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 239000011889 copper foil Substances 0.000 description 1
- PMHQVHHXPFUNSP-UHFFFAOYSA-M copper(1+);methylsulfanylmethane;bromide Chemical compound Br[Cu].CSC PMHQVHHXPFUNSP-UHFFFAOYSA-M 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 108010005905 delta-hGHR Proteins 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000005137 deposition process Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- QPJFIVIVOOQUKD-UHFFFAOYSA-N dipyrazino[2,3-f:2,3-h]quinoxaline Chemical group C1=CN=C2C3=NC=CN=C3C3=NC=CN=C3C2=N1 QPJFIVIVOOQUKD-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 229960001066 disopyramide Drugs 0.000 description 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 229940012414 factor viia Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 102000057308 human HGF Human genes 0.000 description 1
- 102000046645 human LIF Human genes 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 108010042209 insulin receptor tyrosine kinase Proteins 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 description 1
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 238000005459 micromachining Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- SHXOKQKTZJXHHR-UHFFFAOYSA-N n,n-diethyl-5-iminobenzo[a]phenoxazin-9-amine;hydrochloride Chemical compound [Cl-].C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=[NH2+])C2=C1 SHXOKQKTZJXHHR-UHFFFAOYSA-N 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000044158 nucleic acid binding protein Human genes 0.000 description 1
- 108700020942 nucleic acid binding protein Proteins 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 1
- CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920005596 polymer binder Polymers 0.000 description 1
- 239000002491 polymer binding agent Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
- 229960002393 primidone Drugs 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- CVSGFMWKZVZOJD-UHFFFAOYSA-N pyrazino[2,3-f]quinoxaline Chemical compound C1=CN=C2C3=NC=CN=C3C=CC2=N1 CVSGFMWKZVZOJD-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- YYMBJDOZVAITBP-UHFFFAOYSA-N rubrene Chemical compound C1=CC=CC=C1C(C1=C(C=2C=CC=CC=2)C2=CC=CC=C2C(C=2C=CC=CC=2)=C11)=C(C=CC=C2)C2=C1C1=CC=CC=C1 YYMBJDOZVAITBP-UHFFFAOYSA-N 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- SOUHUMACVWVDME-UHFFFAOYSA-N safranin O Chemical compound [Cl-].C12=CC(N)=CC=C2N=C2C=CC(N)=CC2=[N+]1C1=CC=CC=C1 SOUHUMACVWVDME-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 229910052706 scandium Inorganic materials 0.000 description 1
- SIXSYDAISGFNSX-UHFFFAOYSA-N scandium atom Chemical compound [Sc] SIXSYDAISGFNSX-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000005389 semiconductor device fabrication Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 229910010271 silicon carbide Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229910000601 superalloy Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 238000010345 tape casting Methods 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- PCCVSPMFGIFTHU-UHFFFAOYSA-N tetracyanoquinodimethane Chemical compound N#CC(C#N)=C1C=CC(=C(C#N)C#N)C=C1 PCCVSPMFGIFTHU-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003568 thioethers Chemical group 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000005829 trimerization reaction Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000007704 wet chemistry method Methods 0.000 description 1
- 239000001018 xanthene dye Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
- G01N33/5438—Electrodes
Definitions
- This invention relates to the electrical detection of molecular interaction between biological molecules. Specifically, the invention relates to electrical detection of interactions between a probe molecule and a target molecule, wherein the target molecule is a protein or peptide.
- Electrical or electrochemical detection techniques are based on the detection of alterations in the electrical properties of an electrode arising from interactions between one group of molecules attached to the surface of an electrode (often referred to as “probe” molecules) and another set of molecules present in a reaction mixture (often referred to as “target” molecules). Electrical or electrochemical detection eliminates many of the disadvantages inherent in use of radioactive or fluorescent labels to detect interactions between the probe and target molecules. This process offers, for example, a detection technique that is safe, inexpensive, and sensitive, and is not burdened with complex and onerous regulatory requirements.
- Hollis et al. in U.S. Pat. Nos. 5,653,939 and 5,846,708, provide a method and apparatus for identifying molecular structures within a sample substance using a monolithic array of test sites formed on a substrate upon which the sample substance is applied.
- changes in the electromagnetic or acoustic properties—for example, the change in resonant frequency—of the test sites following the addition of the sample substance are detected in order to determine which probes have interacted with target molecules in the sample substance.
- Eggers et al. in U.S. Pat. Nos. 5,532,128, 5,670,322, and 5,891,630, provide a method and apparatus for identifying molecular structures within a sample substance.
- a plurality of test sites to which probes have been bound is exposed to a sample substance and then an electrical signal is applied to the test sites. Changes in the dielectrical properties of the test sites are subsequently detected to determine which probes have interacted with target molecules in the sample substance.
- Another obstacle in the development of a simple and cost-effective electrical and electrochemical detection apparatus for detecting molecular interactions involves limitations in how probe molecules have been attached to electrodes. This is particularly important in fabricating arrays of probes, such as microarrays known in the art.
- the prior art provides microarrays using polyacrylamide pads for attachment of oligonucleotide probes to a solid support.
- the art has not provided such pads in conjunction with electrodes in an electrical or electrochemical detection apparatus.
- the present invention provides an apparatus and methods for the electrical detection of molecular interactions between a probe molecule and a protein or peptide target molecule, but without requiring the use of electrochemical or other reporters to obtain measurable signals.
- the methods can be used for electrical detection of molecular interactions between probe molecules bound to defined regions of an array and protein or peptide target molecules that interact with the probe molecules.
- the apparatus of the present invention comprises a supporting substrate, one or a plurality of microelectrodes in contact with the supporting substrate, one or a plurality of linking moieties in contact with the microelectrodes and to which probe molecules are immobilized, at least one counter-electrode in electrochemical contact with the microelectrodes, a means for producing an electrical signal at each microelectrode, a means for detecting changes in the electrical signal at each microelectrode and an electrolyte solution in contact with the one or a plurality of microelectrodes, linking moieties, and counter-electrodes.
- the apparatus of the present invention may advantageously further comprise at least one reference electrode.
- the apparatus may also further comprise a plurality of wells, each of which encompasses at least one microelectrode in contact with a linker moiety and at least one counter-electrode that is sufficient to interrogate the microelectrodes in contact with linker moieties.
- the apparatus and methods of the present invention are useful for the electrical detection of molecular interactions between probe molecules immobilized on linker moieties in contact with microelectrodes and protein or peptide target molecules in a sample solution.
- a first electrical signal is detected in a plurality of microelectrodes in contact with linker moieties to which probe molecules have been immobilized, the plurality of microelectrodes in contact with linker moieties is exposed to a sample mixture containing protein or peptide target molecules, and a second electrical signal is detected at the plurality of microelectrodes in contact with linker moieties.
- the first and second electrical signals are then compared, and molecular interactions between immobilized probe molecules and protein or peptide target molecules in the sample mixture are detected by determining that and by how much the first electrical signal is different from the second electrical signal.
- the present invention provides an apparatus and methods for the electrical detection of molecular interactions between probe molecules and protein or peptide target molecules, but without the requirement that electrochemical reporters or labeled target molecules be used.
- the apparatus and methods of the present invention are capable of detecting molecular interactions between probe molecules and protein or peptide target molecules that are safer, less expensive, simpler, and that have an increased reproducibility and sensitivity compared to prior art methods.
- FIGS. 1A and 1B illustrate a schematic representation of the structure of a microelectrode in contact with a polyacrylamide gel linker moiety (i.e., a porous hydrogel microelectrode) ( FIG. 1A ) and a schematic representation of the structure of the tip of the porous hydrogel microelectrode ( FIG. 1B );
- a polyacrylamide gel linker moiety i.e., a porous hydrogel microelectrode
- FIG. 1B illustrate a schematic representation of the structure of the tip of the porous hydrogel microelectrode
- FIG. 2 illustrates a porous hydrogel microelectrode
- FIGS. 3A and 3B illustrate plots of capacitance versus frequency ( FIG. 3A ) and resistance versus frequency ( FIG. 3B ) for a streptavidin-modified porous hydrogel microelectrode before (curve 1 ) and after immobilization of rabbit anti-BAP antibody (curve 2 ), and following incubation with BAP antigen (curve 3 ); and
- FIGS. 4A and 4B illustrate plots of capacitance versus frequency ( FIG. 4A ) and resistance versus frequency ( FIG. 4B ) for a streptavidin-modified porous hydrogel microelectrode with immobilized rabbit anti-BAP antibody before (curve 1 ) and after incubation with BAP antigen (curve 2 ), and following incubation with an anti-rabbit IgG secondary antibody (curve 3 ).
- the apparatus and methods of the present invention are useful for the electrical detection of molecular interactions between probe molecules immobilized by linker moieties in contact with microelectrodes and protein or peptide target molecules in a sample mixture.
- array refers to an ordered spatial arrangement, particularly an arrangement of immobilized biomolecules, such as specific binding molecules or probes as further described below.
- the present system finds particular utility in array formats, i.e. wherein there is a matrix of addressable locations (herein generally referred to as “pads”, “addresses” or “micro-locations”).
- “Array” or grammatical equivalents thereof as used herein mean a plurality of probes in an array format; the size of the array will depend on the composition and end use of the array. Arrays containing from about 2 different probes to many thousands can be made.
- the array will comprise from two to as many as 100,000 or more per cm 2 , depending on the size of the pads, as well as the end use of the array. Preferred ranges are from about 2 to about 10,000, with from about 5 to about 1000 being preferred, and from about 10 to about 100 being particularly preferred.
- the compositions of the invention may not be in array format; that is, for some embodiments, compositions comprising a single probe may be made as well.
- multiple substrates may be used, either of different or identical compositions. Thus for example, large arrays may comprise a plurality of smaller substrates.
- bioarray As used herein, the terms “bioarray,” “biochip” and “biochip array” refer to an ordered spatial arrangement of immobilized biomolecules on a microelectrode arrayed on a solid supporting substrate.
- Preferred probe molecules include nucleic acids, oligonucleotides, peptides, ligands, antibodies and antigens; peptides and proteins are the most preferred probe species.
- Biochips as used in the art, encompass substrates containing arrays or microarrays, preferably ordered arrays and most preferably ordered, addressable arrays, of biological molecules that comprise one member of a biological binding pair.
- such arrays are oligonucleotide arrays comprising a nucleotide sequence that is complementary to at least one sequence that may be or is expected to be present in a biological sample.
- proteins, peptides or other small molecules can be arrayed on such biochips for performing, inter alia, immunological analyses (wherein the arrayed molecules are antigens), assaying biological receptors (wherein the arrayed molecules are ligands, agonists or antagonists of said receptors).
- the probes of the invention are specific for a particular species, subspecies or strain of bacteria, and most preferably are specific for viable bacteria of said species, subspecies or strain.
- addressable array refers to an array wherein the individual elements have precisely defined x and y coordinates, so that a given element at a particular position in the array can be identified.
- probe refers to a molecule (preferably a biomolecule) used to detect another biomolecule.
- examples include antigens that detect antibodies, oligonucleotides that detect complimentary oligonucleotides, and ligands that detect receptors.
- probes are preferably immobilized on a microelectrode comprising a substrate.
- Binding ligand or grammatical equivalents thereof as used herein means a compound that is used to probe for the presence of the target analyte, and that will bind to the target analyte.
- the composition of the binding ligand will depend on the composition of the target analyte. Binding ligands for a wide variety of analytes are known or can be readily found using known techniques. For example, when the analyte is a protein, the binding ligands include proteins (particularly including antibodies or fragments thereof (FAbs, etc.)) or small molecules.
- the binding ligand generally comprises traditional metal ion ligands or chelators.
- Preferred binding ligand proteins include peptides.
- suitable binding ligands include substrates and inhibitors.
- Antigen-antibody pairs, receptor-ligands, and carbohydrates and their binding partners are also suitable analyte-binding ligand pairs.
- the binding ligand may be nucleic acid, when nucleic acid binding proteins are the targets; alternatively, as is generally described in U.S. Pat. Nos.
- nucleic acid “aptomers” can be developed for binding to virtually any target analyte.
- nucleic acid “aptomers” can be developed for binding to virtually any target analyte.
- binding ligand is a nucleic acid
- preferred compositions and techniques are outlined in PCT US97/20014, hereby incorporated by reference.
- nucleic acid As used herein “nucleic acid”, “oligonucleotide”or grammatical equivalents mean at least two nucleotides covalently linked together.
- a nucleic acid according to the present invention will generally contain phosphodiester bonds, although in some cases nucleic acid analogs are included that may have alternate backbones, comprising, for example, phosphoramide (Beaucage et al., Tetrahedron 49(10):1925 (1993); Letsinger, J. Org. Chem. 35:3800 (1970); Sblul et al., Eur. J. Biochem. 81:579 (1977); Letsinger et al., Nucl. Acids Res.
- the binding of the target analyte to the binding ligand is specific, and the binding ligand is part of a binding pair.
- “specifically bind” means that the ligand binds the analyte with specificity sufficient to differentiate between the analyte and other components or contaminants within the test sample.
- the systems may use different binding ligands, for example an array of different ligands, and detection of any particular analyte is via its “signature” of binding to a panel of binding ligands, similar to the manner in which “electronic noses” work.
- the binding should be sufficient to remain bound under the conditions of the assay, including wash steps to remove non-specific binding.
- the disassociation constants of the analyte to the binding ligand will be less than about 10 ⁇ 4 -10 ⁇ 6 M ⁇ 1 , with less than about 10 ⁇ 5 to 10 ⁇ 9 M ⁇ 1 being preferred and less than about 10 ⁇ 7 -10 ⁇ 9 M ⁇ 1 being particularly preferred.
- probes or targets may be proteins.
- peptides polypeptides
- proteins or grammatical equivalents thereof mean proteins, oligopeptides, peptides, derivatives and analogs thereof (including without limitation proteins containing non-naturally occurring amino acids and amino acid analogs), and peptidomimetic structures.
- the side chains may be in either the (R) or the (S) configuration.
- the amino acids are in the (S) or L-configuration.
- the probe molecules of the apparatus comprise proteins or peptides.
- the protein or peptide probe molecules of the present invention are preferably peptides comprising from about 5 to about 100 amino acids, more preferably antigen-recognizing peptieds or polypeptides belonging to the immunoglobulin superfamily.
- Said peptide or polypeptide probe molecules are immobilized to the microelectrodes of the invention through linker moieties, using techniques known to those with skill in the art wherein said linkage does not interfere with or inhibit the ability of the probe molecules to interact with protein or peptide target molecules in the sample mixture.
- immobilize or grammatical equivalents thereof means that the probe molecule is fixed relative to the microelectrode.
- a probe molecule may be attached to a linker moiety, the probe molecule may be embedded within a matrix of a linker moiety, or any combination thereof, and the linker moiety is attached to the microelectrode. It will be appreciated that direct attachment of the probe molecule to the electrode is possible; howerver, this is not preferred. Attachment of the probe to a linker moiety is well within the skill of the artisan, and may include without limitation covalent bonding, ionic bonding, van der Waals forces, hydro-phobic/philic interactions, biologic attachment (such as avidin-streptavidin interactions), the latter being preferred.
- antibodies are used as probes.
- a protein may be used to generate polyclonal and monoclonal antibodies to proteins, which are useful as described herein.
- the epitope of the probe is unique; that is, antibodies generated to a unique epitope show little or no cross-reactivity to other proteins.
- epitope “epitope”, “determinant”, or grammatical equivalents thereof means a portion of a protein which will generate and/or bind an antibody. Thus, in most instances, antibodies made to a smaller Apop3 protein will be able to bind to the full length protein.
- antibody includes antibody fragments, as are known in the art, including Fab, Fab 2 , single chain antibodies (F v for example), chimeric antibodies, etc., either produced by the modification of whole antibodies or those synthesized de novo using recombinant DNA technologies.
- antibody further comprises polyclonal antibodies and monoclonal antibodies, which can be agonist or antagonist antibodies.
- the proteins may be from any organism, including prokaryotes and eukaryotes, with enzymes from bacteria, fungi, extremeophiles such as the archebacteria, insects, fish, animals (particularly mammals and particularly human) and birds all possible.
- proteins include fragments and domains of known proteins, including functional domains such as enzymatic domains, binding domains, etc., and smaller fragments, such as turns, loops, etc. That is, portions of proteins may be used as well.
- protein as used herein includes proteins, oligopeptides and peptides.
- protein variants i.e. non-naturally occuring protein analog structures, may be used.
- Suitable proteins for probes or targets include, but are not limited to, industrial and pharmaceutical proteins, including ligands, cell surface receptors, antigens, antibodies, cytokines, hormones, transcription factors, signaling modules, cytoskeletal proteins and enzymes.
- Suitable classes of enzymes include, but are not limited to, hydrolases such as proteases, carbohydrases, lipases; isomerases such as racemases, epimerases, tautomerases, or mutases; transferases, kinases, oxidoreductases, and phophatases.
- Suitable enzymes are listed in the Swiss_Prot enzyme database.
- Suitable protein backbones include, but are not limited to, all of those found in the protein data base compiled and serviced by the Research Collaboratory for Structural Bioinformatics (RCSB, formerly the Brookhaven National Lab).
- preferred target proteins include, but are not limited to, those with known structures (including variants) including cytokines (IL-1ra (+receptor complex), IL-1 (receptor alone), IL-1a, IL-1b (including variants and or receptor complex), IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-10, IFN- ⁇ , INF- ⁇ , IFN- ⁇ -2a; IFN- ⁇ -2B, TNF- ⁇ ; CD40 ligand (chk), Human Obesity Protein Leptin, Granulocyte Colony-Stimulating Factor, Bone Morphogenetic Protein-7, Ciliary Neurotrophic Factor, Granulocyte-Macrophage Colony-Stimulating Factor, Monocyte Chemoattractant Protein 1, Macrophage Migration Inhibitory Factor, Human Glycosylation-Inhibiting Factor, Human Rantes, Human Macrophage Inflammatory Protein 1 Beta, human growth hormone, Leukemia Inhibitory Factor,
- Erythropoietin other extracellular signalling moeities, including, but not limited to, hedgehog Sonic, hedgehog Desert, hedgehog Indian, hCG; coaguation factors including, but not limited to, TPA and Factor VIIa; transcription factors, including but not limited to, p53, p53 tetramerization domain, Zn fingers (of which more than 12 have structures), homeodomains (of which 8 have structures), leucine zippers (of which 4 have structures); antibodies, including, but not limited to, cFv; viral proteins, including, but not limited to, hemagglutinin trimerization domain and hiv Gp41 ectodomain (fusion domain); intracellular signalling modules, including, but not limited to, SH2 domains (of which 8 structures are known), SH3 domains (of which 11 have structures), and Pleckstin Homology Domains; receptors, including, but not limited to, the extracellular Region Of Human Tissue Factor Cytokine-Binding Region Of G
- the target molecules are proteins as defined above.
- the target molecules are naturally occurring proteins or fragments of naturally occurring proteins.
- cellular extracts containing proteins, or random or directed digests of proteinaceous cellular extracts may be used.
- libraries of procaryotic and eukaryotic proteins may be made for screening in accordance with the present invention.
- Particularly preferred in this embodiment are bacterial, fungal, viral, and mammalian proteins (or libraries thereof), with the latter being preferred, and human proteins being especially preferred.
- the probe or target molecules may comprise a natural products library, a peptide library, a phage display library, or a combinatorial library.
- Suitable target protein molecules include, but are not limited to, (1) immunoglobulins, particularly IgEs, IgGs and IgMs, and particularly therapeutically or diagnostically relevant antibodies, including but not limited to, for example, antibodies to human albumin, apolipoproteins (including apolipoprotein E), human chorionic gonadotropin, cortisol, ⁇ -fetoprotein, thyroxin, thyroid stimulating hormone (TSH), antithrombin, antibodies to pharmaceuticals (including antieptileptic drugs (such as phenyloin, primidone, carbariezepin, ethosuximide, valproic acid, and phenobarbitol), cardioactive drugs (such as digoxin, lidocaine, procainamide, and disopyramide), bronchodilators (such as theophylline), antibiotics (such as chloramphenicol, sulfonamides), antidepressants, imniunosuppresants, abused drugs (such as amphet
- cholerae Escherichia , e.g., Enterotoxigenic E. coli, Shigella , e.g., S. dysenteriae; Salmonella , e.g., S. typhi; Mycobacterium e.g., M. tuberculosis, M. leprae; Clostridium , e.g., C. botulinum, C. tetani, C. difficile, C. perfringens; Comyebacterium , e.g., C. diphtheriae; Streptococcus, S. pyogenes, S. pneumoniae; Staphylococcus , e.g., S.
- aureus Haemophilus , e.g., H. influenzae; Neisseria , e.g., N. meningitidis, N. gonorrhoeae; Yersinia , e.g, G. lamblia Y. pestis, Pseudomonas , e.g., P. aeruginosa, P. pulida; Chlamydia , e.g., C. trachomatis; Bordetella , e.g., B. pertussis; Treponema , e.g., T.
- Haemophilus e.g., H. influenzae
- Neisseria e.g., N. meningitidis, N. gonorrhoeae
- Yersinia e.g, G. lamblia Y. pestis
- Pseudomonas e.g.
- any of the biomolecules for which antibodies are tested may be tested directly as well; that is, the virus or bacterial cells, therapeutic and abused drugs, etc., may be the test molecules.
- the apparatus of the present invention comprises a supporting substrate, one or a plurality of microelectrodes in contact with the supporting substrate, one or a plurality of linking moieties in contact with the microelectrodes and to which specific binding molecules are immobilized, at least one counter-electrode in electrochemical contact with the microelectrodes, a means for producing an electrical signal at each microelectrode, a means for detecting changes in the electrical signal at each microelectrode, and an electrolyte solution in contact with the microelectrodes, linking moieties, and counter-electrode.
- the specific binding molecules of the apparatus comprise proteins or peptides.
- the specific binding molecules are antibodies.
- the antibodies immobilized on the linker moieties of the apparatus of the invention may be polyclonal or monoclonal antibodies, F(ab) fragments, F(ab)′ fragments, F(ab) 2 fragments, or F v fragments of polyclonal or monoclonal antibodies, or F(ab) or single chain antibodies selected from in vitro libraries.
- the specific binding molecules are nucleic acids, oligonucleotides, or combinations thereof.
- the specific binding molecules are aptamers (i.e., oligonucleotides capable of interacting with target molecules such as peptides).
- aptamers i.e., oligonucleotides capable of interacting with target molecules such as peptides.
- Natural products libraries such as, inter alia, yeast extracts), phage display libraries, or combinatorial libraries may also be used as specific binding molecules.
- the specific binding molecules are polyclonal antibodies and the antibodies are immobilized on the linker moieties using any technique known in the art that does not interfere with or inhibit the ability of the antibodies to specifically bind to a target analyte, such as and without limitation the conjugate antigen or portion thereof.
- polyclonal antibodies, antiscra, monoclonal antibodies, fragments of said polyclonal or monoclonal antibodies, or other specific ligand binding molecules are immobilized onto and attached to the linker moieties of the apparatus of the invention using biotinylated species thereof that are conjugated with streptavidin added to the linker moiety material.
- the linker moiety material to which the streptavidin is added is polyacrylamide gel.
- the biotinylated specific binding molecule is a protein, peptide, nucleic acid, or oligonucleotide.
- the specific binding molecules are embedded within a matrix, e.g., polymer matrix, of the linker molecules.
- the linker moieties of the apparatus are composed of materials including, but not limited to, polyacrylamide gel, agarose gel, polyethylene glycol, cellulose gel, or sol gels.
- the linker moieties comprise polyacrylamide gel, which form a gel pad.
- the linker moieties, or gel pad comprise a conjugated polymer or copolymer film.
- Such conjugated polymer or copolymer film is composed of materials including, but not limited to, polypyrrole, polythiphene, polyaniline, polyfuran, polypyridine, polycarbazole, polyphenylene, poly(phenylenvinylene), polyfluorene, or polyindole, or their derivatives, their copolymers, and combinations thereof.
- the linker moieties comprise a neutral pyrrole matrix, and the probes are embedded therein.
- Polymeric hydrogels and gel pads are used as binding layers to adhere biological molecules to substrate surfaces, which biomolecules include, but are not limited to, proteins, peptides, oligonucleotides, polynucleotides, and larger nucleic acid fragments.
- the oligonucleotide probes may be bound to the surface of a continuous layer of the hydrogel, to an array of gel pads, or embedded therein.
- the gel pads comprising biochips for use with the apparatus of the present invention are conveniently produced as thin sheets or slabs, typically by depositing a solution of acrylamide monomer, a crosslinker such methylene bisacrylamide, and a catalyst such as N,N, N′,N′-tetramethylethylendiamine (TEMED) and an initiator such as ammonium persulfate for chemical polymerization, or 2,2-dimethoxy-2-phenyl-acetophone (DMPAP) for photopolymerization, in between two glass surfaces (e.g., glass plates or microscope slides) using a spacer to obtain the desired thickness of the polymeric gel.
- TEMED N,N, N′,N′-tetramethylethylendiamine
- DMPAP 2,2-dimethoxy-2-phenyl-acetophone
- the acrylamide monomer and crosslinker are prepared in one solution of about 4-5% acrylamide (having an acrylamide/bisacrylamide ratio of 19/1) in water/glycerol, with a nominal amount of initiator added.
- the solution is polymerized and crosslinked either by ultraviolet (UV) radiation (e.g., 254 m for at least about 15 minutes, or other appropriate UV conditions, collectively termed “photopolymerization”), or by thermal initiation at elevated temperature (e.g., typically at about 40° C.).
- UV radiation ultraviolet
- photopolymerization thermal initiation at elevated temperature
- the top glass slide is removed from the surface to uncover the gel.
- the pore size (and hence the “sieving properties”) of the gel is controlled by varying the amount of crosslinker and the percent solids in the monomer solution.
- the pore size also can be controlled by varying the polymerization temperature.
- the acrylamide solution typically is imaged through a mask during the UV polymerization/crosslinking step.
- the top glass slide is removed after polymerization, and the unpolymerized monomer is washed away (developed) with water, leaving a fine feature pattern of polyacrylamide hydrogel, which is used to produce the crosslinked polyacrylamide hydrogel pads.
- light can be applied to discrete locations on the surface of a polyacrylamide hydrogel to activate these specified regions for the attachment of an oligonucleotide, an antibody, an antigen, a hormone, hormone receptor, a ligand or a polysaccharide on the surface (e.g., a polyacrylamide hydrogel surface) of a solid substrate (see, e.g, WO 91/07087, incorporated herein by reference).
- biomolecules such as oligonucleotides, peptides, polypeptides, or proteins
- a derivatized polymer comprising the cognate chemical group.
- Covalent attachment of the biomolecule to the polymer is usually performed after polymerization and chemical cross-linking of the polymer is completed.
- oligonucleotides bearing 5′-terminal acrylamide modifications can be used that efficiently copolymerize with acrylamide monomers to form DNA-containing polyacrylamide copolymers (Rehman et al., 1999, Nucleic Acids Research 27: 649-655).
- stable probe-containing layers can be fabricated on substrates (e.g., microtiter plates and silanized glass) having exposed acrylic groups.
- substrates e.g., microtiter plates and silanized glass
- the Acrydite moiety is a phosporamidite that contains an ethylene group capable of free-radical copolymerization with acrylamide, and which can be used in standard DNA synthesizers to introduce copolymerizable groups at the 5′ terminus of any oligonucleotide probe.
- the linker moieties or gel pads may be formed using electrochemical techniques. For example, cyclic voltammetry of pyrrole, 3-acetateN—hydrodysuaccinimido pyrrole and PBS buffer, in the presence of probe molecules, forms a polypyrrole/probe film on a microelectrode surface. The probe molecules are embedded or fixed within the film. Other methods of embedding probe molecules within a gel pad matrix will be known to the skilled artisan. For example, polymerization of polyacrylamide gel in the presence of the probe molecules will embed the probe molecules therein.
- the solid substrate can be made of a wide variety of materials and can be configured in a large number of ways, as is discussed herein and will be apparent to one of skill in the art.
- a single device may comprise more than one substrate; for example, there may be a “sample treatment” cassette that interfaces with a separate “detection” cassette; a raw sample is added to the sample treatment cassette and is manipulated to prepare the sample for detection, which is removed from the sample treatment cassette and added to the detection cassette.
- a portion of the substrate may be removable; for example, the sample cassette may have a detachable detection cassette, such that the entire sample cassette is not contacted with the detection apparatus.
- the sample cassette may have a detachable detection cassette, such that the entire sample cassette is not contacted with the detection apparatus.
- composition of the solid substrate will depend on a variety of factors, including the techniques used to create the device, the use of the device, the composition of the sample, the analyte to be detected, the size of the wells and microchannels, the presence or absence of electronic components, etc. Generally, the devices of the invention should be easily sterilizable as well.
- the supporting substrate of the apparatus of the invention is advantageously made from any solid material, including but not limited to silicon such as silicon wafers, silicon dioxide, silicon nitride, glass and fused silica, gallium arsenide, indium phosphide, aluminum, ceramics, polyimide, quartz, plastics, resins and polymers including polymethylmethacrylate, acrylics, polyethylene, polyethylene terepthalate, polycarbonate, polystyrene and other styrene copolymers, polypropylene, polytetrafluoroethylene, superalloys, zircaloy, steel, gold, silver, copper, tungsten, molybdeumn, tantalum, KovarTM, KevlarTM, KaptonTM, MylarTM, brass, sapphire, etc.
- silicon such as silicon wafers, silicon dioxide, silicon nitride, glass and fused silica, gallium arsenide, indium phosphide, aluminum, ceramics, polyimi
- High melting borosilicate or fused silicas may be preferred for their LV transmission properties when any of the sample manipulation steps require light based technologies.
- portions of the internal surfaces of the device may be coated with a variety of coatings as needed, to reduce non-specific binding, to allow the attachment of binding ligands, for biocompatibility, for flow resistance, etc.
- the supporting substrate of the apparatus of the present invention is composed of silicon or glass. The linker moieties are embedded within or placed in contact with the supporting substrate.
- the substrate is made from printed circuit board (PCP) materials, including without limitation, fiberglass, teflon, ceramics, glass, silicon, mica, plastic (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polycarbonate, polyurethanes, TeflonTM, and derivatives thereof, etc.), GETEK (a blend of polypropylene oxide and fiberglass), etc.
- PCP printed circuit board
- the supporting substrate has a surface area of from about 0.01 ⁇ m 2 to about 5 cm 2 containing between 1 and 1 ⁇ 10 8 microelectrodes in contact with said linker moieties. In a preferred embodiment, the supporting substrate has a surface area of 10,000 ⁇ m 2 and contains 10 4 microelectrodes in contact with linker moieties. In preferred embodiments, the microelectrodes are arranged on the supporting substrate so that they are separated by a distance of from about 0.05 ⁇ m to 0.5 mm. In more preferred embodiments, the microelectrodes are regularly spaced on the solid supporting substrate with a uniform spacing there between.
- circuit board materials are those that comprise an insulating substrate that is coated with a conducting layer and processed using lithography techniques, particularly photolithography techniques, to form the patterns of electrodes and interconnects (sometimes referred to in the art as interconnections or leads).
- the insulating substrate is generally, but not always, a polymer.
- one or a plurality of layers may be used, to make either “two dimensional” (e.g. all electrodes and interconnections in a plane) or “three dimensional” (wherein the electrodes are on one surface and the interconnects may go through the board to the other side) boards.
- Circuit board materials are often provided with a foil already attached to the substrate, such as a copper foil, with additional copper added as needed (for example for interconnections), for example by electroplating.
- the copper surface may then need to be roughened, for example through etching, to allow attachment of the adhesion layer.
- the solid substrate comprises ceramic materials, such as are outlined in U.S. Ser. Nos. 09/235,081; 09/337,086; 09/464,490; 09/492,013; 09/466,325; 09/460,281; 09/460,283; 09/387,691; 09/438,600; 09/506,178; and 09/458,534; all of which are expressly incorporated by reference in their entirety.
- the devices are made from layers of green-sheet that have been laminated and sintered together to form a substantially monolithic structure.
- Green-sheet is a composite material that includes inorganic particles of glass, glass-ceramic, ceramic, or mixtures thereof, dispersed in a polymer binder, and may also include additives such as plasticizers and dispersants.
- the green-sheet is preferably in the form of sheets that are 50 to 250 microns thick.
- the ceramic particles are typically metal oxides, such as aluminum oxide or zirconium oxide.
- An example of such a green-sheet that includes glass-ceramic particles is “AX951” that is sold by E.I. Du Pont de Nemours and Company.
- An example of a green-sheet that includes aluminum oxide particles is “Ferro Alumina” that is sold by Ferro Corp.
- the composition of the green-sheet may also be custom formulated to meet particular applications.
- the green-sheet layers are laminated together and then fired to form a substantially monolithic multilayered structure.
- the manufacturing, processing, and applications of ceramic green-sheets are described generally in Richard E. Mistler, “Tape Casting: The Basic Process for Meeting the Needs of the Electronics Industry,” Ceramic Bulletin, 69(6):1022-1026 (1990), and in U.S. Pat. No. 3,991,029, which are incorporated herein by reference.
- the method for fabricating devices begins with providing sheets of green-sheet that are preferably 50 to 250 microns thick.
- the sheets of green-sheet are cut to the desired size, typically 6 inches by 6 inches for conventional processing, although smaller or larger devices may be used as needed.
- Each green-sheet layer may then be textured using various techniques to form desired structures, such as vias, channels, or cavities, in the finished multilayered structure.
- desired structures such as vias, channels, or cavities
- an array of cavities or wells are constructed.
- each well has a micro-electrode in electrical contact with a linking moiety (preferably polyacrylamide gel), wherein the binding molecule is bound to the linking moiety.
- a linking moiety preferably polyacrylamide gel
- Various techniques may be used to texture a green-sheet layer. For example, portions of a green-sheet layer may be punched out to form vias or channels. This operation may be accomplished using conventional multilayer ceramic punches, such as the Pacific Trinetics Corp. Model APS-8718 Automated Punch System. Instead of punching out part of the material, features, such as channels and wells may be embossed into the surface of the green-sheet by pressing the green-sheet against an embossing plate that has a negative image of the desired structure. Texturing may also be accomplished by laser tooling with a laser via system, such as the Pacific Trinetics LVS-3012.
- thick-film pastes typically include the desired material, which may be either a metal or a dielectric, in the form of a powder dispersed in an organic vehicle, and the pastes are designed to have the viscosity appropriate for the desired deposition technique, such as screen-printing.
- the organic vehicle may include resins, solvents, surfactants, and flow-control agents.
- the thick-film paste may also include a small amount of a flux, such as a glass frit, to facilitate sintering.
- Thick-film technology is further described in J. D. Provance, “Performance Review of Thick Film Materials,” Insulation/Circuits (April, 1977) and in Morton L. Topfer, Thick Film Microelectronics, Fabrication, Design, and Applications (1977), pp. 41-59, which are incorporated herein by reference.
- the porosity of the resulting thick-film can be adjusted by adjusting the amount of organic vehicle present in the thick-film paste. Specifically, the porosity of the thick-film can be increased by increasing the percentage of organic vehicle in the thick-film paste. Similarly, the porosity of a green-sheet layer can be increased by increasing the proportion of organic binder. Another way of increasing porosity in thick-films and green-sheet layers is to disperse within the organic vehicle, or the organic binder, another organic phase that is not soluble in the organic vehicle. Polymer microspheres can be used advantageously for this purpose.
- the thick film pastes typically include metal particles, such as silver, platinum, palladium, gold, copper, tungsten, nickel, tin, or alloys thereof.
- metal particles such as silver, platinum, palladium, gold, copper, tungsten, nickel, tin, or alloys thereof.
- Silver pastes are preferred. Examples of suitable silver pastes are silver conductor composition numbers 7025 and 7713 sold by E.I. Du Pont de Nemours and Company.
- the thick-film pastes are preferably applied to a green-sheet layer by screen-printing.
- the thick-film paste is forced through a patterned silk screen so as to be deposited onto the green-sheet layer in a corresponding pattern.
- the silk screen pattern is created photographically by exposure to a mask.
- conductive traces may be applied to a surface of a green-sheet layer.
- Vias present in the green-sheet layer may also be filled with thick-film pastes. If filled with thick-filled pastes containing electrically conductive materials, the vias can serve to provide electrical connections between layers and/or into wells within an array of wells.
- a layer of adhesive is applied to either surface of the green-sheet.
- the adhesive is a room-temperature adhesive.
- room-temperature adhesives have glass transition temperatures below room temperature, i.e.; below about 20° C., so that they can bind substrates together at room temperature.
- room-temperature adhesives bind substrates together by penetrating into the surfaces of the substrates.
- Suitable room-temperature adhesives are typically supplied as water-based emulsions and are available from Rohm and Haas, Inc. and from Air Products, Inc. For example, a material sold by Air Products, Inc. as “Flexcryl 1653” has been found to work well.
- the room-temperature adhesive may be applied to the green-sheet by conventional coating techniques. To facilitate coating, it is often desirable to dilute the supplied pressure-sensitive adhesive in water, depending on the coating technique used, and on the viscosity and solids loading of the starting material. After coating, the room-temperature adhesive is allowed to dry.
- the dried thickness of the film of room-temperature adhesive is preferably in the range of 1 to 10 microns, and the thickness should be uniform over the entire surface of the green-sheet. Film thicknesses that exceed 15 microns are undesirable. With such thick films of adhesive voiding or delamination can occur during firing due to the large quantity of organic material that must be removed. Films that are less than about 0.5 microns thick when dried are too thin, because they provide insufficient adhesion between the layers of green-sheet.
- spin-coating and spraying are the preferred methods. If spin-coating is used, it is preferable to add 1 gram of deionized water for every 10 grams of “Flexcryl 1653.” If spraying is used, a higher dilution level is preferred to facilitate ease of spraying. Additionally, when room-temperature adhesive is sprayed on, it is preferable to hold the green-sheet at an elevated temperature, e.g., about 60 to 70° C., so that the material dries nearly instantaneously as it is deposited onto the green-sheet. The instantaneous drying results in a more uniform and homogeneous film of adhesive.
- elevated temperature e.g., about 60 to 70° C.
- the layers are stacked together to form a multilayered green-sheet structure.
- the layers are stacked in an alignment die, so as to maintain the desired registration between the structures of each layer.
- alignment holes must be added to each green-sheet layer.
- the stacking process alone is sufficient to bind the green-sheet layers together when a room-temperature adhesive is used. In other words, little or no pressure is required to bind the layers together.
- the layers are preferably laminated together after they are stacked.
- the lamination process involves the application of pressure to the stacked layers.
- a uniaxial pressure of about 1000 to 1500 psi is applied to the stacked green-sheet layers that is then followed by an application of an isostatic pressure of about 3000 to 5000 psi for about 10 to 15 minutes at an elevated temperature, such as 70° C.
- Adhesives do not need to be applied to bind the green-sheet layers together when the conventional lamination process is used.
- pressures less than 2500 psi are preferable in order to achieve good control over the dimensions of such structures as internal or external cavities and channels. Even lower pressures are more desirable to allow the formation of larger structures, such as cavities and channels.
- a lamination pressure of 2500 psi is used, the size of well-formed internal cavities and channels is typically limited to no larger than roughly 20 microns.
- pressures less than 1000 psi are more preferred, as such pressures generally enable structures having sizes greater than about 100 microns to be formed with some measure of dimensional control.
- Pressures of less than 300 psi are even more preferred, as such pressures typically allow structures with sizes greater than 250 microns to be formed with some degree of dimensional control.
- Pressures less than 100 psi which are referred to herein as “near-zero pressures,” are most preferred, because at such pressures, few limits exist on the size of internal and external cavities and channels that can be formed in the multilayered structure.
- the pressure is preferably applied in the lamination process by means of a uniaxial press. Alternatively, pressures less than about 100 psi may be applied by hand.
- the multilayered structure may be diced using conventional green-sheet dicing or sawing apparatus to separate the individual devices.
- the high level of peel and shear resistance provided by the room-temperature adhesive results in the occurrence of very little edge delamination during the dicing process. If some layers become separated around the edges after dicing, the layers may be easily re-laminated by applying pressure to the affected edges, for example by hand, without adversely affecting the rest of the device.
- the final processing step is firing to convert the laminated multilayered green-sheet structure from its “green” state to form the finished, substantially monolithic, multilayered structure.
- the firing process occurs in two important stages as the temperature is raised.
- the first important stage is the binder burnout stage that occurs in the temperature range of about 250 to 500° C., during which the other organic materials, such as the binder in the green-sheet layers and the organic components in any applied thick-film pastes, are removed from the structure.
- the sintering stage the next important stage of firing, occurs at a higher temperature, in which the inorganic particles sinter together. Sintering results in the multilayered becoming densified and substantially monolithic.
- the sintering temperature used depends on the nature of the inorganic particles present in the green-sheet. For many types of ceramics, appropriate sintering temperatures range from about 950 to about 1600° C., depending on the material. For example, for green-sheet containing aluminum oxide, sintering temperatures between 1400 and 1600° C. are typical. Other ceramic materials, such as silicon nitride, aluminum nitride, and silicon carbide require higher sintering temperatures, namely 1700 to 2200° C.
- a sintering temperature in the range of 750 to 950° C. is typical.
- Glass particles generally require sintering temperatures in the range of only about 350 to 700° C.
- metal particles may require sintering temperatures anywhere from 550 to 1700° C., depending on the metal.
- the devices are fired for a period of about 4 hours to about 12 hours or more, depending on the material used.
- the firing should be of a sufficient duration so as to remove the organic materials from the structure, and to completely sinter the inorganic particles.
- polymers are present as a binder in the green-sheet and in the room-temperature adhesive, and the firing should be of sufficient temperature and duration to decompose these polymers, and to allow for their removal from the multilayered structure.
- the multilayered structure undergoes a reduction in volume during the firing process.
- a small volume reduction of about 0.5 to 1.5% is normally observed.
- a further volume reduction of about 14 to 17% is typically observed.
- volume change due to firing can be controlled.
- volume changes need not be matched exactly, but any mismatch will typically result in internal stresses in the device.
- symmetrical processing placing the identical material or structure on opposite sides of the device can, to some extent, compensate for shrinkage stresses caused by mismatched materials. Too great a mismatch in either sintering temperatures or volume changes may result in defects in or failure of some or all of the device. For example, the device may delaminate into its individual layers, or it may become warped or distorted.
- Dissimilar materials such as thick-film pastes or other green-sheet layers, may be added prior to or after the firing process.
- any dissimilar materials added to the green-sheet layers prior to firing and the dissimilar materials and the green-sheet layers are co-fired.
- the benefit of co-firing is that the added materials are sintered to the green-sheet layers and become integral to the substantially monolithic microfluidic device.
- the added materials should have sintering temperatures and volume changes due to firing that are matched with those of the green-sheet layers. Sintering temperatures are largely material-dependent, so that matching sintering temperatures simply requires proper selection of materials.
- silver is the preferred metal for providing electrically conductive pathways
- the green-sheet layers contain alumina particles, which require a sintering temperature in the range of 1400 to 1600° C.
- some other metal, such as platinum, must be used due to the relatively low melting point of silver (961° C).
- the addition of other substrates or joining of two post-sintered (i.e. post fired) pieces can be done using any variety of adhesive techniques, including those outlined herein.
- two “halves” of a device can be glued or fused together.
- polyacrylamide gel and biological components which are not stable at high temperature, can be sandwiched in between the two halves.
- ceramic devices comprising open channels or wells can be made, additional substrates or materials placed into the devices, and then they may be sealed with other materials.
- the substrates of the invention can form microfluidic cassettes or devices that can be used to effect a number of manipulations on a sample to ultimately result in cell detection or quantification. These manipulations can include cell handling (cell concentration, cell lysis, cell removal, cell separation, etc.), separation of the desired cell from other sample components, chemical or enzymatic reactions on the cell, detection of the cells or other components, etc.
- the devices of the invention can include one or more wells for sample manipulation, waste or reagents; microchannels to and between these wells, including microchannels containing electrophoretic separation matrices; valves to control fluid movement; on-chip pumps such as electroosmotic, electrohydrodynamic, or electrokinetic pumps; and detection systems.
- the devices of the invention can be configured to manipulate one or multiple samples or analytes.
- the devices of the invention can be made in a variety of ways, as will be appreciated by those in the art. See for example WO96/39260, directed to the formation of fluid-tight electrical conduits; U.S. Pat. No. 5,747,169, directed to sealing; EP 0637996 B1; EP 0637998 B1; WO96/39260; WO97/16835; WO98/13683; WO97/16561; WO97/43629; WO96/39252; WO96/15576; WO96/15450; WO97/37755; and WO97/27324; and U.S. Pat. Nos.
- Suitable fabrication techniques again will depend on the choice of substrate, but preferred methods include, but are not limited to, a variety of micromachining and microfabrication techniques, including film deposition processes such as spin coating, chemical vapor deposition, laser fabrication, photolithographic and other etching techniques using either wet chemical processes or plasma processes, embossing, injection molding and bonding techniques (see U.S. Pat. No. 5,747,169, hereby incorporated by reference).
- film deposition processes such as spin coating, chemical vapor deposition, laser fabrication, photolithographic and other etching techniques using either wet chemical processes or plasma processes, embossing, injection molding and bonding techniques (see U.S. Pat. No. 5,747,169, hereby incorporated by reference).
- the build-up of “ink” can serve to define a flow channel.
- the use of different “inks” or “pastes” can allow different portions of the pathways
- materials can be used to change solute/solvent RF values (the ratio of the distance moved by a particular solute to that moved by a solvent front).
- printed fluid guiding pathways can be manufactured with a printed layer or layers comprised of two different materials, providing different rates of fluid transport. Multi-material fluid guiding pathways can be used when it is desirable to modify retention times of reagents in fluid guiding pathways.
- printed fluid guiding pathways can also provide regions containing reagent substances, by including the reagents in the “inks” or by a subsequent printing step. See for example U.S. Pat. No. 5,795,453, herein incorporated by reference in its entirety.
- planar substrates with microchannels and wells other geometries can be used as well.
- two or more planar substrates can be stacked to produce a three dimensional device, that can contain microchannels flowing within one plane or between planes; similarly, wells may span two or more substrates to allow for larger sample volumes.
- both sides of a substrate can be etched to contain microchannels; see for example U.S. Pat. Nos. 5,603,351 and 5,681,484, both of which are hereby incorporated by reference.
- the devices of the invention may include at least one microchannel or flow channel that allows the flow of sample from the sample inlet port to the other components or modules of the system.
- the collection of microchannels and wells is sometimes referred to in the art as a “mesoscale flow system”.
- the flow channels may be configured in a wide variety of ways, depending on the use of the channel. For example, a single flow channel starting at the sample inlet port may be separated into a variety of smaller channels, such that the original sample is divided into discrete subsamples for parallel processing or analysis. Alternatively, several flow channels from different modules, for example the sample inlet port and a reagent storage module may feed together into a mixing chamber or a reaction chamber.
- the flow channels allow the movement of sample and reagents from one part of the device to another.
- the path lengths of the flow channels may be altered as needed; for example, when mixing and timed reactions are required, longer and sometimes tortuous flow channels can be used.
- the devices herein are designed on a scale suitable to analyze microvolumes, although in some embodiments large samples (e.g. cc's of sample) may be reduced in the device to a small volume for subsequent analysis.
- “mesoscale” as used herein refers to chambers and microchannels that have cross-sectional dimensions on the order of 0.1 ⁇ m to 500 ⁇ m.
- the mesoscale flow channels and wells have preferred depths on the order of 0.1 ⁇ m to 100 ⁇ m, typically 2-50 ⁇ m.
- the channels have preferred widths on the order of 2.0 to 500 ⁇ m, more preferably 3-100 ⁇ m. For many applications, channels of 5-50 ⁇ m are useful.
- the devices of the invention are configured to include one or more of a variety of components, herein referred to as “modules”, that will be present on any given device depending on its use.
- sample inlet ports include, but are not limited to: sample inlet ports; sample introduction or collection modules; cell handling modules (for example, for cell lysis, cell removal, cell concentration, cell separation or capture, cell growth, etc.); separation modules, for example, for electrophoresis, dielectropboresis, gel filtration, ion exchange/affinity chromatography (capture and release) etc.; reaction modules for chemical or biological alteration of the sample, including amplification of the nucleic acids, chemical, physical or enzymatic cleavage or alteration of the sample components, or chemical modification of the target; fluid pumps; fluid valves; thermal modules for heating and cooling; storage modules for assay reagents; mixing chambers; and detection modules.
- cell handling modules for example, for cell lysis, cell removal, cell concentration, cell separation or capture, cell growth, etc.
- separation modules for example, for electrophoresis, dielectropboresis, gel filtration, ion exchange/affinity chromatography (capture and release) etc.
- reaction modules for
- the devices of the invention include at least one sample inlet port for the introduction of the sample to the device.
- This may be part of or separate from a sample introduction or collection module; that is, the sample may be directly fed in from the sample inlet port to a separation chamber, or it may be pretreated in a sample collection well or chamber.
- the devices of the invention include a sample collection module, which can be used to concentrate or enrich the sample if required; for example, see U.S. Pat. No. 5,770,029, including the discussion of enrichment channels and enrichment means.
- the devices of the invention include a cell handling module.
- a cell handling module For example, the detection of particular antibodies in blood can require the removal of the blood cells for efficient analysis, or the cells (and/or nucleus) may be lysed.
- “cells” include eukaryotic and prokaryotic cells, and viral particles that may require treatment prior to analysis, such as the release of nucleic acid from a viral particle prior to detection of target sequences.
- cell handling modules may also utilize a downstream means for determining the presence or absence of cells. Suitable cell handling modules include, but are not limited to, cell lysis modules, cell removal modules, cell concentration modules, and cell separation or capture modules.
- the cell handling module is in fluid communication via a flow channel with at least one other module of the invention.
- the cell handling module includes a cell lysis module.
- cells may be lysed in a variety of ways, depending on the cell type.
- the cell lysis module may comprise cell membrane piercing protrusions that extend from a surface of the cell handling module. As fluid is forced through the device, the cells are ruptured. Similarly, this may be accomplished using sharp edged particles trapped within the cell handling region.
- the cell lysis module can comprise a region of restricted cross-sectional dimension, which results in cell lysis upon pressure.
- the cell lysis module comprises a cell lysing agent, such as guanidium chloride, chaotropic salts, enzymes such as lysozymes, etc.
- a simple dilution with water or buffer can result in hypotonic lysis.
- the lysis agent may be solution form, stored within the cell lysis module or in a storage module and pumped into the lysis module. Alternatively, the lysis agent may be in solid form, that is taken up in solution upon introduction of the sample.
- the cell lysis module may also include, either internally or externally, a filtering module for the removal of cellular debris as needed.
- This filter may be microfabricated between the cell lysis module and the subsequent module to enable the removal of the lysed cell membrane and other cellular debris components; examples of suitable filters are shown in EP 0 637 998 B1, incorporated by reference.
- the cell handling module includes a cell separation or capture module.
- This embodiment utilizes a cell capture region comprising binding sites capable of reversibly binding a cell surface molecule to enable the selective isolation (or removal) of a particular type of cell from the sample.
- binding moieties may be immobilized either on the surface of the module or on a particle trapped within the module (i.e. a bead) by physical absorption or by covalent attachment. Suitable binding moieties will depend on the cell type to be isolated or removed, and generally includes antibodies and other binding ligands, such as ligands for cell surface receptors, etc.
- a particular cell type may be removed from a sample prior to further handling, or the assay is designed to specifically bind the desired cell type, wash away the non-desirable cell types, followed by either release of the bound cells by the addition of reagents or solvents, physical removal (i.e. higher flow rates or pressures), or even in situ lysis.
- a cellular “sieve” can be used to separate cells on the basis of size. This can be done in a variety of ways, including protrusions from the surface that allow size exclusion, a series of narrowing channels, a weir, or a diafiltration type setup.
- the cell handling module includes a cell removal module. This may be used when the sample contains cells that are not required in the assay or are undesirable. Generally, cell removal will be done on the basis of size exclusion as for “sieving”, above, with channels exiting the cell handling module that are too small for the cells.
- the cell handling module includes a cell concentration module. As will be appreciated by those in the art, this is done using “sieving” methods, for example to concentrate the cells from a large volume of sample fluid prior to lysis.
- the microelectrodes project from the surface of the substrate, with such projections extending between 5 ⁇ 10 ⁇ 8 and 1 ⁇ 10 ⁇ 5 cm from the surface of the supporting substrate.
- the microelectrodes comprise a flat disk of conductive material that is embedded in the supporting substrate and is exposed at the substrate surface, with the supporting substrate acting as an insulator in the spaces between the microelectrodes.
- the microelectrodes comprise a gold or platinum conductor and a glass or silicon insulator.
- the microelectrodes comprise conductor substances such as solid or porous foils or films of silver, titanium, or copper, or metal oxides, metal nitrides, metal carbides, carbon, graphite, or combinations thereof.
- the microelectrodes comprise substrate and/or insulator substances such as plastic, rubber, fabric, ceramics, or combinations thereof.
- the microelectrodes of the present invention preferably have an exposed conductive surface of from about 0.01 ⁇ m 2 to 0.5 cm 2 . In a preferred embodiment, the exposed conductive material has an area of from about 100 to 160,000 ⁇ m 2 .
- the microelectrode comprises a glass capillary tube 1 , containing an ultra fine platinum wire 2 , to which a transition wire 3 has been soldered 6 .
- the transition wire 3 is soldered 6 in turn to a hookup wire 4 , which protrudes from an epoxy plug 5 that seals the capillary tube.
- Polyacrylamide gel material 7 is packed into a recess etched into the exposed surface of the platinum wire 2 .
- the polymeric hydrogel pad is preferably at least about 0.1 to 30 ⁇ m thick, more preferably at least about 0.5 to 10 ⁇ m thick, and most preferably about 0.5 ⁇ m thick.
- the apparatus of the present invention comprises at least one counter-electrode.
- the counter-electrode comprises a conductive material, with an exposed surface that is significantly larger than that of the individual microelectrodes.
- the counter electrode comprises platinum wire.
- the counter electrode comprises solid or porous films of gold, silver, platinum, titanium, or copper, or metal oxides, metal nitrides, metal carbides, carbon, graphite, or combinations thereof.
- the apparatus comprises at least one reference electrode.
- the reference electrode is particularly useful in assays for detecting the change in electrical potential after probe and target molecules are allowed to interact and then determining the number or concentration of bacterial cells in a sample using quantitative methods (e.g., voltammetry).
- the reference electrode comprises a silver/silver chloride electrode.
- the reference electrode comprises solid or porous films of gold, platinum, titanium, or copper, or metal oxides, metal nitrides, metal carbides, carbon, graphite, or combinations thereof.
- the apparatus further comprises a plurality of wells each of which encompasses at least one microelectrode in contact with a linker moiety and at least one counter-electrode.
- wells is used herein in its conventional sense, to describe a portion of the supporting substrate in which the microelectrode and at least one counter-electrode are contained in a defined volume; said wells can protrude from the surface of the supporting substrate, or be embedded therein.
- Electrochemical contact between each of the microelectrodes and the counter electrode and/or the reference electrode is advantageously provided using an electrolyte solution in contact with each of the microelectrodes comprising the apparatus of the invention.
- Electrolyte solutions useful in the apparatus and methods of the invention include any electrolyte solution at physiologically-relevant ionic strength (equivalent to about 0.15 M NaCl) and neutral pH.
- Examples of electrolyte solutions useful with the apparatus and methods of the invention include, but are not limited to, phosphate buffered saline, HEPES buffered solutions, and sodium bicarbonate buffered solutions. Said electrolyte solutions are in contact with each of the microelectrodes of the apparatus of the invention, the counter-electrode and the reference electrode if provided, thereby providing electrochemical contact between the electrodes.
- molecular interactions between probe molecules immobilized on linker moieities in contact with microelectrodes and proetin or peptide target molecules in a sample mixture are detected by detecting an electrical signal using AC impedance.
- such molecular interactions are detected by detecting an electrical signal using an lelectrical detection method selected from the group consisting of impedance spectroscopy, cyclic voltammetry, AC voltammetry, pulse voltammetry, square wave voltammetry, AC voltammetry, hydrodynamic modulation voltammetry, conductance, potential step method, potentiometric measurements, amperometric measurements, current step method, other steady-state or transient measurement methods, and combinations thereof.
- the means for producing electrical impedance at each microelectrode is accomplished using a Model 1260 Impedance/Gain-Phase Analyser with Model 1287 Electrochemical Interface (Solartron Inc., Houston, Tex.).
- Other electrical impedance measurement means include, but are not limited to, transient methods using AC signal perturbation superimposed upon a DC potential applied to an electrochemical cell such as AC bridge and AC voltammetry.
- the measurements can be conducted at a certain particular frequency that specifically produces electrical signal changes that are readily detected or otherwise determined to be advantageous. Such particular frequencies are advantageously determined by scanning frequencies to ascertain the frequency producing, for example, the largest difference in electrical signal.
- the means for detecting changes in impedance at each microelectrode as a result of antibody-bacterial cell binding can be accomplished by using any of the above-described instruments and analytical methods.
- the target molecule is a protein (for example and without limitation an antigen, receptor, or ligand), which is detected in a sample using microelectrodes in contact with linker moieties to which binding ligands capable of specifically binding to the target protein (antibodies, small molecules, proteins, peptides, polypeptides, or aptamers) have been immobilized.
- linker moieties to which binding ligands capable of specifically binding to the target protein (antibodies, small molecules, proteins, peptides, polypeptides, or aptamers) have been immobilized.
- AC impedance is measured at a plurality of microelectrodes in contact with linker moieties to which a probe having specificity to the target molecule has been immobilized.
- microelectrodes are then exposed to a sample mixture containing a sample mixture containing the target molecule, and changes in AC impedance resulting from molecular interactions between the target molecules and binding ligands are then detected at each of the microelectrodes.
- electrochemical reporters are used to enhance the detection of target molecules.
- electrochemical reporters (“reporter group”) is attached to the target molecule. Reporters are electrochemically-distinctive redox moieties, or an electron transfer moiety that do not interfere with the molecular interaction to be detected.
- Electrochemically-labeled target molecules are electrochemically active, i.e., they are capable of participating in oxidation/reduction reaction under conditions of applied voltage potential, and are compatible with the probes, target, and solution carrying the target.
- Electrochemically-labeled target molecules useful in the methods of the present invention may be prepared by labeling suitable target molecules with any reporter group having an electrochemically-distinctive property, most preferably a redox (oxidation/reduction) potential that can be distinguished from other components of the binding reaction, and that does not interfere with the molecular interaction to be detected.
- any reporter group having an electrochemically-distinctive property most preferably a redox (oxidation/reduction) potential that can be distinguished from other components of the binding reaction, and that does not interfere with the molecular interaction to be detected.
- ETM electron transfer moiety
- ETM electrostatic transfer moiety
- electrostatic transfer moiety means a compound or group that is capable of reversibly, semi-reversibly, or irreversibly transferring one or more electrons.
- electron donor moiety means a compound or group that is capable of reversibly, semi-reversibly, or irreversibly transferring one or more electrons.
- electron donor moiety refers to molecules capable of electron transfer under certain conditions, for example oxidation-reduction reactions. It is to be understood that electron donor and acceptor capabilities are relative; that is, a molecule which can lose an electron under certain experimental conditions will be able to accept an electron under different experimental conditions.
- electron transfer moieties include, but are not limited to, transition metal complexes, organic electron transfer moieties, and electrodes.
- target molecules are labeled with reporters comprising a transition metal complex or an organic redox couple.
- Transition metals include those whose atoms have a partial or complete d shell of electrons; elements having the atomic numbers 21-30, 39-48, 57-80 and the lanthanide series.
- Suitable transition metals for use in the invention include, but are not limited to, cadmium (Cd), copper (Cu), cobalt (Co), palladium (Pd), zinc (Zn), iron (Fe), ruthenium (Ru), rhodium (Rh), osmium (Os), rhenium (Re), platinium (Pt), scandium (Sc), titanium (Ti), Vanadium (V), chromium (Cr), manganese (Mn), nickel (Ni), Molybdenum (Mo), technetium (Tc), tungsten (W), and iridium (Ir).
- the first series of transition metals the platinum metals (Ru, Rh, Pd, Os, Ir and Pt), along with Fe, Re, W, Mo and Tc, are preferred.
- Particularly preferred are ruthenium, rhenium, osmium, platinium, cobalt and iron.
- transition metals are complexed with a variety of ligands, generally depicted herein as “L”, to form suitable transition metal complexes, as is well known in the art.
- Suitable ligands fall into two categories: ligands which use nitrogen, oxygen, sulfur, carbon or phosphorus atoms (depending on the metal ion) as the coordination atoms (generally referred to in the literature as sigma ( ⁇ ) donors) and organometallic ligands such as metallocene ligands (generally referred to in the literature as pi ( ⁇ ) donors, and depicted herein as L m ).
- Suitable nitrogen donating ligands are well known in the art and include, but are not limited to, NH 2 ; NHR; NRR′; pyridine; pyrazine; isonicotinamide; imidazole; bipyridine and substituted derivatives of bipyridine; terpyridine and substituted derivatives; phenanthrolines, particularly 1,10-phenanthroline (abbreviated phen) and substituted derivatives of phenanthrolines such as 4,7-dimethylphenanthroline and dipyridol[3,2-a:2′,3′-c]phenazine (abbreviated dppz); dipyridophenazine; 1,4,5,8,9,12-hexaazatriphenylene (abbreviated hat); 9,10-phenantlirenequinone diimine (abbreviated phi); 1,4,5,8-tetraazaphenanthrene (abbreviated tap); 1,4,8,11-tetra-azacyclotetradecane (abb
- Substituted derivatives including fused derivatives, may also be used.
- porphyrins and substituted derivatives of the porphyrin family may be used. See, e.g., Comprehensive Coordination Chemistry, Ed. Wilkinson et al., Pergammon Press, 1987, Chapters 13.2 (pp73-98), 21.1 (pp. 813-898) and 21.3 (pp 915-957), all of which are hereby expressly incorporated by reference.
- Suitable sigma donating ligands using carbon, oxygen, sulfur and phosphorus are known in the art.
- suitable sigma carbon donors are found in Cotton and Wilkenson, Advanced Organic Chemistry, 5th Edition, John Wiley & Sons, 1988, hereby incorporated by reference; see page 38, for example.
- suitable oxygen ligands include crown ethers, water and others known in the art.
- Phosphines and substituted phosphines are also suitable; see page 38 of Cotton and Wilkenson.
- the oxygen, sulfur, phosphorus and nitrogen-donating ligands are attached in such a manner as to allow the heteroatoms to serve as coordination atoms.
- organometallic ligands are used as reporters.
- transition metal organometallic compounds with ⁇ -bonded organic ligands see, e.g., Advanced Inorganic Chemistry, 5th Ed., Cotton & Wilkinson, John Wiley & Sons, 1988, chapter 26; Organometallics, A Concise Introduction, Elschenbroich et al., 2nd Ed., 1992; VCH; and Comprehensive Organometallic Chemistry II, A Review of the Literature 1982-1994, Abel et al.
- organometallic ligands include cyclic aromatic compounds such as the cyclopentadienide ion [C 5 H 5 ( ⁇ 1)] and various ring substituted and ring fused derivatives, such as the indenylide ( ⁇ 1) ion, that yield a class of bis(cyclopentadieyl)metal compounds, (i.e. the metallocenes). See, e.g., Robins et al., J. Am. Chem. Soc. 104:1882-1893 (1982); and Gassman et al., J. Am. Chem. Soc.
- ferrocene [(C 5 H 5 ) 2 Fe] and its derivatives are prototypical examples which have been used in a wide variety of chemical (Connelly et al., Chem. Rev. 96:877-910 (1996), incorporated by reference) and electrochemical (Geiger et al., Advances in Organometallic Chemistry 23:1-93; and Geiger et al., Advances in Organometallic Chemistry 24:87, incorporated by reference) electron transfer or “redox” reactions.
- Metallocene derivatives of a variety of the first, second and third row transition metals are potential candidates as redox moieties.
- organometallic ligands include cyclic arenes such as benzene, to yield bis(arenc)metal compounds and their ring substituted and ring fused derivatives, of which bis(benzene)chromium is a prototypical example,
- Other acyclic ⁇ -bonded ligands such as the allyl( ⁇ 1) ion, or butadiene yield potentially suitable organometallic compounds, and all such ligands, in conduction with other ⁇ -bonded and ⁇ -bonded ligands constitute the general class of organometallic compounds in which there is a metal to carbon bond. Electrochemical studies of various dimers and oligomers of such compounds with bridging organic ligands, and additional non-bridging ligands, as well as with and without metal-metal bonds are potential candidate redox moieties.
- organic electron donors and acceptors may be used in the invention.
- organic molecules include, but are not limited to, riboflavin, xanthene dyes, azine dyes, acridine orange, N,N′-dimethyl-2,7-diazapyrenium dichloride (DAP 2+ ), methylviologen, ethidium bromide, quinones such as N,N′-dimethylanthra(2,1,9-def:6,5,10-d′e′f′)diisoquinoline dichloride (ADIQ 2+ ); porphyrins ([meso-tetrakis(N-methyl-x-pyridinium)porphyrin tetrachloride], varlamine blue B hydrochloride, Bindschedler's green; 2,6-dichloroindophenol, 2,6-dibromophenolindophenol; Brilliant crest blue (3-amino-9-dimethyl
- molecules are labeled with the following non-limiting examples of electrochemically-active moieties: 1,4-benzoquinone, ferrocene, tetracyanoquinodimethane, N,N,N′,N′-tetramethyl p-phenylenediamine, tetrathiafulvalene, 9-aminoacridine, acridine orange, aclarubicin, daunomycin, doxorubicin, pirarubicin, ethidium bromide, ethidium monoazide, chlortetracycline, tetracycline, minocycline, Hoechst 33258, Hoechst 33342, 7-aminoactinomycin D, Chromomycin A 3 , mithramycin A, Vinblastine, Rifampicin, Os(bipyridine) 2 (dipyridophenazine) 2 + , Co(bipyridine) 3
- the electrochemically-active moiety comprising the electrochemically active reporter-labeled molecule used in certain embodiments of the methods of the present invention is optionally linked to the antibody molecule through a linker, preferably having a length of from about 10 to-about 20 Angstroms.
- the linker can be an organic moiety such as a hydrocarbon chain (CH 2 ) n , wherein n is an integer from 1 to about 20, or can comprise an ether; ester, carboxyamide, or thioether moiety, or a combination thereof.
- the linker can also be an inorganic moiety such as siloxane (O—Si—O). The length of the linker is selected so that the electrochemically-active moiety does not interfere with the molecular interaction to be detected.
- “Competition assays” may be performed in accordance with an alternative embodiment of the present invention.
- a known amount of a competitor molecule labeled with an electrochemical reporter is exposed to an array of immobilized probe molecules, most preferably before a reaction mixture containing an unlabeled target molecule is exposed to the array.
- the amount of target molecule present in the reaction mixture is then determined indirectly by measuring the amount of labeled competitor molecule that is displaced from the array following the addition of the reaction mixture.
- “Sandwich assays”, in which a target binding molecule labeled with an electrochemical reporter is exposed to an array of immobilized probe molecules following exposure of the array to a reaction mixture may be performed in accordance with another alternative embodiment of the present invention.
- the target binding molecule is selected for its ability to interact with the target molecule without interfering with the interaction between the target molecules and the immobilized probe molecules.
- the “sandwich” assay is particularly useful for detecting target molecules having higher molecular weights and results in an increase in experimental specificity and sensitivity.
- FIGS. 1-6 and Examples 1-3 The preferred embodiments of the present invention are best understood by referring to FIGS. 1-6 and Examples 1-3.
- the Examples, which follow, are illustrative of specific embodiments of the invention, and various uses thereof. They are set forth for explanatory purposes only, and are not to be taken as limiting the invention.
- Streptavidin-modified porous hydrogel microelectrodes used for detecting viable bacteria were prepared as follows. Ultra-fine platinum wire having a diameter of 50 ⁇ m was inserted into glass capillary tubing having a diameter of 2 mm and sealed by heating to form a solidmicroelectrode structure. The tip of the structure was then polished with gamma alumina powder (CH Instruments, Inc., Austin, Tex.) to expose a flat disk of the platinum wire. Microelectrodes were initially polished with 0.3 ⁇ m gamma alumina powder, rinsed with deionized water, and then polished with 0.005 cm powder. Following polishing, the microelectrodes were ultrasonically cleaned for 2 min.
- gamma alumina powder CH Instruments, Inc., Austin, Tex.
- Porous hydrogel microelectrodes were prepared from the above-described microelectrodes as follows.
- the exposed flat disk of platinum of each microelectrode was etched in hot aqua regia to form a recess (i.e., micropore dent) of a specified depth.
- the depth of the recess was controlled by the length of time that the platinum disk was exposed to the etching material, with the depth of the micropore dent ranging from several microns to more than 1 mm.
- the recess thus formed was then packed with 1 ⁇ L of streptavidin-modified polyacrylamide gel material ( FIG.
- porous hydrogel microelectrode FIG. 2
- a porous hydrogel microelectrode having a diameter of about 260 cm was used as described below in Example 2. Prior to attachment of antibodies, porous hydrogel microelectrodes were ultrasonically treated in acetone and then in 1 M HNO 3 for 10 min.
- Streptavidin-modified polyacrylamide gel material was prepared as follows.
- a streptavidin solution was prepared by mixing 101 L of an N-acyloxysuccinimide solution (prepared by dissolving 10 mg of N-acyloxysuccinimide in 72 ⁇ L of DMSO) with 200 ⁇ L of streptavidin stock solution (prepared by dissolving 10 mg streptavidin in 2.5 mL phosphate buffered saline (PBS) at pH 7.6). This mixture was incubated at room temperature for 2-3 hours and then centrifuged for 2 minutes at 13,000 rpm in a conventional desktop eppendorf microcentrifuge to remove precipitated material.
- N-acyloxysuccinimide solution prepared by dissolving 10 mg of N-acyloxysuccinimide in 72 ⁇ L of DMSO
- streptavidin stock solution prepared by dissolving 10 mg streptavidin in 2.5 mL phosphate buffered saline (PBS) at pH 7.6.
- An acrylamide solution was prepared by first dissolving 25 mg bis-acrylamide in 6 mL PBSt pH 7.6, dissolving 475 mg acrylamide monomer in this solution, and then filtering the mixture through a 5 micron filter.
- streptavidin-modified polyacrylamide gel material 290 ⁇ L of the acrylamide solution was mixed with 210 ⁇ L of the streptavidin solution, and 150 ⁇ L of this solution was added to 0.6 ⁇ L of 1 mM methylene blue and 1.8 ⁇ L TEMED, poured into the recesses in the microelectrodes and allowed to polymerize prior to use.
- the microelectrodes were incubated at room temperature or at about 25° C. for 1.5 hours in 500 ⁇ L of a solution consisting of 50 ⁇ g/mL of biotinylated polyclonal anti E. coli antibody (Virostat, Portland, Me.) having specificity for a plurality of E. coli antigens. Following attachment of the antibodies, the microelectrodes were vigorously washed in PBS prior to use.
- FIGS. 3A and 3B illustrate plots of capacitance versus frequency ( FIG. 3A ) and resistance versus frequency ( FIG.
- FIGS. 4A and 4B illustrate plots of capacitance versus frequency ( FIG. 4A ) and resistance versus frequency ( FIG.
- the present invention can be used to create immunoassay sensors utilizing antibodies capable of recognizing and binding the target molecule to increase the signal and improve specificity.
- the apparatus and methods of the present invention would be useful for detecting antibodies to an infectious agent in immunoassays of serum.
- the specificity and sensitivity of such an assay would be increased by the application of a specific capture antibody (i.e., the immobilized probe) and a second target molecule binding antibody, as described herein.
Abstract
The present invention provides an apparatus and methods for the electrical detection of molecular interactions between a probe molecule and a protein or peptide target molecule, but without requiring the use of electrochemical or other reporters to obtain measurable signals. The methods can be used for electrical detection of molecular interactions between probe molecules bound to defined regions of an array and protein or peptide target molecules which are permitted to interact with the probe molecules.
Description
- This invention relates to the electrical detection of molecular interaction between biological molecules. Specifically, the invention relates to electrical detection of interactions between a probe molecule and a target molecule, wherein the target molecule is a protein or peptide.
- A number of commonly-utilized biological applications rely on the ability of analytical technologies to readily detect events related to the interaction between probe and target molecules. However, these detection technologies have traditionally utilized radioactive isotopes or fluorescent compounds to monitor probe-target interactions. For example, Potyrailo et al., 1998, Anal. Chem. 70: 3419-25, describe an apparatus and method for detecting interactions between immobilized fluorescently-labeled aptamers and peptide target molecules. Furthermore, while immunoassays offer some of the most powerful techniques for the molecular detection of peptides, the most sensitive of these techniques requires the use of a fluorescently- or radioactively-labeled target or probe molecule.
- Methods for the electrical or electrochemical detection of probe-target interactions have provided an attractive alternative to detection techniques relying on radioactive or fluorescent labels. Electrical or electrochemical detection techniques are based on the detection of alterations in the electrical properties of an electrode arising from interactions between one group of molecules attached to the surface of an electrode (often referred to as “probe” molecules) and another set of molecules present in a reaction mixture (often referred to as “target” molecules). Electrical or electrochemical detection eliminates many of the disadvantages inherent in use of radioactive or fluorescent labels to detect interactions between the probe and target molecules. This process offers, for example, a detection technique that is safe, inexpensive, and sensitive, and is not burdened with complex and onerous regulatory requirements.
- However, despite these advantages, there are a number of obstacles in using electrical or electrochemical detection techniques for analyzing molecular interactions. One such obstacle is the requirement, in some methods, of incorporating an electrochemical label into the target molecule. Labeled target molecules have been used to increase the electrical signal, thereby permitting molecular interactions between the target molecules and probe molecules to be more readily detected and at lower target concentrations. For example, Meade et al. (in U.S. Pat. Nos. 5,591,578. 5,705,348. 5,770,369, 5,780,234 and 5,824,473) provide methods for the selective covalent modification of target molecules with redox-active moieties such as transition metal complexes. Meade et al. further disclose assays for detecting molecular interactions that employ such covalently-modified target molecules.
- Certain alternative methods that do not employ labeled target molecules have been described in the prior art. For example, Hollis et al. (in U.S. Pat. Nos. 5,653,939 and 5,846,708) provide a method and apparatus for identifying molecular structures within a sample substance using a monolithic array of test sites formed on a substrate upon which the sample substance is applied. In the method of Hollis et al., changes in the electromagnetic or acoustic properties—for example, the change in resonant frequency—of the test sites following the addition of the sample substance are detected in order to determine which probes have interacted with target molecules in the sample substance.
- In addition, Eggers et al. (in U.S. Pat. Nos. 5,532,128, 5,670,322, and 5,891,630) provide a method and apparatus for identifying molecular structures within a sample substance. In the method of Eggers et al. a plurality of test sites to which probes have been bound is exposed to a sample substance and then an electrical signal is applied to the test sites. Changes in the dielectrical properties of the test sites are subsequently detected to determine which probes have interacted with target molecules in the sample substance.
- Another obstacle in the development of a simple and cost-effective electrical and electrochemical detection apparatus for detecting molecular interactions involves limitations in how probe molecules have been attached to electrodes. This is particularly important in fabricating arrays of probes, such as microarrays known in the art. For example, the prior art provides microarrays using polyacrylamide pads for attachment of oligonucleotide probes to a solid support. However, the art has not provided such pads in conjunction with electrodes in an electrical or electrochemical detection apparatus.
- Yang et al., 1997, Anal. Chim. Acta 346: 259-75 describe fabrication of microarrays having immobilized probe molecules wherein molecular interactions between labeled target molecules and probes that have been directly attached to solid electrodes are detected using electrical or electrochemical means. Yang et al., however do not suggest using electrical or electrochemical detection techniques in combination with the immobilization of probes on polyacrylamide gel pads.
- There remains a need in the art to develop alternatives to current detection methods used to detect interactions between biological molecules, particularly molecular interactions involving protein or peptide target molecules. More particularly, there is a need in the art to develop electrical detection methods for detecting interactions between biological molecules that do not require modifying target or probe molecules with reporter labels. The development of such methods would have wide application in the medical, genetic, and molecular biological arts. There further remains a need in the art to develop alternative methods for attaching biological probe molecules to the microelectrodes of an electrical or electrochemical device. Thus, there remains a need in the art to develop inexpensive and safe alternatives to standard immunological and molecular detection methods.
- The present invention provides an apparatus and methods for the electrical detection of molecular interactions between a probe molecule and a protein or peptide target molecule, but without requiring the use of electrochemical or other reporters to obtain measurable signals. The methods can be used for electrical detection of molecular interactions between probe molecules bound to defined regions of an array and protein or peptide target molecules that interact with the probe molecules.
- The apparatus of the present invention comprises a supporting substrate, one or a plurality of microelectrodes in contact with the supporting substrate, one or a plurality of linking moieties in contact with the microelectrodes and to which probe molecules are immobilized, at least one counter-electrode in electrochemical contact with the microelectrodes, a means for producing an electrical signal at each microelectrode, a means for detecting changes in the electrical signal at each microelectrode and an electrolyte solution in contact with the one or a plurality of microelectrodes, linking moieties, and counter-electrodes.
- The apparatus of the present invention may advantageously further comprise at least one reference electrode. The apparatus may also further comprise a plurality of wells, each of which encompasses at least one microelectrode in contact with a linker moiety and at least one counter-electrode that is sufficient to interrogate the microelectrodes in contact with linker moieties.
- The apparatus and methods of the present invention are useful for the electrical detection of molecular interactions between probe molecules immobilized on linker moieties in contact with microelectrodes and protein or peptide target molecules in a sample solution. In methods of the present invention, a first electrical signal is detected in a plurality of microelectrodes in contact with linker moieties to which probe molecules have been immobilized, the plurality of microelectrodes in contact with linker moieties is exposed to a sample mixture containing protein or peptide target molecules, and a second electrical signal is detected at the plurality of microelectrodes in contact with linker moieties. The first and second electrical signals are then compared, and molecular interactions between immobilized probe molecules and protein or peptide target molecules in the sample mixture are detected by determining that and by how much the first electrical signal is different from the second electrical signal.
- The present invention provides an apparatus and methods for the electrical detection of molecular interactions between probe molecules and protein or peptide target molecules, but without the requirement that electrochemical reporters or labeled target molecules be used. As a result, when compared with methods disclosed in the prior art, the apparatus and methods of the present invention are capable of detecting molecular interactions between probe molecules and protein or peptide target molecules that are safer, less expensive, simpler, and that have an increased reproducibility and sensitivity compared to prior art methods.
- Specific preferred embodiments of the present invention will become evident from the following more detailed description of certain preferred embodiments and the claims.
-
FIGS. 1A and 1B illustrate a schematic representation of the structure of a microelectrode in contact with a polyacrylamide gel linker moiety (i.e., a porous hydrogel microelectrode) (FIG. 1A ) and a schematic representation of the structure of the tip of the porous hydrogel microelectrode (FIG. 1B ); -
FIG. 2 illustrates a porous hydrogel microelectrode; -
FIGS. 3A and 3B illustrate plots of capacitance versus frequency (FIG. 3A ) and resistance versus frequency (FIG. 3B ) for a streptavidin-modified porous hydrogel microelectrode before (curve 1) and after immobilization of rabbit anti-BAP antibody (curve 2), and following incubation with BAP antigen (curve 3); and -
FIGS. 4A and 4B illustrate plots of capacitance versus frequency (FIG. 4A ) and resistance versus frequency (FIG. 4B ) for a streptavidin-modified porous hydrogel microelectrode with immobilized rabbit anti-BAP antibody before (curve 1) and after incubation with BAP antigen (curve 2), and following incubation with an anti-rabbit IgG secondary antibody (curve 3). - The apparatus and methods of the present invention are useful for the electrical detection of molecular interactions between probe molecules immobilized by linker moieties in contact with microelectrodes and protein or peptide target molecules in a sample mixture.
- As used herein, the term “array” refers to an ordered spatial arrangement, particularly an arrangement of immobilized biomolecules, such as specific binding molecules or probes as further described below. The present system finds particular utility in array formats, i.e. wherein there is a matrix of addressable locations (herein generally referred to as “pads”, “addresses” or “micro-locations”). “Array” or grammatical equivalents thereof as used herein mean a plurality of probes in an array format; the size of the array will depend on the composition and end use of the array. Arrays containing from about 2 different probes to many thousands can be made. Generally, the array will comprise from two to as many as 100,000 or more per cm2, depending on the size of the pads, as well as the end use of the array. Preferred ranges are from about 2 to about 10,000, with from about 5 to about 1000 being preferred, and from about 10 to about 100 being particularly preferred. In some embodiments, the compositions of the invention may not be in array format; that is, for some embodiments, compositions comprising a single probe may be made as well. In addition, in some arrays, multiple substrates may be used, either of different or identical compositions. Thus for example, large arrays may comprise a plurality of smaller substrates.
- As used herein, the terms “bioarray,” “biochip” and “biochip array” refer to an ordered spatial arrangement of immobilized biomolecules on a microelectrode arrayed on a solid supporting substrate. Preferred probe molecules include nucleic acids, oligonucleotides, peptides, ligands, antibodies and antigens; peptides and proteins are the most preferred probe species. Biochips, as used in the art, encompass substrates containing arrays or microarrays, preferably ordered arrays and most preferably ordered, addressable arrays, of biological molecules that comprise one member of a biological binding pair. Typically, such arrays are oligonucleotide arrays comprising a nucleotide sequence that is complementary to at least one sequence that may be or is expected to be present in a biological sample. Alternatively, and preferably, proteins, peptides or other small molecules can be arrayed on such biochips for performing, inter alia, immunological analyses (wherein the arrayed molecules are antigens), assaying biological receptors (wherein the arrayed molecules are ligands, agonists or antagonists of said receptors). In alternative embodiments, the probes of the invention are specific for a particular species, subspecies or strain of bacteria, and most preferably are specific for viable bacteria of said species, subspecies or strain.
- As used herein, the term “addressable array” refers to an array wherein the individual elements have precisely defined x and y coordinates, so that a given element at a particular position in the array can be identified.
- As used herein, the terms “probe”, “biomolecular probe”, binding molecules”, “binding ligand”, or grammatical equivalents thereof refer to a molecule (preferably a biomolecule) used to detect another biomolecule. Examples include antigens that detect antibodies, oligonucleotides that detect complimentary oligonucleotides, and ligands that detect receptors. Such probes are preferably immobilized on a microelectrode comprising a substrate.
- “Binding ligand” or grammatical equivalents thereof as used herein means a compound that is used to probe for the presence of the target analyte, and that will bind to the target analyte. As will be appreciated by those in the art, the composition of the binding ligand will depend on the composition of the target analyte. Binding ligands for a wide variety of analytes are known or can be readily found using known techniques. For example, when the analyte is a protein, the binding ligands include proteins (particularly including antibodies or fragments thereof (FAbs, etc.)) or small molecules. When the analyte is a metal ion, the binding ligand generally comprises traditional metal ion ligands or chelators. Preferred binding ligand proteins include peptides. For example, when the analyte is an enzyme, suitable binding ligands include substrates and inhibitors. Antigen-antibody pairs, receptor-ligands, and carbohydrates and their binding partners are also suitable analyte-binding ligand pairs. The binding ligand may be nucleic acid, when nucleic acid binding proteins are the targets; alternatively, as is generally described in U.S. Pat. Nos. 5,270,163, 5,475,096, 5,567,588, 5,595,877, 5,637,459, 5,683,867, 5,705,337, and related patents (hereby incorporated by reference) nucleic acid “aptomers” can be developed for binding to virtually any target analyte. Similarly, there is a wide body of literature relating to the development of binding partners based on combinatorial chemistry methods. In this embodiment, when the binding ligand is a nucleic acid, preferred compositions and techniques are outlined in PCT US97/20014, hereby incorporated by reference.
- As used herein “nucleic acid”, “oligonucleotide”or grammatical equivalents mean at least two nucleotides covalently linked together. A nucleic acid according to the present invention will generally contain phosphodiester bonds, although in some cases nucleic acid analogs are included that may have alternate backbones, comprising, for example, phosphoramide (Beaucage et al., Tetrahedron 49(10):1925 (1993); Letsinger, J. Org. Chem. 35:3800 (1970); Sprinzl et al., Eur. J. Biochem. 81:579 (1977); Letsinger et al., Nucl. Acids Res. 14:3487 (1986); Sawai et al, Chem. Lett. 805 (1984), Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); and Pauwels et al., Chemica Scripta 26:141 (1986)), phosphorothioate (Mag et al., Nucleic Acids Res. 19:1437 (1991); and U.S. Pat. No. 5,644,048), phosphorodithioate (Briu et al., J. Am. Chem. Soc. 111:2321 (1989)), O-methylphophoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press), and peptide nucleic acid backbones and linkages (see Egholm, J. Am. Chem. Soc. 114:1895 (1992); Meier et al., Chem. Int. Ed. Engl. 31:1008 (1992); Nielsen, Nature, 365:566 (1993); Carlsson et al., Nature 380:207 (1996)) (all of these references are incorporated herein in their entirety by reference). Other analog nucleic acids include those with positive backbones (Denpcy et al., Proc. Natl. Acad. Sci. USA 92:6097 (1995)), non-ionic backbones (U.S. Pat. Nos. 5,386,023, 5,637,684, 5,602,240, 5,216,141 and 4,469,863; Kiedrowshi et al., Angew. Chem. Intl. Ed. English 30:423 (1991); Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); Letsinger et al., Nucleoside & Nucleotide 13:1597 (1994);
Chapters Chapters - In a preferred embodiment, the binding of the target analyte to the binding ligand is specific, and the binding ligand is part of a binding pair. As used herein “specifically bind”means that the ligand binds the analyte with specificity sufficient to differentiate between the analyte and other components or contaminants within the test sample. However, as will be appreciated by those in the art, it will be possible to detect analytes using binding which is not highly specific; for example, the systems may use different binding ligands, for example an array of different ligands, and detection of any particular analyte is via its “signature” of binding to a panel of binding ligands, similar to the manner in which “electronic noses” work. This finds particular utility in the detection of chemical analytes. The binding should be sufficient to remain bound under the conditions of the assay, including wash steps to remove non-specific binding. In some embodiments, for example in the detection of certain biomolecules, the disassociation constants of the analyte to the binding ligand will be less than about 10−4-10−6 M−1, with less than about 10−5 to 10−9 M−1 being preferred and less than about 10−7-10−9 M−1 being particularly preferred.
- In a preferred embodiment probes or targets may be proteins. As used herein “peptides”, “polypeptides”, “proteins” or grammatical equivalents thereof mean proteins, oligopeptides, peptides, derivatives and analogs thereof (including without limitation proteins containing non-naturally occurring amino acids and amino acid analogs), and peptidomimetic structures. The side chains may be in either the (R) or the (S) configuration. In a preferred embodiment, the amino acids are in the (S) or L-configuration. When the protein is used as a binding ligand, it may be desirable to utilize protein analogs to retard degradation by sample contaminants.
- In some embodiments of the present invention, the probe molecules of the apparatus comprise proteins or peptides. The protein or peptide probe molecules of the present invention are preferably peptides comprising from about 5 to about 100 amino acids, more preferably antigen-recognizing peptieds or polypeptides belonging to the immunoglobulin superfamily. Said peptide or polypeptide probe molecules are immobilized to the microelectrodes of the invention through linker moieties, using techniques known to those with skill in the art wherein said linkage does not interfere with or inhibit the ability of the probe molecules to interact with protein or peptide target molecules in the sample mixture. As used herein “immobilize” or grammatical equivalents thereof means that the probe molecule is fixed relative to the microelectrode. For example and without limitation a probe molecule may be attached to a linker moiety, the probe molecule may be embedded within a matrix of a linker moiety, or any combination thereof, and the linker moiety is attached to the microelectrode. It will be appreciated that direct attachment of the probe molecule to the electrode is possible; howerver, this is not preferred. Attachment of the probe to a linker moiety is well within the skill of the artisan, and may include without limitation covalent bonding, ionic bonding, van der Waals forces, hydro-phobic/philic interactions, biologic attachment (such as avidin-streptavidin interactions), the latter being preferred.
- In one preferred embodiment antibodies are used as probes. A protein may be used to generate polyclonal and monoclonal antibodies to proteins, which are useful as described herein.
- In a preferred embodiment, the epitope of the probe is unique; that is, antibodies generated to a unique epitope show little or no cross-reactivity to other proteins. As used herein “epitope”, “determinant”, or grammatical equivalents thereof means a portion of a protein which will generate and/or bind an antibody. Thus, in most instances, antibodies made to a smaller Apop3 protein will be able to bind to the full length protein. The term “antibody” includes antibody fragments, as are known in the art, including Fab, Fab2, single chain antibodies (Fv for example), chimeric antibodies, etc., either produced by the modification of whole antibodies or those synthesized de novo using recombinant DNA technologies. The term “antibody” further comprises polyclonal antibodies and monoclonal antibodies, which can be agonist or antagonist antibodies.
- The proteins, whether a target or a probe, may be from any organism, including prokaryotes and eukaryotes, with enzymes from bacteria, fungi, extremeophiles such as the archebacteria, insects, fish, animals (particularly mammals and particularly human) and birds all possible. Specifically included within the definition of “protein” are fragments and domains of known proteins, including functional domains such as enzymatic domains, binding domains, etc., and smaller fragments, such as turns, loops, etc. That is, portions of proteins may be used as well. In addition, “protein” as used herein includes proteins, oligopeptides and peptides. In addition, protein variants, i.e. non-naturally occuring protein analog structures, may be used.
- Suitable proteins for probes or targets include, but are not limited to, industrial and pharmaceutical proteins, including ligands, cell surface receptors, antigens, antibodies, cytokines, hormones, transcription factors, signaling modules, cytoskeletal proteins and enzymes. Suitable classes of enzymes include, but are not limited to, hydrolases such as proteases, carbohydrases, lipases; isomerases such as racemases, epimerases, tautomerases, or mutases; transferases, kinases, oxidoreductases, and phophatases. Suitable enzymes are listed in the Swiss_Prot enzyme database. Suitable protein backbones include, but are not limited to, all of those found in the protein data base compiled and serviced by the Research Collaboratory for Structural Bioinformatics (RCSB, formerly the Brookhaven National Lab).
- Specifically, preferred target proteins include, but are not limited to, those with known structures (including variants) including cytokines (IL-1ra (+receptor complex), IL-1 (receptor alone), IL-1a, IL-1b (including variants and or receptor complex), IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-10, IFN-β, INF-γ, IFN-α-2a; IFN-α-2B, TNF-α; CD40 ligand (chk), Human Obesity Protein Leptin, Granulocyte Colony-Stimulating Factor, Bone Morphogenetic Protein-7, Ciliary Neurotrophic Factor, Granulocyte-Macrophage Colony-Stimulating Factor, Monocyte Chemoattractant Protein 1, Macrophage Migration Inhibitory Factor, Human Glycosylation-Inhibiting Factor, Human Rantes, Human Macrophage Inflammatory Protein 1 Beta, human growth hormone, Leukemia Inhibitory Factor, Human Melanoma Growth Stimulatory Activity, neutrophil activating peptide-2, Cc-Chemokine Mcp-3, Platelet Factor M2, Neutrophil Activating Peptide 2, Eotaxin, Stromal Cell-Derived Factor-1, Insulin, Insulin-like Growth Factor I, Insulin-like Growth Factor II, Transforming Growth Factor B1, Transforming Growth Factor B2, Transforming Growth Factor B3, Transforming Growth Factor A, Vascular Endothelial growth factor (VEGF), acidic Fibroblast growth factor, basic Fibroblast growth factor, Endothelial growth factor, Nerve growth factor, Brain Derived Neurotrophic Factor, Ciliary Neurotrophic Factor, Platelet Derived Growth Factor, Human Hepatocyte Growth Factor, Glial Cell-Derived Neurotrophic Factor, (as well as the 55 cytokines in PDB Jan. 12, 1999)); Erythropoietin; other extracellular signalling moeities, including, but not limited to, hedgehog Sonic, hedgehog Desert, hedgehog Indian, hCG; coaguation factors including, but not limited to, TPA and Factor VIIa; transcription factors, including but not limited to, p53, p53 tetramerization domain, Zn fingers (of which more than 12 have structures), homeodomains (of which 8 have structures), leucine zippers (of which 4 have structures); antibodies, including, but not limited to, cFv; viral proteins, including, but not limited to, hemagglutinin trimerization domain and hiv Gp41 ectodomain (fusion domain); intracellular signalling modules, including, but not limited to, SH2 domains (of which 8 structures are known), SH3 domains (of which 11 have structures), and Pleckstin Homology Domains; receptors, including, but not limited to, the extracellular Region Of Human Tissue Factor Cytokine-Binding Region Of Gp 130, G-CSF receptor, erythropoietin receptor, Fibroblast Growth Factor receptor, TNF receptor, IL-1 receptor, IL-1 receptor/IL 1ra complex, IL-4 receptor, INF-γ receptor alpha chain, MHC Class I, MHC Class II, T Cell Receptor, Insulin receptor, insulin receptor tyrosine kinase and human growth hormone receptor. It will be understood fragments and domains of these proteins, including functional domains, may also be used as probes.
- In an alternative embodiment, the target molecules are proteins as defined above. In a preferred embodiment, the target molecules are naturally occurring proteins or fragments of naturally occurring proteins. Thus, for example, cellular extracts containing proteins, or random or directed digests of proteinaceous cellular extracts, may be used. In this way libraries of procaryotic and eukaryotic proteins may be made for screening in accordance with the present invention. Particularly preferred in this embodiment are bacterial, fungal, viral, and mammalian proteins (or libraries thereof), with the latter being preferred, and human proteins being especially preferred.
- As will be appreciated, the probe or target molecules may comprise a natural products library, a peptide library, a phage display library, or a combinatorial library.
- Suitable target protein molecules include, but are not limited to, (1) immunoglobulins, particularly IgEs, IgGs and IgMs, and particularly therapeutically or diagnostically relevant antibodies, including but not limited to, for example, antibodies to human albumin, apolipoproteins (including apolipoprotein E), human chorionic gonadotropin, cortisol, α-fetoprotein, thyroxin, thyroid stimulating hormone (TSH), antithrombin, antibodies to pharmaceuticals (including antieptileptic drugs (such as phenyloin, primidone, carbariezepin, ethosuximide, valproic acid, and phenobarbitol), cardioactive drugs (such as digoxin, lidocaine, procainamide, and disopyramide), bronchodilators (such as theophylline), antibiotics (such as chloramphenicol, sulfonamides), antidepressants, imniunosuppresants, abused drugs (such as amphetamine, methamphetamine, cannabinoids, cocaine and opiates), and antibodies to any number of viruses (such as orthomyxoviruses, (e.g., influenza virus), paramyxoviruses (e.g., respiratory syncytial virus, mumps virus, measles virus), adenoviruses, rhinoviruses, coronaviruses, reoviruses, togaviruses (e.g., rubella virus), parvoviruses, poxviruses (e.g., variola virus, vaccinia virus), enteroviruses (e.g., poliovirus, coxsackievirus), hepatitis viruses (including A, B and C), herpesviruses (e.g., Herpes simplex virus, varicella_zoster virus, cytomegalovirus, Epstein_Barr virus), rotaviruses, Norwalk viruses, hantavirus, arenavirus, rhabdovirus (e.g., rabies virus), retroviruses (including HIV, HTLV_I and _II), papovaviruses (e.g., papillomavirus), polyomaviruses, and picornaviruses.), and bacteria (including a wide variety of pathogenic and non_pathogenic prokaryotes of interest including Bacillus; Vibrio, e.g., V. cholerae; Escherichia, e.g., Enterotoxigenic E. coli, Shigella, e.g., S. dysenteriae; Salmonella, e.g., S. typhi; Mycobacterium e.g., M. tuberculosis, M. leprae; Clostridium, e.g., C. botulinum, C. tetani, C. difficile, C. perfringens; Comyebacterium, e.g., C. diphtheriae; Streptococcus, S. pyogenes, S. pneumoniae; Staphylococcus, e.g., S. aureus; Haemophilus, e.g., H. influenzae; Neisseria, e.g., N. meningitidis, N. gonorrhoeae; Yersinia, e.g, G. lamblia Y. pestis, Pseudomonas, e.g., P. aeruginosa, P. pulida; Chlamydia, e.g., C. trachomatis; Bordetella, e.g., B. pertussis; Treponema, e.g., T. palladium; and the like); (2) enzymes (and other proteins), including but not limited to, enzymes used as indicators of or treatment for heart disease, including creatine kinase, lactate dehydrogenase, aspartate amino transferase, troponin T, myoglobin, fibrinogen, cholesterol, triglycerides, thrombin, tissue plasminogen activator (tPA); pancreatic disease indicators including amylase, lipase, chymotrypsin and trypsin; liver function enzymes and proteins including cholinesterase, bilirubin, and alkaline phosphotase; aldolase, prostatic acid phosphatase, terminal deoxynucleotidyl transferase, and bacterial and viral enzymes such as HIV protease; (3) hormones and cytokines (many of which serve as ligands for cellular receptors) such as erythropoietin (EPO), thrombopoietin (TPO), the interleukins (including IL-1 through IL-17), insulin, insulin-like growth factors (including IGF-1 and -2), epidermal growth factor (EGF), transforming growth factors (including TGF-α and TGF-β), human growth hormone, transferrin, epidermal growth factor (EGF), low density lipoprotein, high density lipoprotein, leptin, VEGF, PDGF, ciliary neurotrophic factor, prolactin, adrenocorticotropic hormone (ACTH), calcitonin, human chorionic gonadotropin, cotrisol, estradiol, follicle stimulating hormone (FSH), thyroid-stimulating hormone (TSH), leutinzing hormone (LH), progeterone, testosterone; and (4) other proteins (including α-fetoprotein, carcinoembryonic antigen CEA.
- In addition, any of the biomolecules for which antibodies are tested may be tested directly as well; that is, the virus or bacterial cells, therapeutic and abused drugs, etc., may be the test molecules.
- In preferred embodiments, the apparatus of the present invention comprises a supporting substrate, one or a plurality of microelectrodes in contact with the supporting substrate, one or a plurality of linking moieties in contact with the microelectrodes and to which specific binding molecules are immobilized, at least one counter-electrode in electrochemical contact with the microelectrodes, a means for producing an electrical signal at each microelectrode, a means for detecting changes in the electrical signal at each microelectrode, and an electrolyte solution in contact with the microelectrodes, linking moieties, and counter-electrode.
- In some embodiments of the present invention, the specific binding molecules of the apparatus comprise proteins or peptides. In one preferred embodiment, the specific binding molecules are antibodies. The antibodies immobilized on the linker moieties of the apparatus of the invention may be polyclonal or monoclonal antibodies, F(ab) fragments, F(ab)′ fragments, F(ab)2 fragments, or Fv fragments of polyclonal or monoclonal antibodies, or F(ab) or single chain antibodies selected from in vitro libraries. In alternative embodiments of the present invention, the specific binding molecules are nucleic acids, oligonucleotides, or combinations thereof. In one preferred embodiment of the present invention, the specific binding molecules are aptamers (i.e., oligonucleotides capable of interacting with target molecules such as peptides). Natural products libraries (such as, inter alia, yeast extracts), phage display libraries, or combinatorial libraries may also be used as specific binding molecules.
- In one preferred embodiment of the present invention, the specific binding molecules are polyclonal antibodies and the antibodies are immobilized on the linker moieties using any technique known in the art that does not interfere with or inhibit the ability of the antibodies to specifically bind to a target analyte, such as and without limitation the conjugate antigen or portion thereof. In preferred embodiments, polyclonal antibodies, antiscra, monoclonal antibodies, fragments of said polyclonal or monoclonal antibodies, or other specific ligand binding molecules, are immobilized onto and attached to the linker moieties of the apparatus of the invention using biotinylated species thereof that are conjugated with streptavidin added to the linker moiety material. In more preferred embodiments, the linker moiety material to which the streptavidin is added is polyacrylamide gel. In other embodiments the biotinylated specific binding molecule is a protein, peptide, nucleic acid, or oligonucleotide. Alternatively and as further described below, the specific binding molecules are embedded within a matrix, e.g., polymer matrix, of the linker molecules.
- In some embodiments of the present invention, the linker moieties of the apparatus are composed of materials including, but not limited to, polyacrylamide gel, agarose gel, polyethylene glycol, cellulose gel, or sol gels. In preferred embodiments, the linker moieties comprise polyacrylamide gel, which form a gel pad. In alternative embodiments of the present invention, the linker moieties, or gel pad comprise a conjugated polymer or copolymer film. Such conjugated polymer or copolymer film is composed of materials including, but not limited to, polypyrrole, polythiphene, polyaniline, polyfuran, polypyridine, polycarbazole, polyphenylene, poly(phenylenvinylene), polyfluorene, or polyindole, or their derivatives, their copolymers, and combinations thereof. In preferred embodiments, the linker moieties comprise a neutral pyrrole matrix, and the probes are embedded therein.
- Polymeric hydrogels and gel pads are used as binding layers to adhere biological molecules to substrate surfaces, which biomolecules include, but are not limited to, proteins, peptides, oligonucleotides, polynucleotides, and larger nucleic acid fragments. The oligonucleotide probes may be bound to the surface of a continuous layer of the hydrogel, to an array of gel pads, or embedded therein. The gel pads comprising biochips for use with the apparatus of the present invention are conveniently produced as thin sheets or slabs, typically by depositing a solution of acrylamide monomer, a crosslinker such methylene bisacrylamide, and a catalyst such as N,N, N′,N′-tetramethylethylendiamine (TEMED) and an initiator such as ammonium persulfate for chemical polymerization, or 2,2-dimethoxy-2-phenyl-acetophone (DMPAP) for photopolymerization, in between two glass surfaces (e.g., glass plates or microscope slides) using a spacer to obtain the desired thickness of the polymeric gel. Generally, the acrylamide monomer and crosslinker are prepared in one solution of about 4-5% acrylamide (having an acrylamide/bisacrylamide ratio of 19/1) in water/glycerol, with a nominal amount of initiator added. The solution is polymerized and crosslinked either by ultraviolet (UV) radiation (e.g., 254 m for at least about 15 minutes, or other appropriate UV conditions, collectively termed “photopolymerization”), or by thermal initiation at elevated temperature (e.g., typically at about 40° C.). Following polymerization and crosslinking, the top glass slide is removed from the surface to uncover the gel. The pore size (and hence the “sieving properties”) of the gel is controlled by varying the amount of crosslinker and the percent solids in the monomer solution. The pore size also can be controlled by varying the polymerization temperature.
- In the fabrication of arrays of polyacrylamide (i.e., patterned gels), in an embodiment of the present invention, the acrylamide solution typically is imaged through a mask during the UV polymerization/crosslinking step. The top glass slide is removed after polymerization, and the unpolymerized monomer is washed away (developed) with water, leaving a fine feature pattern of polyacrylamide hydrogel, which is used to produce the crosslinked polyacrylamide hydrogel pads. Further, in an application of lithographic techniques known in the semiconductor industry, light can be applied to discrete locations on the surface of a polyacrylamide hydrogel to activate these specified regions for the attachment of an oligonucleotide, an antibody, an antigen, a hormone, hormone receptor, a ligand or a polysaccharide on the surface (e.g., a polyacrylamide hydrogel surface) of a solid substrate (see, e.g, WO 91/07087, incorporated herein by reference).
- For hydrogel-based arrays using polyacrylamide, biomolecules (such as oligonucleotides, peptides, polypeptides, or proteins) are covalently attached by forming an amide, ester or disulfide bond between the biomolecule and a derivatized polymer comprising the cognate chemical group. Covalent attachment of the biomolecule to the polymer is usually performed after polymerization and chemical cross-linking of the polymer is completed.
- Alternatively, oligonucleotides bearing 5′-terminal acrylamide modifications can be used that efficiently copolymerize with acrylamide monomers to form DNA-containing polyacrylamide copolymers (Rehman et al., 1999, Nucleic Acids Research 27: 649-655). Using this approach, stable probe-containing layers can be fabricated on substrates (e.g., microtiter plates and silanized glass) having exposed acrylic groups. This approach has made available the commercially marketed “Acrydite™” capture probes (available from Mosaic Technologies, Boston, Mass.). The Acrydite moiety is a phosporamidite that contains an ethylene group capable of free-radical copolymerization with acrylamide, and which can be used in standard DNA synthesizers to introduce copolymerizable groups at the 5′ terminus of any oligonucleotide probe.
- Alternatively, the linker moieties or gel pads may be formed using electrochemical techniques. For example, cyclic voltammetry of pyrrole, 3-acetateN—hydrodysuaccinimido pyrrole and PBS buffer, in the presence of probe molecules, forms a polypyrrole/probe film on a microelectrode surface. The probe molecules are embedded or fixed within the film. Other methods of embedding probe molecules within a gel pad matrix will be known to the skilled artisan. For example, polymerization of polyacrylamide gel in the presence of the probe molecules will embed the probe molecules therein.
- The solid substrate can be made of a wide variety of materials and can be configured in a large number of ways, as is discussed herein and will be apparent to one of skill in the art. In addition, a single device may comprise more than one substrate; for example, there may be a “sample treatment” cassette that interfaces with a separate “detection” cassette; a raw sample is added to the sample treatment cassette and is manipulated to prepare the sample for detection, which is removed from the sample treatment cassette and added to the detection cassette. There may be an additional functional cassette into which the device fits; for example, a heating element which is placed in contact with the sample cassette to effect reactions such as PCR. In some cases, a portion of the substrate may be removable; for example, the sample cassette may have a detachable detection cassette, such that the entire sample cassette is not contacted with the detection apparatus. See for example U.S. Pat. No. 5,603,351, PCT US96/17116, and “Multilayered Microfluidic Devices for Analyte Reactions” filed in the PCT Dec. 11, 2000, Serial No. PCT/US00/33499, hereby incorporated by reference.
- The composition of the solid substrate will depend on a variety of factors, including the techniques used to create the device, the use of the device, the composition of the sample, the analyte to be detected, the size of the wells and microchannels, the presence or absence of electronic components, etc. Generally, the devices of the invention should be easily sterilizable as well.
- The supporting substrate of the apparatus of the invention is advantageously made from any solid material, including but not limited to silicon such as silicon wafers, silicon dioxide, silicon nitride, glass and fused silica, gallium arsenide, indium phosphide, aluminum, ceramics, polyimide, quartz, plastics, resins and polymers including polymethylmethacrylate, acrylics, polyethylene, polyethylene terepthalate, polycarbonate, polystyrene and other styrene copolymers, polypropylene, polytetrafluoroethylene, superalloys, zircaloy, steel, gold, silver, copper, tungsten, molybdeumn, tantalum, Kovar™, Kevlar™, Kapton™, Mylar™, brass, sapphire, etc. High melting borosilicate or fused silicas may be preferred for their LV transmission properties when any of the sample manipulation steps require light based technologies. In addition, as outlined herein, portions of the internal surfaces of the device may be coated with a variety of coatings as needed, to reduce non-specific binding, to allow the attachment of binding ligands, for biocompatibility, for flow resistance, etc. In preferred embodiments, the supporting substrate of the apparatus of the present invention is composed of silicon or glass. The linker moieties are embedded within or placed in contact with the supporting substrate.
- In another preferred embodiment, the substrate is made from printed circuit board (PCP) materials, including without limitation, fiberglass, teflon, ceramics, glass, silicon, mica, plastic (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polycarbonate, polyurethanes, Teflon™, and derivatives thereof, etc.), GETEK (a blend of polypropylene oxide and fiberglass), etc.
- The supporting substrate has a surface area of from about 0.01 μm2 to about 5 cm2 containing between 1 and 1×108 microelectrodes in contact with said linker moieties. In a preferred embodiment, the supporting substrate has a surface area of 10,000 μm2 and contains 104 microelectrodes in contact with linker moieties. In preferred embodiments, the microelectrodes are arranged on the supporting substrate so that they are separated by a distance of from about 0.05 μm to 0.5 mm. In more preferred embodiments, the microelectrodes are regularly spaced on the solid supporting substrate with a uniform spacing there between.
- In general, circuit board materials are those that comprise an insulating substrate that is coated with a conducting layer and processed using lithography techniques, particularly photolithography techniques, to form the patterns of electrodes and interconnects (sometimes referred to in the art as interconnections or leads). The insulating substrate is generally, but not always, a polymer. As is known in the art, one or a plurality of layers may be used, to make either “two dimensional” (e.g. all electrodes and interconnections in a plane) or “three dimensional” (wherein the electrodes are on one surface and the interconnects may go through the board to the other side) boards. Three dimensional systems frequently rely on the use of drilling or etching, followed by electroplating with a metal such as copper, such that the “through board” interconnections are made. Circuit board materials are often provided with a foil already attached to the substrate, such as a copper foil, with additional copper added as needed (for example for interconnections), for example by electroplating. The copper surface may then need to be roughened, for example through etching, to allow attachment of the adhesion layer.
- In an alternative embodiment the solid substrate comprises ceramic materials, such as are outlined in U.S. Ser. Nos. 09/235,081; 09/337,086; 09/464,490; 09/492,013; 09/466,325; 09/460,281; 09/460,283; 09/387,691; 09/438,600; 09/506,178; and 09/458,534; all of which are expressly incorporated by reference in their entirety. In this embodiment, the devices are made from layers of green-sheet that have been laminated and sintered together to form a substantially monolithic structure. Green-sheet is a composite material that includes inorganic particles of glass, glass-ceramic, ceramic, or mixtures thereof, dispersed in a polymer binder, and may also include additives such as plasticizers and dispersants. The green-sheet is preferably in the form of sheets that are 50 to 250 microns thick. The ceramic particles are typically metal oxides, such as aluminum oxide or zirconium oxide. An example of such a green-sheet that includes glass-ceramic particles is “AX951” that is sold by E.I. Du Pont de Nemours and Company. An example of a green-sheet that includes aluminum oxide particles is “Ferro Alumina” that is sold by Ferro Corp. The composition of the green-sheet may also be custom formulated to meet particular applications. The green-sheet layers are laminated together and then fired to form a substantially monolithic multilayered structure. The manufacturing, processing, and applications of ceramic green-sheets are described generally in Richard E. Mistler, “Tape Casting: The Basic Process for Meeting the Needs of the Electronics Industry,” Ceramic Bulletin, 69(6):1022-1026 (1990), and in U.S. Pat. No. 3,991,029, which are incorporated herein by reference.
- The method for fabricating devices begins with providing sheets of green-sheet that are preferably 50 to 250 microns thick. The sheets of green-sheet are cut to the desired size, typically 6 inches by 6 inches for conventional processing, although smaller or larger devices may be used as needed. Each green-sheet layer may then be textured using various techniques to form desired structures, such as vias, channels, or cavities, in the finished multilayered structure. In preferred embodiments an array of cavities or wells are constructed. In this preferred embodiment, each well has a micro-electrode in electrical contact with a linking moiety (preferably polyacrylamide gel), wherein the binding molecule is bound to the linking moiety.
- Various techniques may be used to texture a green-sheet layer. For example, portions of a green-sheet layer may be punched out to form vias or channels. This operation may be accomplished using conventional multilayer ceramic punches, such as the Pacific Trinetics Corp. Model APS-8718 Automated Punch System. Instead of punching out part of the material, features, such as channels and wells may be embossed into the surface of the green-sheet by pressing the green-sheet against an embossing plate that has a negative image of the desired structure. Texturing may also be accomplished by laser tooling with a laser via system, such as the Pacific Trinetics LVS-3012.
- Next, a wide variety of materials may be applied, preferably in the form of thick-film pastes, to each textured green-sheet layer. For example, electrically conductive pathways may be provided by depositing metal-containing thick-film pastes onto the green-sheet layers. Thick-film pastes typically include the desired material, which may be either a metal or a dielectric, in the form of a powder dispersed in an organic vehicle, and the pastes are designed to have the viscosity appropriate for the desired deposition technique, such as screen-printing. The organic vehicle may include resins, solvents, surfactants, and flow-control agents. The thick-film paste may also include a small amount of a flux, such as a glass frit, to facilitate sintering. Thick-film technology is further described in J. D. Provance, “Performance Review of Thick Film Materials,” Insulation/Circuits (April, 1977) and in Morton L. Topfer, Thick Film Microelectronics, Fabrication, Design, and Applications (1977), pp. 41-59, which are incorporated herein by reference.
- The porosity of the resulting thick-film can be adjusted by adjusting the amount of organic vehicle present in the thick-film paste. Specifically, the porosity of the thick-film can be increased by increasing the percentage of organic vehicle in the thick-film paste. Similarly, the porosity of a green-sheet layer can be increased by increasing the proportion of organic binder. Another way of increasing porosity in thick-films and green-sheet layers is to disperse within the organic vehicle, or the organic binder, another organic phase that is not soluble in the organic vehicle. Polymer microspheres can be used advantageously for this purpose.
- To add electrically conductive pathways, the thick film pastes typically include metal particles, such as silver, platinum, palladium, gold, copper, tungsten, nickel, tin, or alloys thereof. Silver pastes are preferred. Examples of suitable silver pastes are silver conductor composition numbers 7025 and 7713 sold by E.I. Du Pont de Nemours and Company.
- The thick-film pastes are preferably applied to a green-sheet layer by screen-printing. In the screen-printing process, the thick-film paste is forced through a patterned silk screen so as to be deposited onto the green-sheet layer in a corresponding pattern. Typically, the silk screen pattern is created photographically by exposure to a mask. In this way, conductive traces may be applied to a surface of a green-sheet layer. Vias present in the green-sheet layer may also be filled with thick-film pastes. If filled with thick-filled pastes containing electrically conductive materials, the vias can serve to provide electrical connections between layers and/or into wells within an array of wells.
- After the desired structures are formed in each layer of green-sheet, preferably a layer of adhesive is applied to either surface of the green-sheet. Preferably, the adhesive is a room-temperature adhesive. Such room-temperature adhesives have glass transition temperatures below room temperature, i.e.; below about 20° C., so that they can bind substrates together at room temperature. Moreover, rather than undergoing a chemical change or chemically reacting with or dissolving components of the substrates, such room-temperature adhesives bind substrates together by penetrating into the surfaces of the substrates. Sometimes such room-temperature adhesives are referred to as “pressure-sensitive adhesives.” Suitable room-temperature adhesives are typically supplied as water-based emulsions and are available from Rohm and Haas, Inc. and from Air Products, Inc. For example, a material sold by Air Products, Inc. as “Flexcryl 1653” has been found to work well.
- The room-temperature adhesive may be applied to the green-sheet by conventional coating techniques. To facilitate coating, it is often desirable to dilute the supplied pressure-sensitive adhesive in water, depending on the coating technique used, and on the viscosity and solids loading of the starting material. After coating, the room-temperature adhesive is allowed to dry. The dried thickness of the film of room-temperature adhesive is preferably in the range of 1 to 10 microns, and the thickness should be uniform over the entire surface of the green-sheet. Film thicknesses that exceed 15 microns are undesirable. With such thick films of adhesive voiding or delamination can occur during firing due to the large quantity of organic material that must be removed. Films that are less than about 0.5 microns thick when dried are too thin, because they provide insufficient adhesion between the layers of green-sheet.
- From among conventional coating techniques, spin-coating and spraying are the preferred methods. If spin-coating is used, it is preferable to add 1 gram of deionized water for every 10 grams of “Flexcryl 1653.” If spraying is used, a higher dilution level is preferred to facilitate ease of spraying. Additionally, when room-temperature adhesive is sprayed on, it is preferable to hold the green-sheet at an elevated temperature, e.g., about 60 to 70° C., so that the material dries nearly instantaneously as it is deposited onto the green-sheet. The instantaneous drying results in a more uniform and homogeneous film of adhesive.
- After the room-temperature adhesive has been applied to the green-sheet layers, the layers are stacked together to form a multilayered green-sheet structure. Preferably, the layers are stacked in an alignment die, so as to maintain the desired registration between the structures of each layer. When an alignment die is used, alignment holes must be added to each green-sheet layer.
- Typically, the stacking process alone is sufficient to bind the green-sheet layers together when a room-temperature adhesive is used. In other words, little or no pressure is required to bind the layers together. However, in order to effect a more secure binding of the layers, the layers are preferably laminated together after they are stacked.
- The lamination process involves the application of pressure to the stacked layers. For example, in the conventional lamination process, a uniaxial pressure of about 1000 to 1500 psi is applied to the stacked green-sheet layers that is then followed by an application of an isostatic pressure of about 3000 to 5000 psi for about 10 to 15 minutes at an elevated temperature, such as 70° C. Adhesives do not need to be applied to bind the green-sheet layers together when the conventional lamination process is used.
- However, pressures less than 2500 psi are preferable in order to achieve good control over the dimensions of such structures as internal or external cavities and channels. Even lower pressures are more desirable to allow the formation of larger structures, such as cavities and channels. For example, if a lamination pressure of 2500 psi is used, the size of well-formed internal cavities and channels is typically limited to no larger than roughly 20 microns. Accordingly, pressures less than 1000 psi are more preferred, as such pressures generally enable structures having sizes greater than about 100 microns to be formed with some measure of dimensional control. Pressures of less than 300 psi are even more preferred, as such pressures typically allow structures with sizes greater than 250 microns to be formed with some degree of dimensional control. Pressures less than 100 psi, which are referred to herein as “near-zero pressures,” are most preferred, because at such pressures, few limits exist on the size of internal and external cavities and channels that can be formed in the multilayered structure.
- The pressure is preferably applied in the lamination process by means of a uniaxial press. Alternatively, pressures less than about 100 psi may be applied by hand.
- As with semiconductor device fabrication, many devices may be present on each sheet.
- Accordingly, after lamination the multilayered structure may be diced using conventional green-sheet dicing or sawing apparatus to separate the individual devices. The high level of peel and shear resistance provided by the room-temperature adhesive results in the occurrence of very little edge delamination during the dicing process. If some layers become separated around the edges after dicing, the layers may be easily re-laminated by applying pressure to the affected edges, for example by hand, without adversely affecting the rest of the device.
- The final processing step is firing to convert the laminated multilayered green-sheet structure from its “green” state to form the finished, substantially monolithic, multilayered structure. The firing process occurs in two important stages as the temperature is raised. The first important stage is the binder burnout stage that occurs in the temperature range of about 250 to 500° C., during which the other organic materials, such as the binder in the green-sheet layers and the organic components in any applied thick-film pastes, are removed from the structure.
- The sintering stage, the next important stage of firing, occurs at a higher temperature, in which the inorganic particles sinter together. Sintering results in the multilayered becoming densified and substantially monolithic. The sintering temperature used depends on the nature of the inorganic particles present in the green-sheet. For many types of ceramics, appropriate sintering temperatures range from about 950 to about 1600° C., depending on the material. For example, for green-sheet containing aluminum oxide, sintering temperatures between 1400 and 1600° C. are typical. Other ceramic materials, such as silicon nitride, aluminum nitride, and silicon carbide require higher sintering temperatures, namely 1700 to 2200° C. For green-sheet with glass-ceramic particles, a sintering temperature in the range of 750 to 950° C. is typical. Glass particles generally require sintering temperatures in the range of only about 350 to 700° C. Finally, metal particles may require sintering temperatures anywhere from 550 to 1700° C., depending on the metal.
- Typically, the devices are fired for a period of about 4 hours to about 12 hours or more, depending on the material used. Generally, the firing should be of a sufficient duration so as to remove the organic materials from the structure, and to completely sinter the inorganic particles. In particular, polymers are present as a binder in the green-sheet and in the room-temperature adhesive, and the firing should be of sufficient temperature and duration to decompose these polymers, and to allow for their removal from the multilayered structure.
- Typically, the multilayered structure undergoes a reduction in volume during the firing process. During the binder burnout phase, a small volume reduction of about 0.5 to 1.5% is normally observed. At higher temperatures, during the sintering stage, a further volume reduction of about 14 to 17% is typically observed.
- The volume change due to firing, on the other hand, can be controlled. In particular, to match volume changes in two materials, such as green-sheet and thick-film paste, one should match: (1) the particle sizes; and (2) the percentage of organic components, such as binders, which are removed during the firing process. Volume changes need not be matched exactly, but any mismatch will typically result in internal stresses in the device. Additionally, symmetrical processing, placing the identical material or structure on opposite sides of the device can, to some extent, compensate for shrinkage stresses caused by mismatched materials. Too great a mismatch in either sintering temperatures or volume changes may result in defects in or failure of some or all of the device. For example, the device may delaminate into its individual layers, or it may become warped or distorted.
- Dissimilar materials, such as thick-film pastes or other green-sheet layers, may be added prior to or after the firing process. As noted above, preferably any dissimilar materials added to the green-sheet layers prior to firing, and the dissimilar materials and the green-sheet layers are co-fired. The benefit of co-firing is that the added materials are sintered to the green-sheet layers and become integral to the substantially monolithic microfluidic device. However, to be co-fireable, the added materials should have sintering temperatures and volume changes due to firing that are matched with those of the green-sheet layers. Sintering temperatures are largely material-dependent, so that matching sintering temperatures simply requires proper selection of materials. For example, although silver is the preferred metal for providing electrically conductive pathways, if the green-sheet layers contain alumina particles, which require a sintering temperature in the range of 1400 to 1600° C., some other metal, such as platinum, must be used due to the relatively low melting point of silver (961° C).
- Alternatively, the addition of other substrates or joining of two post-sintered (i.e. post fired) pieces can be done using any variety of adhesive techniques, including those outlined herein. For example, two “halves” of a device can be glued or fused together. Thus, in a preferred embodiment polyacrylamide gel and biological components, which are not stable at high temperature, can be sandwiched in between the two halves. Alternatively, ceramic devices comprising open channels or wells can be made, additional substrates or materials placed into the devices, and then they may be sealed with other materials.
- The substrates of the invention can form microfluidic cassettes or devices that can be used to effect a number of manipulations on a sample to ultimately result in cell detection or quantification. These manipulations can include cell handling (cell concentration, cell lysis, cell removal, cell separation, etc.), separation of the desired cell from other sample components, chemical or enzymatic reactions on the cell, detection of the cells or other components, etc. The devices of the invention can include one or more wells for sample manipulation, waste or reagents; microchannels to and between these wells, including microchannels containing electrophoretic separation matrices; valves to control fluid movement; on-chip pumps such as electroosmotic, electrohydrodynamic, or electrokinetic pumps; and detection systems. The devices of the invention can be configured to manipulate one or multiple samples or analytes.
- The devices of the invention can be made in a variety of ways, as will be appreciated by those in the art. See for example WO96/39260, directed to the formation of fluid-tight electrical conduits; U.S. Pat. No. 5,747,169, directed to sealing; EP 0637996 B1; EP 0637998 B1; WO96/39260; WO97/16835; WO98/13683; WO97/16561; WO97/43629; WO96/39252; WO96/15576; WO96/15450; WO97/37755; and WO97/27324; and U.S. Pat. Nos. 5,304,487; 5,071,531; 5,061,336; 5,747,169; 5,296,375; 5,110,745; 5,587,128; 5,498,392; 5,643,738; 5,750,015; 5,726,026; 5,35,358; 5,126,022; 5,770,029; 5,631,337; 5,569,364; 5,135,627; 5,632,876; 5,593,838; 5,585,069; 5,637,469; 5,486,335; 5,755,942; 5,681,484; and 5,603,351, all of which are hereby incorporated by reference. Suitable fabrication techniques again will depend on the choice of substrate, but preferred methods include, but are not limited to, a variety of micromachining and microfabrication techniques, including film deposition processes such as spin coating, chemical vapor deposition, laser fabrication, photolithographic and other etching techniques using either wet chemical processes or plasma processes, embossing, injection molding and bonding techniques (see U.S. Pat. No. 5,747,169, hereby incorporated by reference). In addition, there are printing techniques for the creation of desired fluid guiding pathways; that is, patterns of printed material can permit directional fluid transport. Thus, the build-up of “ink” can serve to define a flow channel. In addition, the use of different “inks” or “pastes” can allow different portions of the pathways having different flow properties. For example, materials can be used to change solute/solvent RF values (the ratio of the distance moved by a particular solute to that moved by a solvent front). For example, printed fluid guiding pathways can be manufactured with a printed layer or layers comprised of two different materials, providing different rates of fluid transport. Multi-material fluid guiding pathways can be used when it is desirable to modify retention times of reagents in fluid guiding pathways. Furthermore, printed fluid guiding pathways can also provide regions containing reagent substances, by including the reagents in the “inks” or by a subsequent printing step. See for example U.S. Pat. No. 5,795,453, herein incorporated by reference in its entirety.
- In addition, it should be understood that while most of the discussion herein is directed to the use of planar substrates with microchannels and wells, other geometries can be used as well. For example, two or more planar substrates can be stacked to produce a three dimensional device, that can contain microchannels flowing within one plane or between planes; similarly, wells may span two or more substrates to allow for larger sample volumes. Thus for example, both sides of a substrate can be etched to contain microchannels; see for example U.S. Pat. Nos. 5,603,351 and 5,681,484, both of which are hereby incorporated by reference.
- Thus, the devices of the invention may include at least one microchannel or flow channel that allows the flow of sample from the sample inlet port to the other components or modules of the system. The collection of microchannels and wells is sometimes referred to in the art as a “mesoscale flow system”. As will be appreciated by those in the art, the flow channels may be configured in a wide variety of ways, depending on the use of the channel. For example, a single flow channel starting at the sample inlet port may be separated into a variety of smaller channels, such that the original sample is divided into discrete subsamples for parallel processing or analysis. Alternatively, several flow channels from different modules, for example the sample inlet port and a reagent storage module may feed together into a mixing chamber or a reaction chamber. As will be appreciated by those in the art, there are a large number of possible configurations; what is important is that the flow channels allow the movement of sample and reagents from one part of the device to another. For example, the path lengths of the flow channels may be altered as needed; for example, when mixing and timed reactions are required, longer and sometimes tortuous flow channels can be used.
- In some embodiments, the devices herein are designed on a scale suitable to analyze microvolumes, although in some embodiments large samples (e.g. cc's of sample) may be reduced in the device to a small volume for subsequent analysis. That is, “mesoscale” as used herein refers to chambers and microchannels that have cross-sectional dimensions on the order of 0.1 μm to 500 μm. The mesoscale flow channels and wells have preferred depths on the order of 0.1 μm to 100 μm, typically 2-50 μm. The channels have preferred widths on the order of 2.0 to 500 μm, more preferably 3-100 μm. For many applications, channels of 5-50 μm are useful. However, for many applications, larger dimensions on the scale of millimeters may be used. Similarly, chambers (sometimes also referred to herein as “wells”) in the substrates often will have larger dimensions, on the scale of a few millimeters. In addition to the flow channel system, the devices of the invention are configured to include one or more of a variety of components, herein referred to as “modules”, that will be present on any given device depending on its use. These modules include, but are not limited to: sample inlet ports; sample introduction or collection modules; cell handling modules (for example, for cell lysis, cell removal, cell concentration, cell separation or capture, cell growth, etc.); separation modules, for example, for electrophoresis, dielectropboresis, gel filtration, ion exchange/affinity chromatography (capture and release) etc.; reaction modules for chemical or biological alteration of the sample, including amplification of the nucleic acids, chemical, physical or enzymatic cleavage or alteration of the sample components, or chemical modification of the target; fluid pumps; fluid valves; thermal modules for heating and cooling; storage modules for assay reagents; mixing chambers; and detection modules.
- In a preferred embodiment, the devices of the invention include at least one sample inlet port for the introduction of the sample to the device. This may be part of or separate from a sample introduction or collection module; that is, the sample may be directly fed in from the sample inlet port to a separation chamber, or it may be pretreated in a sample collection well or chamber.
- In a preferred embodiment, the devices of the invention include a sample collection module, which can be used to concentrate or enrich the sample if required; for example, see U.S. Pat. No. 5,770,029, including the discussion of enrichment channels and enrichment means.
- In a preferred embodiment, the devices of the invention include a cell handling module. Thus, for example, the detection of particular antibodies in blood can require the removal of the blood cells for efficient analysis, or the cells (and/or nucleus) may be lysed. In this context, “cells” include eukaryotic and prokaryotic cells, and viral particles that may require treatment prior to analysis, such as the release of nucleic acid from a viral particle prior to detection of target sequences. In addition, cell handling modules may also utilize a downstream means for determining the presence or absence of cells. Suitable cell handling modules include, but are not limited to, cell lysis modules, cell removal modules, cell concentration modules, and cell separation or capture modules. In addition, as for all the modules of the invention, the cell handling module is in fluid communication via a flow channel with at least one other module of the invention.
- In a preferred embodiment, the cell handling module includes a cell lysis module. As is known in the art, cells may be lysed in a variety of ways, depending on the cell type. In one embodiment, as described in
EP 0 637 998 B1 and U.S. Pat. No. 5,635,358, hereby incorporated by reference, the cell lysis module may comprise cell membrane piercing protrusions that extend from a surface of the cell handling module. As fluid is forced through the device, the cells are ruptured. Similarly, this may be accomplished using sharp edged particles trapped within the cell handling region. Alternatively, the cell lysis module can comprise a region of restricted cross-sectional dimension, which results in cell lysis upon pressure. - In a preferred embodiment, the cell lysis module comprises a cell lysing agent, such as guanidium chloride, chaotropic salts, enzymes such as lysozymes, etc. In some embodiments, for example for blood cells, a simple dilution with water or buffer can result in hypotonic lysis. The lysis agent may be solution form, stored within the cell lysis module or in a storage module and pumped into the lysis module. Alternatively, the lysis agent may be in solid form, that is taken up in solution upon introduction of the sample.
- The cell lysis module may also include, either internally or externally, a filtering module for the removal of cellular debris as needed. This filter may be microfabricated between the cell lysis module and the subsequent module to enable the removal of the lysed cell membrane and other cellular debris components; examples of suitable filters are shown in
EP 0 637 998 B1, incorporated by reference. - In a preferred embodiment, the cell handling module includes a cell separation or capture module. This embodiment utilizes a cell capture region comprising binding sites capable of reversibly binding a cell surface molecule to enable the selective isolation (or removal) of a particular type of cell from the sample. These binding moieties may be immobilized either on the surface of the module or on a particle trapped within the module (i.e. a bead) by physical absorption or by covalent attachment. Suitable binding moieties will depend on the cell type to be isolated or removed, and generally includes antibodies and other binding ligands, such as ligands for cell surface receptors, etc. as outlined herein Thus, a particular cell type may be removed from a sample prior to further handling, or the assay is designed to specifically bind the desired cell type, wash away the non-desirable cell types, followed by either release of the bound cells by the addition of reagents or solvents, physical removal (i.e. higher flow rates or pressures), or even in situ lysis.
- Alternatively, a cellular “sieve” can be used to separate cells on the basis of size. This can be done in a variety of ways, including protrusions from the surface that allow size exclusion, a series of narrowing channels, a weir, or a diafiltration type setup.
- In a preferred embodiment, the cell handling module includes a cell removal module. This may be used when the sample contains cells that are not required in the assay or are undesirable. Generally, cell removal will be done on the basis of size exclusion as for “sieving”, above, with channels exiting the cell handling module that are too small for the cells.
- In a preferred embodiment, the cell handling module includes a cell concentration module. As will be appreciated by those in the art, this is done using “sieving” methods, for example to concentrate the cells from a large volume of sample fluid prior to lysis.
- In some embodiments of the present invention, the microelectrodes project from the surface of the substrate, with such projections extending between 5×10−8 and 1×10−5 cm from the surface of the supporting substrate. In other embodiments, the microelectrodes comprise a flat disk of conductive material that is embedded in the supporting substrate and is exposed at the substrate surface, with the supporting substrate acting as an insulator in the spaces between the microelectrodes.
- In a preferred embodiment of the present invention the microelectrodes comprise a gold or platinum conductor and a glass or silicon insulator. In alternative embodiments, the microelectrodes comprise conductor substances such as solid or porous foils or films of silver, titanium, or copper, or metal oxides, metal nitrides, metal carbides, carbon, graphite, or combinations thereof. In additional embodiments, the microelectrodes comprise substrate and/or insulator substances such as plastic, rubber, fabric, ceramics, or combinations thereof. The microelectrodes of the present invention preferably have an exposed conductive surface of from about 0.01 μm2 to 0.5 cm2. In a preferred embodiment, the exposed conductive material has an area of from about 100 to 160,000 μm2.
- One embodiment of the present invention is shown in
FIG. 1A , wherein the microelectrode comprises aglass capillary tube 1, containing an ultrafine platinum wire 2, to which atransition wire 3 has been soldered 6. Thetransition wire 3 is soldered 6 in turn to ahookup wire 4, which protrudes from anepoxy plug 5 that seals the capillary tube.Polyacrylamide gel material 7 is packed into a recess etched into the exposed surface of theplatinum wire 2. The polymeric hydrogel pad is preferably at least about 0.1 to 30 μm thick, more preferably at least about 0.5 to 10 μm thick, and most preferably about 0.5 μm thick. - The apparatus of the present invention comprises at least one counter-electrode. In a preferred embodiment of the present invention, the counter-electrode comprises a conductive material, with an exposed surface that is significantly larger than that of the individual microelectrodes. In a preferred embodiment, the counter electrode comprises platinum wire. In alternative embodiments, the counter electrode comprises solid or porous films of gold, silver, platinum, titanium, or copper, or metal oxides, metal nitrides, metal carbides, carbon, graphite, or combinations thereof.
- In other embodiments of the present invention, the apparatus comprises at least one reference electrode. The reference electrode is particularly useful in assays for detecting the change in electrical potential after probe and target molecules are allowed to interact and then determining the number or concentration of bacterial cells in a sample using quantitative methods (e.g., voltammetry). In preferred embodiments, the reference electrode comprises a silver/silver chloride electrode. In alternative embodiments, the reference electrode comprises solid or porous films of gold, platinum, titanium, or copper, or metal oxides, metal nitrides, metal carbides, carbon, graphite, or combinations thereof.
- In still further embodiments of the present invention, the apparatus further comprises a plurality of wells each of which encompasses at least one microelectrode in contact with a linker moiety and at least one counter-electrode. The term “wells” is used herein in its conventional sense, to describe a portion of the supporting substrate in which the microelectrode and at least one counter-electrode are contained in a defined volume; said wells can protrude from the surface of the supporting substrate, or be embedded therein.
- Electrochemical contact between each of the microelectrodes and the counter electrode and/or the reference electrode is advantageously provided using an electrolyte solution in contact with each of the microelectrodes comprising the apparatus of the invention. Electrolyte solutions useful in the apparatus and methods of the invention include any electrolyte solution at physiologically-relevant ionic strength (equivalent to about 0.15 M NaCl) and neutral pH. Examples of electrolyte solutions useful with the apparatus and methods of the invention include, but are not limited to, phosphate buffered saline, HEPES buffered solutions, and sodium bicarbonate buffered solutions. Said electrolyte solutions are in contact with each of the microelectrodes of the apparatus of the invention, the counter-electrode and the reference electrode if provided, thereby providing electrochemical contact between the electrodes.
- In preferred embodiments of the present invention, molecular interactions between probe molecules immobilized on linker moieities in contact with microelectrodes and proetin or peptide target molecules in a sample mixture are detected by detecting an electrical signal using AC impedance. In other embodiments, such molecular interactions are detected by detecting an electrical signal using an lelectrical detection method selected from the group consisting of impedance spectroscopy, cyclic voltammetry, AC voltammetry, pulse voltammetry, square wave voltammetry, AC voltammetry, hydrodynamic modulation voltammetry, conductance, potential step method, potentiometric measurements, amperometric measurements, current step method, other steady-state or transient measurement methods, and combinations thereof.
- In one embodiment of the apparatus of the present invention, the means for producing electrical impedance at each microelectrode is accomplished using a Model 1260 Impedance/Gain-Phase Analyser with Model 1287 Electrochemical Interface (Solartron Inc., Houston, Tex.). Other electrical impedance measurement means include, but are not limited to, transient methods using AC signal perturbation superimposed upon a DC potential applied to an electrochemical cell such as AC bridge and AC voltammetry. The measurements can be conducted at a certain particular frequency that specifically produces electrical signal changes that are readily detected or otherwise determined to be advantageous. Such particular frequencies are advantageously determined by scanning frequencies to ascertain the frequency producing, for example, the largest difference in electrical signal. The means for detecting changes in impedance at each microelectrode as a result of antibody-bacterial cell binding can be accomplished by using any of the above-described instruments and analytical methods.
- In a preferred embodiment of the present invention the target molecule is a protein (for example and without limitation an antigen, receptor, or ligand), which is detected in a sample using microelectrodes in contact with linker moieties to which binding ligands capable of specifically binding to the target protein (antibodies, small molecules, proteins, peptides, polypeptides, or aptamers) have been immobilized. In one method of the invention, AC impedance is measured at a plurality of microelectrodes in contact with linker moieties to which a probe having specificity to the target molecule has been immobilized. The microelectrodes are then exposed to a sample mixture containing a sample mixture containing the target molecule, and changes in AC impedance resulting from molecular interactions between the target molecules and binding ligands are then detected at each of the microelectrodes.
- In some embodiments electrochemical reporters are used to enhance the detection of target molecules. For example and without limitation, electrochemical reporters (“reporter group”) is attached to the target molecule. Reporters are electrochemically-distinctive redox moieties, or an electron transfer moiety that do not interfere with the molecular interaction to be detected. Electrochemically-labeled target molecules are electrochemically active, i.e., they are capable of participating in oxidation/reduction reaction under conditions of applied voltage potential, and are compatible with the probes, target, and solution carrying the target. Electrochemically-labeled target molecules useful in the methods of the present invention may be prepared by labeling suitable target molecules with any reporter group having an electrochemically-distinctive property, most preferably a redox (oxidation/reduction) potential that can be distinguished from other components of the binding reaction, and that does not interfere with the molecular interaction to be detected.
- As used herein “electron transfer moiety”, “ETM”, or grammatical equivalents thereof means a compound or group that is capable of reversibly, semi-reversibly, or irreversibly transferring one or more electrons. As used herein “electron donor moiety”, “electron acceptor moiety”, “electron transfer moieties” or grammatical equivalents thereof refers to molecules capable of electron transfer under certain conditions, for example oxidation-reduction reactions. It is to be understood that electron donor and acceptor capabilities are relative; that is, a molecule which can lose an electron under certain experimental conditions will be able to accept an electron under different experimental conditions. It is to be understood that the number of possible electron donor moieties and electron acceptor moieties is very large, and that one skilled in the art of electron transfer compounds will be able to utilize a number of compounds in the present invention. Preferred electron transfer moieties include, but are not limited to, transition metal complexes, organic electron transfer moieties, and electrodes.
- In preferred embodiments target molecules are labeled with reporters comprising a transition metal complex or an organic redox couple. Transition metals include those whose atoms have a partial or complete d shell of electrons; elements having the atomic numbers 21-30, 39-48, 57-80 and the lanthanide series. Suitable transition metals for use in the invention include, but are not limited to, cadmium (Cd), copper (Cu), cobalt (Co), palladium (Pd), zinc (Zn), iron (Fe), ruthenium (Ru), rhodium (Rh), osmium (Os), rhenium (Re), platinium (Pt), scandium (Sc), titanium (Ti), Vanadium (V), chromium (Cr), manganese (Mn), nickel (Ni), Molybdenum (Mo), technetium (Tc), tungsten (W), and iridium (Ir). That is, the first series of transition metals, the platinum metals (Ru, Rh, Pd, Os, Ir and Pt), along with Fe, Re, W, Mo and Tc, are preferred. Particularly preferred are ruthenium, rhenium, osmium, platinium, cobalt and iron.
- The transition metals are complexed with a variety of ligands, generally depicted herein as “L”, to form suitable transition metal complexes, as is well known in the art.
- Suitable ligands fall into two categories: ligands which use nitrogen, oxygen, sulfur, carbon or phosphorus atoms (depending on the metal ion) as the coordination atoms (generally referred to in the literature as sigma (σ) donors) and organometallic ligands such as metallocene ligands (generally referred to in the literature as pi (π) donors, and depicted herein as Lm). Suitable nitrogen donating ligands are well known in the art and include, but are not limited to, NH2; NHR; NRR′; pyridine; pyrazine; isonicotinamide; imidazole; bipyridine and substituted derivatives of bipyridine; terpyridine and substituted derivatives; phenanthrolines, particularly 1,10-phenanthroline (abbreviated phen) and substituted derivatives of phenanthrolines such as 4,7-dimethylphenanthroline and dipyridol[3,2-a:2′,3′-c]phenazine (abbreviated dppz); dipyridophenazine; 1,4,5,8,9,12-hexaazatriphenylene (abbreviated hat); 9,10-phenantlirenequinone diimine (abbreviated phi); 1,4,5,8-tetraazaphenanthrene (abbreviated tap); 1,4,8,11-tetra-azacyclotetradecane (abbreviated cyclam) and isocyanide. Substituted derivatives, including fused derivatives, may also be used. In some embodiments, porphyrins and substituted derivatives of the porphyrin family may be used. See, e.g., Comprehensive Coordination Chemistry, Ed. Wilkinson et al., Pergammon Press, 1987, Chapters 13.2 (pp73-98), 21.1 (pp. 813-898) and 21.3 (pp 915-957), all of which are hereby expressly incorporated by reference.
- Suitable sigma donating ligands using carbon, oxygen, sulfur and phosphorus are known in the art. For example, suitable sigma carbon donors are found in Cotton and Wilkenson, Advanced Organic Chemistry, 5th Edition, John Wiley & Sons, 1988, hereby incorporated by reference; see page 38, for example. Similarly, suitable oxygen ligands include crown ethers, water and others known in the art. Phosphines and substituted phosphines are also suitable; see page 38 of Cotton and Wilkenson. The oxygen, sulfur, phosphorus and nitrogen-donating ligands are attached in such a manner as to allow the heteroatoms to serve as coordination atoms.
- In a preferred embodiment, organometallic ligands are used as reporters. In addition to purely organic compounds for use as redox moieties, and various transition metal coordination complexes with δ-bonded organic ligand with donor atoms as heterocyclic or exocyclic substituents, there is available a wide variety of transition metal organometallic compounds with π-bonded organic ligands (see, e.g., Advanced Inorganic Chemistry, 5th Ed., Cotton & Wilkinson, John Wiley & Sons, 1988, chapter 26; Organometallics, A Concise Introduction, Elschenbroich et al., 2nd Ed., 1992; VCH; and Comprehensive Organometallic Chemistry II, A Review of the Literature 1982-1994, Abel et al. Ed., Vol. 7,
chapters 7, 8, 10 & 11, Pergarnon Press, all hereby expressly incorporated by reference). Such organometallic ligands include cyclic aromatic compounds such as the cyclopentadienide ion [C5H5(−1)] and various ring substituted and ring fused derivatives, such as the indenylide (−1) ion, that yield a class of bis(cyclopentadieyl)metal compounds, (i.e. the metallocenes). See, e.g., Robins et al., J. Am. Chem. Soc. 104:1882-1893 (1982); and Gassman et al., J. Am. Chem. Soc. 108:42284229 (1986), incorporated by reference. Of these, ferrocene [(C5H5)2Fe] and its derivatives are prototypical examples which have been used in a wide variety of chemical (Connelly et al., Chem. Rev. 96:877-910 (1996), incorporated by reference) and electrochemical (Geiger et al., Advances in Organometallic Chemistry 23:1-93; and Geiger et al., Advances in Organometallic Chemistry 24:87, incorporated by reference) electron transfer or “redox” reactions. Metallocene derivatives of a variety of the first, second and third row transition metals are potential candidates as redox moieties. Other potentially suitable organometallic ligands include cyclic arenes such as benzene, to yield bis(arenc)metal compounds and their ring substituted and ring fused derivatives, of which bis(benzene)chromium is a prototypical example, Other acyclic π-bonded ligands such as the allyl(−1) ion, or butadiene yield potentially suitable organometallic compounds, and all such ligands, in conduction with other π-bonded and δ-bonded ligands constitute the general class of organometallic compounds in which there is a metal to carbon bond. Electrochemical studies of various dimers and oligomers of such compounds with bridging organic ligands, and additional non-bridging ligands, as well as with and without metal-metal bonds are potential candidate redox moieties. - In addition to transition metal complexes, other organic electron donors and acceptors may be used in the invention. These organic molecules include, but are not limited to, riboflavin, xanthene dyes, azine dyes, acridine orange, N,N′-dimethyl-2,7-diazapyrenium dichloride (DAP2+), methylviologen, ethidium bromide, quinones such as N,N′-dimethylanthra(2,1,9-def:6,5,10-d′e′f′)diisoquinoline dichloride (ADIQ2+); porphyrins ([meso-tetrakis(N-methyl-x-pyridinium)porphyrin tetrachloride], varlamine blue B hydrochloride, Bindschedler's green; 2,6-dichloroindophenol, 2,6-dibromophenolindophenol; Brilliant crest blue (3-amino-9-dimethyl-amino-10-methylphenoxyazine chloride), methylene blue; Nile blue A (aminoaphthodiethylaminophenoxazine sulfate), indigo-5,5′,7,7′-tetrasulfonic acid, indigo-5,5′,7-trisulfonic acid; phenosafranine, indigo-5-monosulfonic acid; safranine T; bis(dimethylglyoximato)-iron(II) chloride; induline scarlet, neutral red, anthracene, coronene, pyrene, 9-phenylanthracene, rubrene, binaphthyl, DPA, phenothiazene, fluoranthene, phenanthrene, chrysene, 1,8-diphenyl-1,3,5,7-octatetracene, naphthalene, acenaphthalene, perylene, TMPD and analogs and subsitituted derivatives of these compounds.
- In other embodiments of the present invention, molecules are labeled with the following non-limiting examples of electrochemically-active moieties: 1,4-benzoquinone, ferrocene, tetracyanoquinodimethane, N,N,N′,N′-tetramethyl p-phenylenediamine, tetrathiafulvalene, 9-aminoacridine, acridine orange, aclarubicin, daunomycin, doxorubicin, pirarubicin, ethidium bromide, ethidium monoazide, chlortetracycline, tetracycline, minocycline, Hoechst 33258, Hoechst 33342, 7-aminoactinomycin D, Chromomycin A3, mithramycin A, Vinblastine, Rifampicin, Os(bipyridine)2(dipyridophenazine)2 +, Co(bipyridine)3 3+, or Fe-bleomycin.
- The electrochemically-active moiety comprising the electrochemically active reporter-labeled molecule used in certain embodiments of the methods of the present invention is optionally linked to the antibody molecule through a linker, preferably having a length of from about 10 to-about 20 Angstroms. The linker can be an organic moiety such as a hydrocarbon chain (CH2)n, wherein n is an integer from 1 to about 20, or can comprise an ether; ester, carboxyamide, or thioether moiety, or a combination thereof. The linker can also be an inorganic moiety such as siloxane (O—Si—O). The length of the linker is selected so that the electrochemically-active moiety does not interfere with the molecular interaction to be detected.
- “Competition assays” may be performed in accordance with an alternative embodiment of the present invention. In this embodiment a known amount of a competitor molecule labeled with an electrochemical reporter is exposed to an array of immobilized probe molecules, most preferably before a reaction mixture containing an unlabeled target molecule is exposed to the array. The amount of target molecule present in the reaction mixture is then determined indirectly by measuring the amount of labeled competitor molecule that is displaced from the array following the addition of the reaction mixture. “Sandwich assays”, in which a target binding molecule labeled with an electrochemical reporter is exposed to an array of immobilized probe molecules following exposure of the array to a reaction mixture, may be performed in accordance with another alternative embodiment of the present invention. The target binding molecule is selected for its ability to interact with the target molecule without interfering with the interaction between the target molecules and the immobilized probe molecules. The “sandwich” assay is particularly useful for detecting target molecules having higher molecular weights and results in an increase in experimental specificity and sensitivity.
- The preferred embodiments of the present invention are best understood by referring to
FIGS. 1-6 and Examples 1-3. The Examples, which follow, are illustrative of specific embodiments of the invention, and various uses thereof. They are set forth for explanatory purposes only, and are not to be taken as limiting the invention. - Streptavidin-modified porous hydrogel microelectrodes used for detecting viable bacteria were prepared as follows. Ultra-fine platinum wire having a diameter of 50 μm was inserted into glass capillary tubing having a diameter of 2 mm and sealed by heating to form a solidmicroelectrode structure. The tip of the structure was then polished with gamma alumina powder (CH Instruments, Inc., Austin, Tex.) to expose a flat disk of the platinum wire. Microelectrodes were initially polished with 0.3 μm gamma alumina powder, rinsed with deionized water, and then polished with 0.005 cm powder. Following polishing, the microelectrodes were ultrasonically cleaned for 2 min. in deionized water, soaked in 1N HNO3 for 20 min., vigorously washed in deionized water, immersed in acetone for 10 min., and again washed vigorously in deionized water. Through the use of micromanufacturing techniques employed in the fabrication of semiconductors, modifications of this procedure can be applied to the preparation of microelectrodes of a size required for the construction of alternative embodiments of the microelectrodes, such as bioarray chips (see co-owned and co-pending U.S. patent application Ser. Nos. 09/458,501 and 09/458,533, incorporated by reference).
- Porous hydrogel microelectrodes were prepared from the above-described microelectrodes as follows. The exposed flat disk of platinum of each microelectrode was etched in hot aqua regia to form a recess (i.e., micropore dent) of a specified depth. The depth of the recess was controlled by the length of time that the platinum disk was exposed to the etching material, with the depth of the micropore dent ranging from several microns to more than 1 mm. The recess thus formed was then packed with 1 μL of streptavidin-modified polyacrylamide gel material (
FIG. 1B ) and polymerized under UV irradiation in a Stratalinker (Stratagene, La Jolla, Calif.) for 20 min. to form a porous hydrogel microelectrode (FIG. 2 ). A porous hydrogel microelectrode having a diameter of about 260 cm was used as described below in Example 2. Prior to attachment of antibodies, porous hydrogel microelectrodes were ultrasonically treated in acetone and then in 1 M HNO3 for 10 min. - Streptavidin-modified polyacrylamide gel material was prepared as follows. A streptavidin solution was prepared by mixing 101 L of an N-acyloxysuccinimide solution (prepared by dissolving 10 mg of N-acyloxysuccinimide in 72 μL of DMSO) with 200 μL of streptavidin stock solution (prepared by dissolving 10 mg streptavidin in 2.5 mL phosphate buffered saline (PBS) at pH 7.6). This mixture was incubated at room temperature for 2-3 hours and then centrifuged for 2 minutes at 13,000 rpm in a conventional desktop eppendorf microcentrifuge to remove precipitated material. An acrylamide solution was prepared by first dissolving 25 mg bis-acrylamide in 6 mL PBSt pH 7.6, dissolving 475 mg acrylamide monomer in this solution, and then filtering the mixture through a 5 micron filter. To prepare streptavidin-modified polyacrylamide gel material, 290 ˜L of the acrylamide solution was mixed with 210 μL of the streptavidin solution, and 150 μL of this solution was added to 0.6 μL of 1 mM methylene blue and 1.8 μL TEMED, poured into the recesses in the microelectrodes and allowed to polymerize prior to use.
- To attach antibodies to the microelectrodes prepared in Example 1, the microelectrodes were incubated at room temperature or at about 25° C. for 1.5 hours in 500 μL of a solution consisting of 50 μg/mL of biotinylated polyclonal anti E. coli antibody (Virostat, Portland, Me.) having specificity for a plurality of E. coli antigens. Following attachment of the antibodies, the microelectrodes were vigorously washed in PBS prior to use.
- Molecular interactions between antibodies immobilized on a porous hydrogel microelectrode and antigens in a sample solution were detected using the porous hydrogel microelectrodes described herein to measure changes in AC impedance. AC impedance was measured using a Model 1260 Impedance/Gain-Phase Analyser with Model 1287 Electrochemical Interface (Solartron Inc.). A platinum wire having a surface area larger than the porous hydrogel microelectrode was used as the counter-electrode. Impedance measurements were made under open circuit voltage (OCV) conditions in PBS and samples were excited at an amplitude of 20 mV.
- Using streptavidin-modified porous hydrogel microelectrodes prepared as described in Example 1, baseline AC impedance was measured in PBS. Following incubation of microelectrodes in anti-BAP antibody as described in Example 2, AC impedance was measured again. Microelectrodes were then incubated in a 50 μg/mL BAP antigen solution (Sigma, St. Louis, Mo.) at about 4° C. for 15 hours. Following vigorous rinsing in PBS, AC impedance was once again measured.
FIGS. 3A and 3B illustrate plots of capacitance versus frequency (FIG. 3A ) and resistance versus frequency (FIG. 3B ) for microelectrodes before (curve 1) and after (curve 2) immobilization of rabbit anti-BAP antibody, and follou ing incubation with BAP antigen (curve 3). These plots indicate that, following immobilization of anti-BAP antibody, there was an increase in capacitance and a decrease in resistance, and following interaction with BAP antigen, there was a further increase in capacitance and a further decrease in resistance. These results suggest that molecular interactions between an antibody probe immobilized on porous hydrogel microelectrodes and antigen target molecules in a sample solution can be detected by examining changes in AC impedance. - To examine whether molecular interactions between an immobilized antibody and secondary antibody could be electrically detected, microelectrodes with anti-BAP antibody-BAP antigen complexes were allowed to interact with fluorescein-labeled antirabbit IgG antibody (Boehringer-Mannheim, Indianapolis, Ind.) at a concentration of 40 μg/mL at 4° C. for 24 hours. Following this incubation, AC impedance was once again measured.
FIGS. 4A and 4B illustrate plots of capacitance versus frequency (FIG. 4A ) and resistance versus frequency (FIG. 4B ) for microelectrodes with immobilized rabbit anti-BAP antibody before (curve 1) and after (curve 2) incubation with BAP antigen, and following incubation with an anti-rabbit IgG secondary antibody (curve 3). These plots indicate that. follouing interaction with the secondary antibody, there was a further increase in capacitance and a further decrease in resistance over that detected for the primary antibody-antigen complex alone. These results suggest that molecular interactions between antibody-antigen complexes immobilized on porous hydrogel microelectrodes and secondary antibody target molecules in a sample solution can be detected by examining changes in AC impedance. - In addition, these results indicate that the present invention can be used to create immunoassay sensors utilizing antibodies capable of recognizing and binding the target molecule to increase the signal and improve specificity. The apparatus and methods of the present invention, for example, would be useful for detecting antibodies to an infectious agent in immunoassays of serum. The specificity and sensitivity of such an assay would be increased by the application of a specific capture antibody (i.e., the immobilized probe) and a second target molecule binding antibody, as described herein.
- It should be understood that the foregoing disclosure emphasizes certain specific embodiments of the invention and that all modifications or alternatives equivalent thereto are within the spirit and scope of the invention as set forth in the appended claims.
Claims (51)
1. An apparatus for the electrical detection of molecular interactions between an immobilized probe molecule and a protein or peptide target molecule. comprising:
(a) a supporting substrate;
(b) one or a plurality of microelectrodes in contact with the supporting substrate;
(c) one or a plurality of linking moieties in contact with the microelectrodes and to which probe molecules have been immobilized;
(d) at least one counter-electrode in electrochemical contact with the microelectrodes;
(e) a means for producing an electrical signal at each microelectrode;
(f) a means for detecting changes in the electrical signal at each microelectrode; and
(g) an electrolyte solution in contact with the microelectrodes. the linking moieties, and the counter-electrode, wherein molecular interactions between the immobilized probe molecules and protein or peptide target molecule are detected as a difference in the electrical signal at each microclectrode in the presence and absence of the protein or peptide target molecule.
2. The apparatus of claim 1 , w herein the linking moieties comprise polyacrylamide gel, agarose gel, polyethylene glycol, cellulose gel, sol gel, or combinations thereof.
3. The apparatus of claim 2 , wherein the linking moieties comprise polyacrylamide gel.
4. The apparatus of claim 1 . wherein the linking moieties comprise a conjugated polymer or copolymer film.
5. The apparatus of claim 4 , wherein the conjugated polymer or copolymer film is polypyrrole, polythiphene, polyaniline, polyfuran, polypyridine, polycarbazole, polyphenylene, poly(phenylenvinylene), polyfluorene, or polyindole, or their derivatives copolymers, or combinations thereof.
6. The apparatus of claim 1 , wherein the linking moieties comprise a neutral pyrrole matrix.
7. The apparatus of claim 1 , wherein the supporting substrate comprises ceramic, glass, silicon, silicon nitride, fabric, rubber, plastic, printed circuit board, or combinations thereof.
8. The apparatus of claim 1 , wherein the microelectrodes comprise a conductive material and an insulating material.
9. The apparatus of claim 8 , wherein the conductive material is solid or porous gold, silver, platinum, titanium, copper, chromium, or aluminum, or metal oxide, metal nitride, metal carbide, carbon, graphite, conductive plastic, metal impregnated polymers or combinations thereof.
10. The apparatus of claim 9 , wherein the conductive material is platinum.
11. The apparatus of claim 9 , wherein the conductive material is gold.
12. The apparatus of claim 8 , wherein the insulating material is glass, silicon, silicon nitride, plastic, rubber, fabric, ceramic, printed circuit board, or combinations thereof.
13. The apparatus of claim 12 , wherein the insulating material is silicon.
14. The apparatus of claim 12 , wherein the insulating material is glass.
15. The apparatus of claim 8 , wherein the conductive material is embedded the supporting substrate and the supporting substrate comprises the insulating material.
16. The apparatus of claim 1 , further comprising at least one reference electrode.
17. The apparatus of claim 16 . wherein the reference electrode comprises a conductive material and an insulating material.
18. The apparatus of claim 17 , wherein the conductive material is solid or porous gold, silver, platinum, titanium, copper, chromium, or aluminum, or metal oxide, metal nitride, metal carbide, carbon, graphite, conductive plastic, metal impregnated polymers or combinations thereof.
19. The apparatus of claim 17 . wherein the conductive material is silver/silver chloride.
20. The apparatus of claim 17 , wherein the insulating material is glass, silicon, silicon nitride, plastic, rubber, fabric. ceramic. printed circuit board, or combinations thereof.
21. The apparatus of claim 1 , wherein the supporting substrate further comprises a plurality of wells, each of which encompasses at least one microelectrode in contact with a linker moiety and at least one counter-electrode.
22. The apparatus of claim 1 . wherein the probe molecules are oligonucleotides or nucleic acids.
23. The apparatus of claim 22 , wherein the probe molecules are aptamers.
24. The apparatus of claim 1 , wherein the probe molecules are proteins or peptides.
25. The apparatus of claim 24 , wherein the probe molecules are antibodies.
26. The apparatus of claim 25 , wherein the antibodies are polyclonal antisera, polyclonal antibodies, or F(ab), F(ab)′, F(ab)2, or Fv fragments thereof.
27. The apparatus of claim 25 , wherein the antibodies are monoclonal antibodies, or F(ab), F(ab)′, F(ab)2, or Fv fragments thereof.
28. The apparatus of claim 25 , wherein the antibodies are F(ab) fragments or single-chain Fv fragments produced by in vitro libraries.
29. The apparatus of claim 1 , wherein the probe molecules comprise a natural products library, a peptide library. a phage display library, or a combinatorial library.
30. The apparatus of claim 1 , wherein the linking moieties further comprise streptavidin and the probe molecules are biotinylated.
31. The apparatus of claim 1 , wherein molecular interactions between probe molecules and protein or peptide target molecules are detected by using an electrical detection method selected from the group consisting of impedance spectroscopy, cyclic voltammetry, AC voltammetry, pulse voltammetry, square wave voltammetry, AC voltammetry, hydrodynamic modulation voltammetry, conductance, potential step method, potentiometric measurements, amperometric measurements. current step method, other steady-state or transient measurement methods, and combinations thereof.
32. A method for the electrical detection of molecular interactions between an immobilized probe molecule and a protein or peptide target molecule. comprising:
(a) detecting a first electrical signal in one or a plurality of microelectrodes in contact with linker moieties to which probe molecules have been immobilized;
(b) exposing the one or a plurality of microelectrodes in contact with linker moieties to which probe molecules have been immobilized to a sample mixture containing protein or peptide target molecules;
(c) detecting a second electrical signal in one or a plurality of microelectrodes in contact with linker moieties to which probe molecules have been immobilized;
(d) comparing the first electrical signal with the second electrical signal, and
(e) determining whether the first electrical signal is different from the second electrical signal.
33. The method of claim 32 . wherein molecular interactions between probe molecules and protein or peptide target molecules are detected by using an electrical detection method selected from the group consisting of impedance spectroscopy, cyclic voltammetrv, AC voltammetry, pulse voltammetry. square wave voltammetry, AC voltammetry, hydrodynamic modulation voltammetry, conductance, potential step method, potentiometric measurements, amperometric measurements, current step method, other steady-state or transient measurement methods, and combinations thereof.
34. The method of claim 32 , wherein the electrical detection method is AC impedance that is measured over a range of frequencies.
35. The method of claim 32 , wherein the electrical detection method is AC impedance that is measured by transient methods with AC signal perturbation superimposed upon a DC potential applied to an electrochemical cell.
36. The method of claim 32 , wherein the electrical detection method is AC impedance that is measured by impedance analyzer. lock-in amplifier, AC bridge, AC voltammetry, or combinations thereof.
37. The method of claim 32 , wherein the linker moieties comprise polyacrylamide gel, agarose gel. polyethylene glycol. cellulose gel. sol gel, or combinations thereof and the protein or peptide target molecules are labeled with an electrochemically active reporter molecule prior to exposing the one or a plurality of microelectrodes in contact with linker moieties to which probe molecules have been immobilized to the sample mixture containing protein or peptide target molecules.
38. The method of claim 37 , wherein the electrochemically active reporter molecule comprises a transition metal complex.
39. The method of claim 37 , wherein the transition metal ion is ruthenium, cobalt, iron. zinc, copper, magnesium, nickel, or osmium.
40. The method of claim 37 , wherein the electrochemically active reporter labeled target molecules are labeled with electrochemical reporter groups selected from the group consisting of 1,4-benzoquinone, ferrocene, tetracyanoqublodimethane, N,N,N′,N′-tetramethyl-p-phenylenediamine, and tetrathiafulvalene.
41. The method of claim 37 , wherein the electrochemically active reporter labeled target molecules are labeled with electrochemical reporter groups selected from the group consisting of 9-aminoacridine, acridine orange, aclarubicin, daunomycin, doxorubicin, pirarubicin, ethidium bromide, ethidium monoazide, chlortetracycline, tetracycline, minocycline, Hoechst 33258, Hoechst 33342, 7-aminoactinomycin D, Chromomycin A3, mithramycin A, Vinblastine, Rifampicin, Os(bipyridine)2(dipyridophenazine)2 +, Co(bipyridine)3 3+, and Fe-bleomycin.
42. The method of claim 32 , further comprising:
(f) exposing the one or a plurality of microelectrodes in contact with linker moieties to which probe molecules have been immobilized to an electrochemically labeled target binding molecule;
(g) detecting a third electrical signal in one or a plurality of microelectrodes in contact with linker moieties to which probe molecules have been immobilized.
(h) comparing the second electrical signal with the third electrical signal, and
(i) determining whether the second electrical signal is different from the third electrical signal.
43. The method of claim 42 . wherein the target binding molecules are oligonucleotides or nucleic acids.
44. The method of claim 43 , wherein the target binding molecules are aptamers.
45. The method of claim 42 . wherein the target binding molecules are proteins or peptides.
46. The method of claim 45 . wherein the target binding molecules are antibodies.
47. The method of claim 46 , wherein the antibodies are polyclonal antisera, polyclonal antibodies, or F(ab), F(ab)′, F(ab)2, or Fv fragments thereof.
48. The method of claim 46 , wherein the antibodies are monoclonal antibodies, or F(ab), F(ab)′, F(ab)2, or Fv fragments thereof.
49. The method of claim 46 , wherein the antibodies are F(ab) fragments or single-chain Fv fragments produced by in vitro libraries.
50. The method of claim 42 , wherein the target binding molecules are a natural products library, a peptide library, a phage display library, or a combinatorial library.
51. A method for the electrical detection of molecular interactions between an immobilized probe molecule and a protein or peptide target molecule, comprising:
(a) detecting a first electrical signal in one or a plurality of microelectrodes in contact with linker moieties to which probe molecules have been immobilized;
(b) exposing the one or a plurality of microelectrodes in contact with linker moieties to which probe molecules have been immobilized to a sample mixture containing a first protein or peptide target molecule and to a second protein or peptide target molecule, wherein the second protein or peptide target molecule is labeled with an electrochemical reporter;
(c) detecting a second electrical signal in one or a plurality of microelectrodes in contact with linker moieties to which probe molecules have been immobilized;
(d) comparing the first electrical signal with the second electrical signal; and
(e) determining whether the first electrical signal is different from the second electrical signal.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/203,874 US20050023155A1 (en) | 2000-02-17 | 2001-02-20 | Protein and peptide sensors using electrical detection methods |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/506,178 US6824669B1 (en) | 2000-02-17 | 2000-02-17 | Protein and peptide sensors using electrical detection methods |
US10/203,874 US20050023155A1 (en) | 2000-02-17 | 2001-02-20 | Protein and peptide sensors using electrical detection methods |
PCT/US2001/005476 WO2001061053A2 (en) | 2000-02-17 | 2001-02-20 | Protein and peptide sensors using electrical detection methods |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/506,178 Continuation-In-Part US6824669B1 (en) | 2000-02-17 | 2000-02-17 | Protein and peptide sensors using electrical detection methods |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050023155A1 true US20050023155A1 (en) | 2005-02-03 |
Family
ID=24013530
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/506,178 Expired - Lifetime US6824669B1 (en) | 2000-02-17 | 2000-02-17 | Protein and peptide sensors using electrical detection methods |
US10/203,874 Abandoned US20050023155A1 (en) | 2000-02-17 | 2001-02-20 | Protein and peptide sensors using electrical detection methods |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/506,178 Expired - Lifetime US6824669B1 (en) | 2000-02-17 | 2000-02-17 | Protein and peptide sensors using electrical detection methods |
Country Status (5)
Country | Link |
---|---|
US (2) | US6824669B1 (en) |
EP (1) | EP1257820A2 (en) |
AU (1) | AU2001238573A1 (en) |
CA (1) | CA2404492A1 (en) |
WO (1) | WO2001061053A2 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006116242A2 (en) * | 2005-04-25 | 2006-11-02 | Infotonics Technology Center, Inc. | Microneedle with glucose sensor and method thereof |
US20090156756A1 (en) * | 2005-09-26 | 2009-06-18 | Board Of Trustees Of Michigan State University | Synthesis of conducto-magnetic polymers as nano-transducers in biosensor design |
US20100305499A1 (en) * | 2009-03-09 | 2010-12-02 | Leonid Matsiev | Systems and methods for the identification of compounds in medical fluids using admittance spectroscopy |
US20110009817A1 (en) * | 2008-03-10 | 2011-01-13 | Bennett James W | Intravenous fluid monitoring |
US20130157351A1 (en) * | 2010-12-21 | 2013-06-20 | The Regents Of The University Of California | Compact wide-field fluorescent imaging on a mobile device |
KR101429193B1 (en) | 2013-05-10 | 2014-08-13 | 호서대학교 산학협력단 | Nucleic acid aptamer specifically binding to chlortetracycline |
US8838395B2 (en) | 2010-09-09 | 2014-09-16 | S.E.A. Medical Systems, Inc. | Systems and methods for intravenous drug management using immittance spectroscopy |
US9052276B2 (en) | 2009-06-08 | 2015-06-09 | S.E.A. Medical Systems, Inc. | Systems and methods for the identification of compounds using admittance spectroscopy |
US20150164397A1 (en) * | 2012-07-16 | 2015-06-18 | Diagnostic Biochips, Inc. | In Vivo Biosensor |
WO2017062349A1 (en) * | 2015-10-05 | 2017-04-13 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Development and parameter assessment for vertically aligned platinum wire aptasensor arrays for impedimetric detection of cardiac biomarkers |
US20180080932A1 (en) * | 2003-07-12 | 2018-03-22 | Accelerate Diagnostics, Inc. | Sensitive and rapid determination of antimicrobial susceptibility |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6071699A (en) | 1996-06-07 | 2000-06-06 | California Institute Of Technology | Nucleic acid mediated electron transfer |
EP1272672A2 (en) * | 2000-03-30 | 2003-01-08 | Infineon Technologies AG | Method for detecting macromolecular biopolymers by means of an electrode arrangement |
US20030003523A1 (en) * | 2001-06-19 | 2003-01-02 | Mark Jensen | Conductometric detection process |
US10539561B1 (en) * | 2001-08-30 | 2020-01-21 | Customarray, Inc. | Enzyme-amplified redox microarray detection process |
GB0205455D0 (en) | 2002-03-07 | 2002-04-24 | Molecular Sensing Plc | Nucleic acid probes, their synthesis and use |
JP4257217B2 (en) * | 2002-03-28 | 2009-04-22 | オリンパス株式会社 | Method for producing test piece for analysis of biological material and test method for test piece for biological material |
US6878523B2 (en) | 2002-05-08 | 2005-04-12 | Gentel Bio Surfaces, Inc. | Molecular interaction assays on a solid surface |
GB0211449D0 (en) * | 2002-05-17 | 2002-06-26 | Oxford Biosensors Ltd | Analyte measurement |
US20050006234A1 (en) * | 2003-02-13 | 2005-01-13 | Arjang Hassibi | Semiconductor electrochemical bio-sensor array |
GB2404738B (en) | 2003-08-04 | 2005-09-28 | Schlumberger Holdings | System and method for sensing using diamond based microelectrodes |
JP2007523326A (en) | 2004-02-06 | 2007-08-16 | バイエル・ヘルスケア・エルエルシー | Oxidizable species as internal standards for biosensors and methods of use |
US7548092B2 (en) | 2004-02-25 | 2009-06-16 | Ternarylogic Llc | Implementing logic functions with non-magnitude based physical phenomena |
US7696785B2 (en) * | 2004-02-25 | 2010-04-13 | Ternarylogic Llc | Implementing logic functions with non-magnitude based physical phenomena |
WO2005095991A1 (en) | 2004-04-01 | 2005-10-13 | Nanyang Technological University | Addressable chem/bio chip array |
EP1751533A2 (en) * | 2004-05-14 | 2007-02-14 | Bayer Healthcare, LLC | Voltammetric systems for assaying biological analytes |
US20100164548A1 (en) * | 2004-09-08 | 2010-07-01 | Ternarylogic Llc | Implementing Logic Functions With Non-Magnitude Based Physical Phenomena |
US20060102471A1 (en) | 2004-11-18 | 2006-05-18 | Karl Maurer | Electrode array device having an adsorbed porous reaction layer |
US20070034513A1 (en) | 2005-03-25 | 2007-02-15 | Combimatrix Corporation | Electrochemical deblocking solution for electrochemical oligomer synthesis on an electrode array |
US9394167B2 (en) | 2005-04-15 | 2016-07-19 | Customarray, Inc. | Neutralization and containment of redox species produced by circumferential electrodes |
ES2717135T3 (en) | 2005-07-20 | 2019-06-19 | Ascensia Diabetes Care Holdings Ag | Method to signal the user to add an additional sample to a test strip, method to measure the temperature of a sample and methods to determine the concentration of an analyte based on controlled amperometry |
US20070292855A1 (en) | 2005-08-19 | 2007-12-20 | Intel Corporation | Method and CMOS-based device to analyze molecules and nanomaterials based on the electrical readout of specific binding events on functionalized electrodes |
US20070065877A1 (en) | 2005-09-19 | 2007-03-22 | Combimatrix Corporation | Microarray having a base cleavable succinate linker |
CN101273266B (en) | 2005-09-30 | 2012-08-22 | 拜尔健康护理有限责任公司 | Gated voltammetry |
FI20065478L (en) * | 2006-07-05 | 2008-01-25 | Valtion Teknillinen | Biosensor |
DK2062051T3 (en) * | 2006-09-16 | 2016-05-09 | Univ Leeds | METHODS AND DEVICES FOR DETECTING STRUCTURAL CHANGES IN A MOLECULE IN MEASURING ELECTROCHEMICAL IMPEDANCE |
EP2083674B1 (en) | 2006-10-24 | 2018-03-07 | Ascensia Diabetes Care Holdings AG | Transient decay amperometry |
WO2009076302A1 (en) | 2007-12-10 | 2009-06-18 | Bayer Healthcare Llc | Control markers for auto-detection of control solution and methods of use |
WO2010148365A2 (en) | 2009-06-19 | 2010-12-23 | The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona For And On Behalf Of Arizona State University | Compound arrays for sample profiling |
WO2011090793A2 (en) | 2010-01-20 | 2011-07-28 | Customarray, Inc. | Multiplex microarray of serially deposited biomolecules on a microarray |
EP2562536B1 (en) * | 2011-08-22 | 2018-08-01 | Nxp B.V. | Analyte detection method and analyte detection apparatus |
GB201207583D0 (en) * | 2012-05-01 | 2012-06-13 | Isis Innovation | Electrochemical detection method and related aspects |
GB201211775D0 (en) | 2012-07-03 | 2012-08-15 | Isis Innovation | An electrode and use thereof |
US20140322706A1 (en) | 2012-10-24 | 2014-10-30 | Jon Faiz Kayyem | Integrated multipelx target analysis |
US9957553B2 (en) | 2012-10-24 | 2018-05-01 | Genmark Diagnostics, Inc. | Integrated multiplex target analysis |
US9453613B2 (en) | 2013-03-15 | 2016-09-27 | Genmark Diagnostics, Inc. | Apparatus, devices, and methods for manipulating deformable fluid vessels |
USD881409S1 (en) | 2013-10-24 | 2020-04-14 | Genmark Diagnostics, Inc. | Biochip cartridge |
US9498778B2 (en) | 2014-11-11 | 2016-11-22 | Genmark Diagnostics, Inc. | Instrument for processing cartridge for performing assays in a closed sample preparation and reaction system |
US9598722B2 (en) | 2014-11-11 | 2017-03-21 | Genmark Diagnostics, Inc. | Cartridge for performing assays in a closed sample preparation and reaction system |
WO2016077364A2 (en) | 2014-11-11 | 2016-05-19 | Genmark Diagnostics, Inc. | Instrument and cartridge for performing assays in a closed sample preparation and reaction system |
US10005080B2 (en) | 2014-11-11 | 2018-06-26 | Genmark Diagnostics, Inc. | Instrument and cartridge for performing assays in a closed sample preparation and reaction system employing electrowetting fluid manipulation |
US10758886B2 (en) | 2015-09-14 | 2020-09-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Conditioned surfaces for in situ molecular array synthesis |
US11747334B2 (en) | 2016-06-20 | 2023-09-05 | Cowper Sciences Inc. | Methods for differential diagnosis of autoimmune diseases |
JP2019526786A (en) | 2016-06-20 | 2019-09-19 | ヘルステル・インコーポレイテッドHealthtell Inc. | Methods for diagnosis and treatment of autoimmune diseases |
CA3036572A1 (en) | 2016-09-19 | 2018-03-22 | Genmark Diagnostics, Inc. | Instrument for processing cartridge for performing assays in a closed sample preparation and reaction system |
CA3043264A1 (en) | 2016-11-11 | 2018-05-17 | Healthtell Inc. | Methods for identifying candidate biomarkers |
EP3673086A1 (en) | 2017-08-24 | 2020-07-01 | Clinical Micro Sensors, Inc. (DBA GenMark Diagnostics, Inc.) | Electrochemical detection of bacterial and/or fungal infections |
US20190062809A1 (en) | 2017-08-24 | 2019-02-28 | Clinical Micro Sensors, Inc. (dba GenMark Diagnostics, Inc.) | Electrochemical detection of bacterial and/or fungal infections |
Citations (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3934209A (en) * | 1974-04-23 | 1976-01-20 | Minnesota Mining And Manufacturing Company | High voltage DC coupled amplifier |
US4072576A (en) * | 1975-10-06 | 1978-02-07 | Ab Kabi | Method for studying enzymatic and other biochemical reactions |
US4098645A (en) * | 1976-02-24 | 1978-07-04 | W. R. Grace & Co. | Immobilization of proteins with polyurethane polymers |
US4656127A (en) * | 1983-04-22 | 1987-04-07 | Amersham International Plc. | Method of detecting mutations in DNA and RNA |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4839017A (en) * | 1986-03-31 | 1989-06-13 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Potential-causing membrane for immunosensor |
US4840893A (en) * | 1983-12-16 | 1989-06-20 | Medisense, Inc. | Electrochemical assay for nucleic acids and nucleic acid probes |
US4920047A (en) * | 1988-05-20 | 1990-04-24 | General Electric Company | Electrical detection of the immune reaction |
US4945045A (en) * | 1984-07-06 | 1990-07-31 | Serono Diagnostics Ltd. | Electrochemical methods of assay |
US4988617A (en) * | 1988-03-25 | 1991-01-29 | California Institute Of Technology | Method of detecting a nucleotide change in nucleic acids |
US4995960A (en) * | 1987-11-24 | 1991-02-26 | Public Health Laboratory Service Board | Electrochemical electrodes |
US5001048A (en) * | 1987-06-05 | 1991-03-19 | Aurthur D. Little, Inc. | Electrical biosensor containing a biological receptor immobilized and stabilized in a protein film |
US5089112A (en) * | 1989-03-20 | 1992-02-18 | Associated Universities, Inc. | Electrochemical biosensor based on immobilized enzymes and redox polymers |
US5106751A (en) * | 1988-09-15 | 1992-04-21 | Biotronic Systems Corporation | Apparatus for supporting a biochemical sensor responsive to bubbles |
US5108573A (en) * | 1990-06-05 | 1992-04-28 | The United States Of America As Represented By The United States Department Of Energy | Morphology in electrochemically grown conducting polymer films |
US5126034A (en) * | 1988-07-21 | 1992-06-30 | Medisense, Inc. | Bioelectrochemical electrodes |
US5180968A (en) * | 1991-03-01 | 1993-01-19 | Research Foundation Of State University Of New York | Method and apparatus for compensation of double layer charging current in electrochemical cells |
US5187096A (en) * | 1991-08-08 | 1993-02-16 | Rensselaer Polytechnic Institute | Cell substrate electrical impedance sensor with multiple electrode array |
US5192507A (en) * | 1987-06-05 | 1993-03-09 | Arthur D. Little, Inc. | Receptor-based biosensors |
US5194133A (en) * | 1990-05-04 | 1993-03-16 | The General Electric Company, P.L.C. | Sensor devices |
US5202261A (en) * | 1990-07-19 | 1993-04-13 | Miles Inc. | Conductive sensors and their use in diagnostic assays |
US5296375A (en) * | 1992-05-01 | 1994-03-22 | Trustees Of The University Of Pennsylvania | Mesoscale sperm handling devices |
US5304487A (en) * | 1992-05-01 | 1994-04-19 | Trustees Of The University Of Pennsylvania | Fluid handling in mesoscale analytical devices |
US5308754A (en) * | 1988-03-21 | 1994-05-03 | Kankare Jouko J | Electrogenerated luminescence in solution |
US5312527A (en) * | 1992-10-06 | 1994-05-17 | Concordia University | Voltammetric sequence-selective sensor for target polynucleotide sequences |
US5320725A (en) * | 1989-08-02 | 1994-06-14 | E. Heller & Company | Electrode and method for the detection of hydrogen peroxide |
US5324457A (en) * | 1989-10-02 | 1994-06-28 | Board Of Regents, The University Of Tx System | Devices and methods for generating electrogenerated chemiluminescence |
US5328847A (en) * | 1990-02-20 | 1994-07-12 | Case George D | Thin membrane sensor with biochemical switch |
US5391272A (en) * | 1992-03-06 | 1995-02-21 | Andcare, Inc. | Electrochemical immunoassay methods |
US5403451A (en) * | 1993-03-05 | 1995-04-04 | Riviello; John M. | Method and apparatus for pulsed electrochemical detection using polymer electroactive electrodes |
US5436161A (en) * | 1988-11-10 | 1995-07-25 | Pharmacia Biosensor Ab | Matrix coating for sensing surfaces capable of selective biomolecular interactions, to be used in biosensor systems |
US5486335A (en) * | 1992-05-01 | 1996-01-23 | Trustees Of The University Of Pennsylvania | Analysis based on flow restriction |
US5491097A (en) * | 1989-06-15 | 1996-02-13 | Biocircuits Corporation | Analyte detection with multilayered bioelectronic conductivity sensors |
US5498392A (en) * | 1992-05-01 | 1996-03-12 | Trustees Of The University Of Pennsylvania | Mesoscale polynucleotide amplification device and method |
US5505321A (en) * | 1994-12-05 | 1996-04-09 | Teledyne Industries, Inc. | Fabrication multilayer combined rigid/flex printed circuit board |
US5519635A (en) * | 1993-09-20 | 1996-05-21 | Hitachi Ltd. | Apparatus for chemical analysis with detachable analytical units |
US5591578A (en) * | 1993-12-10 | 1997-01-07 | California Institute Of Technology | Nucleic acid mediated electron transfer |
US5593838A (en) * | 1994-11-10 | 1997-01-14 | David Sarnoff Research Center, Inc. | Partitioned microelectronic device array |
US5603351A (en) * | 1995-06-07 | 1997-02-18 | David Sarnoff Research Center, Inc. | Method and system for inhibiting cross-contamination in fluids of combinatorial chemistry device |
US5605662A (en) * | 1993-11-01 | 1997-02-25 | Nanogen, Inc. | Active programmable electronic devices for molecular biological analysis and diagnostics |
US5632957A (en) * | 1993-11-01 | 1997-05-27 | Nanogen | Molecular biological diagnostic systems including electrodes |
US5632878A (en) * | 1994-02-01 | 1997-05-27 | Fet Engineering, Inc. | Method for manufacturing an electroforming mold |
US5637469A (en) * | 1992-05-01 | 1997-06-10 | Trustees Of The University Of Pennsylvania | Methods and apparatus for the detection of an analyte utilizing mesoscale flow systems |
US5638878A (en) * | 1996-07-08 | 1997-06-17 | Valley Machine Works Ltd. | Log debarking apparatus |
US5705346A (en) * | 1992-11-27 | 1998-01-06 | Canon Kabushiki Kaisha | Method for detecting a target nucleic acid by using an interaction of two kinds of reagents |
US5710028A (en) * | 1992-07-02 | 1998-01-20 | Eyal; Nurit | Method of quick screening and identification of specific DNA sequences by single nucleotide primer extension and kits therefor |
US5726026A (en) * | 1992-05-01 | 1998-03-10 | Trustees Of The University Of Pennsylvania | Mesoscale sample preparation device and systems for determination and processing of analytes |
US5727548A (en) * | 1983-05-05 | 1998-03-17 | Medisense, Inc. | Strip electrode with screen printing |
US5728532A (en) * | 1996-05-31 | 1998-03-17 | Ackley; Donald E. | Electrode configuration for matrix addressing of a molecular detection device |
US5741462A (en) * | 1995-04-25 | 1998-04-21 | Irori | Remotely programmable matrices with memories |
US5747169A (en) * | 1995-11-09 | 1998-05-05 | David Sarnoff Research Center, Inc. | Field-assisted sealing |
US5766515A (en) * | 1994-05-06 | 1998-06-16 | Bayer Aktiengessellschaft | Conductive coatings |
US5770721A (en) * | 1993-08-11 | 1998-06-23 | University Of Chicago | Method of manufacturing a matrix for the detection of mismatches |
US5770029A (en) * | 1996-07-30 | 1998-06-23 | Soane Biosciences | Integrated electrophoretic microdevices |
US5770369A (en) * | 1993-12-10 | 1998-06-23 | California Institute Of Technology | Nucleic acid mediated electron transfer |
US5871633A (en) * | 1993-06-17 | 1999-02-16 | Rutgers, The State University | Impedance type humidity sensor with protonconducting electrolyte and method of using same |
US5874316A (en) * | 1989-01-27 | 1999-02-23 | Australian Membrane Biotechnology Research Institute | Receptor membranes and ionophore gating |
US5891630A (en) * | 1991-11-19 | 1999-04-06 | Houston Advanced Res Center | Multi-site detection apparatus |
US6013166A (en) * | 1991-05-09 | 2000-01-11 | Nanogen, Inc. | Method for reducing the linear dimension necessary for high resolution electrophoretic separation |
US6013459A (en) * | 1997-06-12 | 2000-01-11 | Clinical Micro Sensors, Inc. | Detection of analytes using reorganization energy |
US6017696A (en) * | 1993-11-01 | 2000-01-25 | Nanogen, Inc. | Methods for electronic stringency control for molecular biological analysis and diagnostics |
US6048692A (en) * | 1997-10-07 | 2000-04-11 | Motorola, Inc. | Sensors for electrically sensing binding events for supported molecular receptors |
US6048690A (en) * | 1991-11-07 | 2000-04-11 | Nanogen, Inc. | Methods for electronic fluorescent perturbation for analysis and electronic perturbation catalysis for synthesis |
US6051380A (en) * | 1993-11-01 | 2000-04-18 | Nanogen, Inc. | Methods and procedures for molecular biological analysis and diagnostics |
US6060023A (en) * | 1998-03-31 | 2000-05-09 | Motorola, Inc. | Molecular sensing apparatus |
US6060327A (en) * | 1997-05-14 | 2000-05-09 | Keensense, Inc. | Molecular wire injection sensors |
US6063573A (en) * | 1998-01-27 | 2000-05-16 | Clinical Micro Sensors, Inc. | Cycling probe technology using electron transfer detection |
US6067246A (en) * | 1991-11-07 | 2000-05-23 | Nanogen | Method for writing data to and reading multiple bit data words from a DNA optical storage device |
US6068818A (en) * | 1993-11-01 | 2000-05-30 | Nanogen, Inc. | Multicomponent devices for molecular biological analysis and diagnostics |
US6071699A (en) * | 1996-06-07 | 2000-06-06 | California Institute Of Technology | Nucleic acid mediated electron transfer |
US6071394A (en) * | 1996-09-06 | 2000-06-06 | Nanogen, Inc. | Channel-less separation of bioparticles on a bioelectronic chip by dielectrophoresis |
US6168948B1 (en) * | 1995-06-29 | 2001-01-02 | Affymetrix, Inc. | Miniaturized genetic analysis systems and methods |
US6180352B1 (en) * | 1993-12-10 | 2001-01-30 | California Insitute Of Technology | Nucleic acid mediated electron transfer |
US6207369B1 (en) * | 1995-03-10 | 2001-03-27 | Meso Scale Technologies, Llc | Multi-array, multi-specific electrochemiluminescence testing |
US6207373B1 (en) * | 1998-02-25 | 2001-03-27 | Nanogen, Inc. | Methods for determining nature of repeat units in DNA |
US6221583B1 (en) * | 1996-11-05 | 2001-04-24 | Clinical Micro Sensors, Inc. | Methods of detecting nucleic acids using electrodes |
US6225059B1 (en) * | 1993-11-01 | 2001-05-01 | Nanogen, Inc. | Advanced active electronic devices including collection electrodes for molecular biological analysis and diagnostics |
US6232062B1 (en) * | 1997-03-07 | 2001-05-15 | Clinical Micro Sensors, Inc. | AC methods for the detection of nucleic acids |
US6238909B1 (en) * | 1999-05-04 | 2001-05-29 | Motorola, Inc. | Method and apparatus for obtaining electric field-enhanced bioconjugation |
US6245508B1 (en) * | 1993-11-01 | 2001-06-12 | Nanogen, Inc. | Method for fingerprinting utilizing an electronically addressable array |
US6249784B1 (en) * | 1999-05-19 | 2001-06-19 | Nanogen, Inc. | System and method for searching and processing databases comprising named annotated text strings |
US6375899B1 (en) * | 1993-11-01 | 2002-04-23 | Nanogen, Inc. | Electrophoretic buss for transport of charged materials in a multi-chamber system |
US6379897B1 (en) * | 2000-11-09 | 2002-04-30 | Nanogen, Inc. | Methods for gene expression monitoring on electronic microarrays |
US20030003473A1 (en) * | 1996-11-05 | 2003-01-02 | Clinical Micro Sensors, Inc. | Electrodes linked via conductive oligomers to nucleic acids |
US20030088785A1 (en) * | 2001-05-10 | 2003-05-08 | Makoto Fujiwara | ID installable LSI, secret key installation method, LSI test method, and LSI development method |
US20030096283A1 (en) * | 1999-12-13 | 2003-05-22 | Motorola Inc, A Corporation Of The State Of Delaware | Electrochemical detection of single base extension |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5747494A (en) | 1980-09-02 | 1982-03-18 | Fuji Photo Film Co Ltd | Method of determining a trace amount of enzyme |
US5238808A (en) | 1984-10-31 | 1993-08-24 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
US4713347A (en) | 1985-01-14 | 1987-12-15 | Sensor Diagnostics, Inc. | Measurement of ligand/anti-ligand interactions using bulk conductance |
EP0213825A3 (en) | 1985-08-22 | 1989-04-26 | Molecular Devices Corporation | Multiple chemically modulated capacitance |
GB8530715D0 (en) | 1985-12-13 | 1986-01-22 | Unilever Plc | Microchemical testing |
US5066372A (en) | 1986-05-02 | 1991-11-19 | Ciba Corning Diagnostics Corp. | Unitary multiple electrode sensor |
US4787963A (en) | 1987-05-04 | 1988-11-29 | Syntro Corporation | Method and means for annealing complementary nucleic acid molecules at an accelerated rate |
US5540828A (en) | 1987-06-08 | 1996-07-30 | Yacynych; Alexander | Method for making electrochemical sensors and biosensors having a polymer modified surface |
US5200051A (en) | 1988-11-14 | 1993-04-06 | I-Stat Corporation | Wholly microfabricated biosensors and process for the manufacture and use thereof |
CS274231B1 (en) | 1988-12-05 | 1991-04-11 | Jan Rndr Krejci | Regenerable enzyme sensor with exchangeable membrane system |
US5110745A (en) | 1989-06-01 | 1992-05-05 | The Trustees Of The University Of Pennsylvania | Methods of detecting glycated proteins |
US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
US5156810A (en) | 1989-06-15 | 1992-10-20 | Biocircuits Corporation | Biosensors employing electrical, optical and mechanical signals |
US5262035A (en) | 1989-08-02 | 1993-11-16 | E. Heller And Company | Enzyme electrodes |
US5105348A (en) | 1989-08-17 | 1992-04-14 | Sharp Kabushiki Kaisha | Printing apparatus, and facsimile apparatus using standard or fine modes |
US5776672A (en) | 1990-09-28 | 1998-07-07 | Kabushiki Kaisha Toshiba | Gene detection method |
DE69231853T2 (en) | 1991-11-07 | 2001-09-13 | Nanotronics Inc | HYBRIDIZING POLYNUCLEOTIDS CONJUGED WITH CHROMOPHORES AND FLUOROPHORS TO GENERATE A DONOR-TO-DONOR ENERGY TRANSFER SYSTEM |
US5846708A (en) | 1991-11-19 | 1998-12-08 | Massachusetts Institiute Of Technology | Optical and electrical methods and apparatus for molecule detection |
US5353786A (en) | 1992-01-24 | 1994-10-11 | Wilk Peter J | Surgical lighting method |
US6100099A (en) | 1994-09-06 | 2000-08-08 | Abbott Laboratories | Test strip having a diagonal array of capture spots |
GB9210176D0 (en) | 1992-05-12 | 1992-06-24 | Cemu Bioteknik Ab | Chemical method |
IL102930A (en) | 1992-08-25 | 1997-03-18 | Yissum Res Dev Co | Electrobiochemical analytical method and electrodes |
FR2703359B1 (en) | 1993-03-31 | 1995-06-23 | Cis Bio Int | Nucleotide (s) / electronic conductive polymer; its preparation process and its use. |
US6309602B1 (en) | 1993-11-01 | 2001-10-30 | Nanogen, Inc. | Stacked, reconfigurable system for electrophoretic transport of charged materials |
US6309601B1 (en) | 1993-11-01 | 2001-10-30 | Nanogen, Inc. | Scanning optical detection system |
US5965452A (en) | 1996-07-09 | 1999-10-12 | Nanogen, Inc. | Multiplexed active biologic array |
US6287517B1 (en) | 1993-11-01 | 2001-09-11 | Nanogen, Inc. | Laminated assembly for active bioelectronic devices |
US6319472B1 (en) | 1993-11-01 | 2001-11-20 | Nanogen, Inc. | System including functionally separated regions in electrophoretic system |
US6254827B1 (en) | 1993-11-01 | 2001-07-03 | Nanogen, Inc. | Methods for fabricating multi-component devices for molecular biological analysis and diagnostics |
US6129828A (en) | 1996-09-06 | 2000-10-10 | Nanogen, Inc. | Apparatus and methods for active biological sample preparation |
US6315953B1 (en) | 1993-11-01 | 2001-11-13 | Nanogen, Inc. | Devices for molecular biological analysis and diagnostics including waveguides |
US6099803A (en) | 1994-07-07 | 2000-08-08 | Nanogen, Inc. | Advanced active electronic devices for molecular biological analysis and diagnostics |
US6331274B1 (en) | 1993-11-01 | 2001-12-18 | Nanogen, Inc. | Advanced active circuits and devices for molecular biological analysis and diagnostics |
US6306348B1 (en) | 1993-11-01 | 2001-10-23 | Nanogen, Inc. | Inorganic permeation layer for micro-electric device |
IL108726A (en) | 1994-02-22 | 1999-12-31 | Yissum Res Dev Co | Electrobiochemical method and system for the determination of an analyte which is a member of a recognition pair in a liquid medium and electrodes therefor |
FR2720832A1 (en) | 1994-04-22 | 1995-12-08 | Francis Garnier | Electroactive electrodes and membranes based on bioactive peptides, for the recognition, extraction or release of biologically active species. |
GB9417211D0 (en) | 1994-08-25 | 1994-10-12 | Solicitor For The Affairs Of H | Nucleotide sequencing method |
JPH10509025A (en) | 1994-08-26 | 1998-09-08 | アイジェン, インコーポレイテッド | Biosensor and method for electrogenerated chemiluminescent detection of nucleic acids adsorbed on solid surface |
JP3135194B2 (en) | 1994-09-16 | 2001-02-13 | キヤノン株式会社 | Distance measuring device and protective cover for distance measuring device |
US5632876A (en) | 1995-06-06 | 1997-05-27 | David Sarnoff Research Center, Inc. | Apparatus and methods for controlling fluid flow in microchannels |
US5623051A (en) | 1994-11-10 | 1997-04-22 | University Of Washington | Methods and compositions for screening for presynaptic calcium channel blockers |
DE4442253A1 (en) | 1994-11-28 | 1996-05-30 | Bayer Corp N D Ges D Staates I | Electrochemical enzyme biosensor |
US5679519A (en) | 1995-05-09 | 1997-10-21 | Oprandy; John J. | Multi-label complex for enhanced sensitivity in electrochemiluminescence assay |
US5589136A (en) | 1995-06-20 | 1996-12-31 | Regents Of The University Of California | Silicon-based sleeve devices for chemical reactions |
US5968745A (en) | 1995-06-27 | 1999-10-19 | The University Of North Carolina At Chapel Hill | Polymer-electrodes for detecting nucleic acid hybridization and method of use thereof |
US5972199A (en) | 1995-10-11 | 1999-10-26 | E. Heller & Company | Electrochemical analyte sensors using thermostable peroxidase |
US5662787A (en) | 1996-01-19 | 1997-09-02 | Beckman Instruments, Inc. | Device for profiling oligosaccharides released from glycoproteins |
US5795453A (en) | 1996-01-23 | 1998-08-18 | Gilmartin; Markas A. T. | Electrodes and metallo isoindole ringed compounds |
US6114122A (en) | 1996-03-26 | 2000-09-05 | Affymetrix, Inc. | Fluidics station with a mounting system and method of using |
US6107080A (en) | 1996-04-25 | 2000-08-22 | Mcgill University | Biosensor device and method |
US5958791A (en) * | 1996-09-27 | 1999-09-28 | Innovative Biotechnologies, Inc. | Interdigitated electrode arrays for liposome-enhanced immunoassay and test device |
US6110354A (en) | 1996-11-01 | 2000-08-29 | University Of Washington | Microband electrode arrays |
US6306584B1 (en) * | 1997-01-21 | 2001-10-23 | President And Fellows Of Harvard College | Electronic-property probing of biological molecules at surfaces |
AU5301598A (en) | 1997-02-10 | 1998-08-13 | Gist-Brocades B.V. | Detection of analytes using electrochemistry |
US5981268A (en) | 1997-05-30 | 1999-11-09 | Board Of Trustees, Leland Stanford, Jr. University | Hybrid biosensors |
US5922183A (en) | 1997-06-23 | 1999-07-13 | Eic Laboratories, Inc. | Metal oxide matrix biosensors |
US6136533A (en) | 1997-07-03 | 2000-10-24 | Id Biomedical | Additives for use in cycling probe reactions |
AU8903998A (en) | 1997-08-12 | 1999-03-01 | Fraunhofer Institut Siliziumtechnologie | Electrochemical reporter system for detecting analytical immunoassay and mol ecular biology procedures |
DE19741716A1 (en) | 1997-09-22 | 1999-03-25 | Hoechst Ag | Recognition system |
US6132683A (en) | 1998-12-23 | 2000-10-17 | Matsushita Electric Industrial Co., Ltd. | Cell potential measuring electrode and measuring apparatus using the same |
US6595323B2 (en) | 1998-03-25 | 2003-07-22 | Lindsey Manufacturing Company | Pole step and attachment mount for poles |
AU765597B2 (en) | 1998-05-06 | 2003-09-25 | Clinical Micro Sensors, Inc. | Electronic detection of nucleic acids using monolayers |
US6290839B1 (en) * | 1998-06-23 | 2001-09-18 | Clinical Micro Sensors, Inc. | Systems for electrophoretic transport and detection of analytes |
US6300141B1 (en) | 1999-03-02 | 2001-10-09 | Helix Biopharma Corporation | Card-based biosensor device |
US6258266B1 (en) | 1999-04-21 | 2001-07-10 | Sta-Rite Industries, Inc. | Faucet mount water filtration device |
CA2376532A1 (en) | 1999-06-10 | 2000-12-21 | Song Shi | Biosensors which utilize charge neutral conjugated polymers |
WO2001004090A2 (en) | 1999-07-09 | 2001-01-18 | Ortho-Mcneil Pharmaceutical, Inc. | Neurotrophic tetrahydroisoquinolines and tetrahydrothienopyridines, and related compositions and methods |
JP2003516165A (en) | 1999-12-09 | 2003-05-13 | モトローラ・インコーポレイテッド | Methods and compositions for electrical detection of nucleic acid reactions |
US6303082B1 (en) | 1999-12-15 | 2001-10-16 | Nanogen, Inc. | Permeation layer attachment chemistry and method |
EP1251955A2 (en) | 1999-12-15 | 2002-10-30 | Motorola, Inc. | Column and row addressable high density biochip array |
US6284117B1 (en) | 1999-12-22 | 2001-09-04 | Nanogen, Inc. | Apparatus and method for removing small molecules and ions from low volume biological samples |
AU2767001A (en) | 2000-01-06 | 2001-07-16 | Motorola, Inc. | Three-dimensional network for biomolecule detection |
CA2401640A1 (en) | 2000-02-01 | 2001-08-09 | Jaymie Robin Sawyer | Detection and differentiation of bacteria using electrical detection methods |
US20030138845A1 (en) | 2001-08-23 | 2003-07-24 | Changming Li | Protein and peptide sensors using electrical detection methods |
-
2000
- 2000-02-17 US US09/506,178 patent/US6824669B1/en not_active Expired - Lifetime
-
2001
- 2001-02-20 CA CA002404492A patent/CA2404492A1/en not_active Abandoned
- 2001-02-20 AU AU2001238573A patent/AU2001238573A1/en not_active Abandoned
- 2001-02-20 EP EP01911028A patent/EP1257820A2/en not_active Withdrawn
- 2001-02-20 WO PCT/US2001/005476 patent/WO2001061053A2/en not_active Application Discontinuation
- 2001-02-20 US US10/203,874 patent/US20050023155A1/en not_active Abandoned
Patent Citations (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3934209A (en) * | 1974-04-23 | 1976-01-20 | Minnesota Mining And Manufacturing Company | High voltage DC coupled amplifier |
US4072576A (en) * | 1975-10-06 | 1978-02-07 | Ab Kabi | Method for studying enzymatic and other biochemical reactions |
US4098645A (en) * | 1976-02-24 | 1978-07-04 | W. R. Grace & Co. | Immobilization of proteins with polyurethane polymers |
US4656127A (en) * | 1983-04-22 | 1987-04-07 | Amersham International Plc. | Method of detecting mutations in DNA and RNA |
US5727548A (en) * | 1983-05-05 | 1998-03-17 | Medisense, Inc. | Strip electrode with screen printing |
US4840893A (en) * | 1983-12-16 | 1989-06-20 | Medisense, Inc. | Electrochemical assay for nucleic acids and nucleic acid probes |
US4945045A (en) * | 1984-07-06 | 1990-07-31 | Serono Diagnostics Ltd. | Electrochemical methods of assay |
US4683195B1 (en) * | 1986-01-30 | 1990-11-27 | Cetus Corp | |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4839017A (en) * | 1986-03-31 | 1989-06-13 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Potential-causing membrane for immunosensor |
US5001048A (en) * | 1987-06-05 | 1991-03-19 | Aurthur D. Little, Inc. | Electrical biosensor containing a biological receptor immobilized and stabilized in a protein film |
US5192507A (en) * | 1987-06-05 | 1993-03-09 | Arthur D. Little, Inc. | Receptor-based biosensors |
US4995960A (en) * | 1987-11-24 | 1991-02-26 | Public Health Laboratory Service Board | Electrochemical electrodes |
US5308754A (en) * | 1988-03-21 | 1994-05-03 | Kankare Jouko J | Electrogenerated luminescence in solution |
US4988617A (en) * | 1988-03-25 | 1991-01-29 | California Institute Of Technology | Method of detecting a nucleotide change in nucleic acids |
US4920047A (en) * | 1988-05-20 | 1990-04-24 | General Electric Company | Electrical detection of the immune reaction |
US5126034A (en) * | 1988-07-21 | 1992-06-30 | Medisense, Inc. | Bioelectrochemical electrodes |
US5106751A (en) * | 1988-09-15 | 1992-04-21 | Biotronic Systems Corporation | Apparatus for supporting a biochemical sensor responsive to bubbles |
US5436161A (en) * | 1988-11-10 | 1995-07-25 | Pharmacia Biosensor Ab | Matrix coating for sensing surfaces capable of selective biomolecular interactions, to be used in biosensor systems |
US5874316A (en) * | 1989-01-27 | 1999-02-23 | Australian Membrane Biotechnology Research Institute | Receptor membranes and ionophore gating |
US5089112A (en) * | 1989-03-20 | 1992-02-18 | Associated Universities, Inc. | Electrochemical biosensor based on immobilized enzymes and redox polymers |
US5491097A (en) * | 1989-06-15 | 1996-02-13 | Biocircuits Corporation | Analyte detection with multilayered bioelectronic conductivity sensors |
US5320725A (en) * | 1989-08-02 | 1994-06-14 | E. Heller & Company | Electrode and method for the detection of hydrogen peroxide |
US5324457A (en) * | 1989-10-02 | 1994-06-28 | Board Of Regents, The University Of Tx System | Devices and methods for generating electrogenerated chemiluminescence |
US5328847A (en) * | 1990-02-20 | 1994-07-12 | Case George D | Thin membrane sensor with biochemical switch |
US5194133A (en) * | 1990-05-04 | 1993-03-16 | The General Electric Company, P.L.C. | Sensor devices |
US5108573A (en) * | 1990-06-05 | 1992-04-28 | The United States Of America As Represented By The United States Department Of Energy | Morphology in electrochemically grown conducting polymer films |
US5202261A (en) * | 1990-07-19 | 1993-04-13 | Miles Inc. | Conductive sensors and their use in diagnostic assays |
US5180968A (en) * | 1991-03-01 | 1993-01-19 | Research Foundation Of State University Of New York | Method and apparatus for compensation of double layer charging current in electrochemical cells |
US6013166A (en) * | 1991-05-09 | 2000-01-11 | Nanogen, Inc. | Method for reducing the linear dimension necessary for high resolution electrophoretic separation |
US5187096A (en) * | 1991-08-08 | 1993-02-16 | Rensselaer Polytechnic Institute | Cell substrate electrical impedance sensor with multiple electrode array |
US6067246A (en) * | 1991-11-07 | 2000-05-23 | Nanogen | Method for writing data to and reading multiple bit data words from a DNA optical storage device |
US6048690A (en) * | 1991-11-07 | 2000-04-11 | Nanogen, Inc. | Methods for electronic fluorescent perturbation for analysis and electronic perturbation catalysis for synthesis |
US6385080B1 (en) * | 1991-11-07 | 2002-05-07 | Nanogen, Inc. | DNA optical storage device using Forster energy transfer mechanism |
US5891630A (en) * | 1991-11-19 | 1999-04-06 | Houston Advanced Res Center | Multi-site detection apparatus |
US5391272A (en) * | 1992-03-06 | 1995-02-21 | Andcare, Inc. | Electrochemical immunoassay methods |
US5726026A (en) * | 1992-05-01 | 1998-03-10 | Trustees Of The University Of Pennsylvania | Mesoscale sample preparation device and systems for determination and processing of analytes |
US5635358A (en) * | 1992-05-01 | 1997-06-03 | Trustees Of The University Of Pennsylvania | Fluid handling methods for use in mesoscale analytical devices |
US5866345A (en) * | 1992-05-01 | 1999-02-02 | The Trustees Of The University Of Pennsylvania | Apparatus for the detection of an analyte utilizing mesoscale flow systems |
US5304487A (en) * | 1992-05-01 | 1994-04-19 | Trustees Of The University Of Pennsylvania | Fluid handling in mesoscale analytical devices |
US5498392A (en) * | 1992-05-01 | 1996-03-12 | Trustees Of The University Of Pennsylvania | Mesoscale polynucleotide amplification device and method |
US5486335A (en) * | 1992-05-01 | 1996-01-23 | Trustees Of The University Of Pennsylvania | Analysis based on flow restriction |
US5296375A (en) * | 1992-05-01 | 1994-03-22 | Trustees Of The University Of Pennsylvania | Mesoscale sperm handling devices |
US5637469A (en) * | 1992-05-01 | 1997-06-10 | Trustees Of The University Of Pennsylvania | Methods and apparatus for the detection of an analyte utilizing mesoscale flow systems |
US5710028A (en) * | 1992-07-02 | 1998-01-20 | Eyal; Nurit | Method of quick screening and identification of specific DNA sequences by single nucleotide primer extension and kits therefor |
US5312527A (en) * | 1992-10-06 | 1994-05-17 | Concordia University | Voltammetric sequence-selective sensor for target polynucleotide sequences |
US5705346A (en) * | 1992-11-27 | 1998-01-06 | Canon Kabushiki Kaisha | Method for detecting a target nucleic acid by using an interaction of two kinds of reagents |
US5403451A (en) * | 1993-03-05 | 1995-04-04 | Riviello; John M. | Method and apparatus for pulsed electrochemical detection using polymer electroactive electrodes |
US5871633A (en) * | 1993-06-17 | 1999-02-16 | Rutgers, The State University | Impedance type humidity sensor with protonconducting electrolyte and method of using same |
US5770721A (en) * | 1993-08-11 | 1998-06-23 | University Of Chicago | Method of manufacturing a matrix for the detection of mismatches |
US5519635A (en) * | 1993-09-20 | 1996-05-21 | Hitachi Ltd. | Apparatus for chemical analysis with detachable analytical units |
US6051380A (en) * | 1993-11-01 | 2000-04-18 | Nanogen, Inc. | Methods and procedures for molecular biological analysis and diagnostics |
US6017696A (en) * | 1993-11-01 | 2000-01-25 | Nanogen, Inc. | Methods for electronic stringency control for molecular biological analysis and diagnostics |
US6238624B1 (en) * | 1993-11-01 | 2001-05-29 | Nanogen, Inc. | Methods for transport in molecular biological analysis and diagnostics |
US6375899B1 (en) * | 1993-11-01 | 2002-04-23 | Nanogen, Inc. | Electrophoretic buss for transport of charged materials in a multi-chamber system |
US6225059B1 (en) * | 1993-11-01 | 2001-05-01 | Nanogen, Inc. | Advanced active electronic devices including collection electrodes for molecular biological analysis and diagnostics |
US5632957A (en) * | 1993-11-01 | 1997-05-27 | Nanogen | Molecular biological diagnostic systems including electrodes |
US6245508B1 (en) * | 1993-11-01 | 2001-06-12 | Nanogen, Inc. | Method for fingerprinting utilizing an electronically addressable array |
US5605662A (en) * | 1993-11-01 | 1997-02-25 | Nanogen, Inc. | Active programmable electronic devices for molecular biological analysis and diagnostics |
US6068818A (en) * | 1993-11-01 | 2000-05-30 | Nanogen, Inc. | Multicomponent devices for molecular biological analysis and diagnostics |
US6238870B1 (en) * | 1993-12-10 | 2001-05-29 | California Institute Of Technology | Nucleic acid mediated electron transfer |
US6180352B1 (en) * | 1993-12-10 | 2001-01-30 | California Insitute Of Technology | Nucleic acid mediated electron transfer |
US6177250B1 (en) * | 1993-12-10 | 2001-01-23 | California Institute Of Technology | Nucleic acid mediated electron transfer |
US5591578A (en) * | 1993-12-10 | 1997-01-07 | California Institute Of Technology | Nucleic acid mediated electron transfer |
US5705348A (en) * | 1993-12-10 | 1998-01-06 | California Institute Of Technology | Nucleic acid mediated electron transfer |
US5770369A (en) * | 1993-12-10 | 1998-06-23 | California Institute Of Technology | Nucleic acid mediated electron transfer |
US6200761B1 (en) * | 1993-12-10 | 2001-03-13 | California Institute Of Technology | Nucleic acid mediated electron transfer |
US5632878A (en) * | 1994-02-01 | 1997-05-27 | Fet Engineering, Inc. | Method for manufacturing an electroforming mold |
US5766515A (en) * | 1994-05-06 | 1998-06-16 | Bayer Aktiengessellschaft | Conductive coatings |
US5755942A (en) * | 1994-11-10 | 1998-05-26 | David Sarnoff Research Center, Inc. | Partitioned microelectronic device array |
US5593838A (en) * | 1994-11-10 | 1997-01-14 | David Sarnoff Research Center, Inc. | Partitioned microelectronic device array |
US5505321A (en) * | 1994-12-05 | 1996-04-09 | Teledyne Industries, Inc. | Fabrication multilayer combined rigid/flex printed circuit board |
US6207369B1 (en) * | 1995-03-10 | 2001-03-27 | Meso Scale Technologies, Llc | Multi-array, multi-specific electrochemiluminescence testing |
US5741462A (en) * | 1995-04-25 | 1998-04-21 | Irori | Remotely programmable matrices with memories |
US5603351A (en) * | 1995-06-07 | 1997-02-18 | David Sarnoff Research Center, Inc. | Method and system for inhibiting cross-contamination in fluids of combinatorial chemistry device |
US6168948B1 (en) * | 1995-06-29 | 2001-01-02 | Affymetrix, Inc. | Miniaturized genetic analysis systems and methods |
US5747169A (en) * | 1995-11-09 | 1998-05-05 | David Sarnoff Research Center, Inc. | Field-assisted sealing |
US5728532A (en) * | 1996-05-31 | 1998-03-17 | Ackley; Donald E. | Electrode configuration for matrix addressing of a molecular detection device |
US6071699A (en) * | 1996-06-07 | 2000-06-06 | California Institute Of Technology | Nucleic acid mediated electron transfer |
US5638878A (en) * | 1996-07-08 | 1997-06-17 | Valley Machine Works Ltd. | Log debarking apparatus |
US5770029A (en) * | 1996-07-30 | 1998-06-23 | Soane Biosciences | Integrated electrophoretic microdevices |
US6071394A (en) * | 1996-09-06 | 2000-06-06 | Nanogen, Inc. | Channel-less separation of bioparticles on a bioelectronic chip by dielectrophoresis |
US20030003473A1 (en) * | 1996-11-05 | 2003-01-02 | Clinical Micro Sensors, Inc. | Electrodes linked via conductive oligomers to nucleic acids |
US6221583B1 (en) * | 1996-11-05 | 2001-04-24 | Clinical Micro Sensors, Inc. | Methods of detecting nucleic acids using electrodes |
US6232062B1 (en) * | 1997-03-07 | 2001-05-15 | Clinical Micro Sensors, Inc. | AC methods for the detection of nucleic acids |
US6060327A (en) * | 1997-05-14 | 2000-05-09 | Keensense, Inc. | Molecular wire injection sensors |
US20020033345A1 (en) * | 1997-06-12 | 2002-03-21 | Clinical Micro Sensors, Inc. | Detection of analytes using reorganization energy |
US6013170A (en) * | 1997-06-12 | 2000-01-11 | Clinical Micro Sensors, Inc. | Detection of analytes using reorganization energy |
US6013459A (en) * | 1997-06-12 | 2000-01-11 | Clinical Micro Sensors, Inc. | Detection of analytes using reorganization energy |
US6248229B1 (en) * | 1997-06-12 | 2001-06-19 | Clinical Micro Sensors, Inc. | Detection of analytes using reorganization energy |
US6048692A (en) * | 1997-10-07 | 2000-04-11 | Motorola, Inc. | Sensors for electrically sensing binding events for supported molecular receptors |
US6063573A (en) * | 1998-01-27 | 2000-05-16 | Clinical Micro Sensors, Inc. | Cycling probe technology using electron transfer detection |
US6395493B1 (en) * | 1998-02-25 | 2002-05-28 | Nanogen, Inc. | Methods and apparatus for determination of length polymorphisms in DNA |
US6207373B1 (en) * | 1998-02-25 | 2001-03-27 | Nanogen, Inc. | Methods for determining nature of repeat units in DNA |
US6060023A (en) * | 1998-03-31 | 2000-05-09 | Motorola, Inc. | Molecular sensing apparatus |
US6238909B1 (en) * | 1999-05-04 | 2001-05-29 | Motorola, Inc. | Method and apparatus for obtaining electric field-enhanced bioconjugation |
US6249784B1 (en) * | 1999-05-19 | 2001-06-19 | Nanogen, Inc. | System and method for searching and processing databases comprising named annotated text strings |
US20030096283A1 (en) * | 1999-12-13 | 2003-05-22 | Motorola Inc, A Corporation Of The State Of Delaware | Electrochemical detection of single base extension |
US6379897B1 (en) * | 2000-11-09 | 2002-04-30 | Nanogen, Inc. | Methods for gene expression monitoring on electronic microarrays |
US20030088785A1 (en) * | 2001-05-10 | 2003-05-08 | Makoto Fujiwara | ID installable LSI, secret key installation method, LSI test method, and LSI development method |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11054420B2 (en) * | 2003-07-12 | 2021-07-06 | Accelerate Diagnostics, Inc. | Sensitive and rapid determination of antimicrobial susceptibility |
US20180080932A1 (en) * | 2003-07-12 | 2018-03-22 | Accelerate Diagnostics, Inc. | Sensitive and rapid determination of antimicrobial susceptibility |
WO2006116242A2 (en) * | 2005-04-25 | 2006-11-02 | Infotonics Technology Center, Inc. | Microneedle with glucose sensor and method thereof |
US20060264716A1 (en) * | 2005-04-25 | 2006-11-23 | Dennis Zander | Microneedle with glucose sensor and methods thereof |
WO2006116242A3 (en) * | 2005-04-25 | 2007-12-21 | Infotonics Technology Ct Inc | Microneedle with glucose sensor and method thereof |
US20090156756A1 (en) * | 2005-09-26 | 2009-06-18 | Board Of Trustees Of Michigan State University | Synthesis of conducto-magnetic polymers as nano-transducers in biosensor design |
US20110060198A1 (en) * | 2008-03-10 | 2011-03-10 | Bennett James W | Multi-Parametric Fluid Determination Systems Using Complex Admittance |
US9014775B2 (en) | 2008-03-10 | 2015-04-21 | S.E.A. Medical Systems, Inc. | Multi-parametric fluid determination systems using complex admittance |
US8728025B2 (en) | 2008-03-10 | 2014-05-20 | S.E.A. Medical Systems, Inc. | Intravenous fluid monitoring |
US20110009817A1 (en) * | 2008-03-10 | 2011-01-13 | Bennett James W | Intravenous fluid monitoring |
US9173600B2 (en) | 2009-03-09 | 2015-11-03 | S.E.A. Medical Systems, Inc. | Systems and methods for the identification of compounds in medical fluids using admittance spectroscopy |
US20100305499A1 (en) * | 2009-03-09 | 2010-12-02 | Leonid Matsiev | Systems and methods for the identification of compounds in medical fluids using admittance spectroscopy |
US9052276B2 (en) | 2009-06-08 | 2015-06-09 | S.E.A. Medical Systems, Inc. | Systems and methods for the identification of compounds using admittance spectroscopy |
US8838395B2 (en) | 2010-09-09 | 2014-09-16 | S.E.A. Medical Systems, Inc. | Systems and methods for intravenous drug management using immittance spectroscopy |
US9057702B2 (en) * | 2010-12-21 | 2015-06-16 | The Regents Of The University Of California | Compact wide-field fluorescent imaging on a mobile device |
US20130157351A1 (en) * | 2010-12-21 | 2013-06-20 | The Regents Of The University Of California | Compact wide-field fluorescent imaging on a mobile device |
US20150164397A1 (en) * | 2012-07-16 | 2015-06-18 | Diagnostic Biochips, Inc. | In Vivo Biosensor |
US9883826B2 (en) * | 2012-07-16 | 2018-02-06 | Diagnostic Biochips, Inc. | In vivo biosensor |
KR101429193B1 (en) | 2013-05-10 | 2014-08-13 | 호서대학교 산학협력단 | Nucleic acid aptamer specifically binding to chlortetracycline |
JP2018536151A (en) * | 2015-10-05 | 2018-12-06 | ユニバーシティ オブ ピッツバーグ−オブ ザ コモンウェルス システム オブ ハイヤー エデュケーションUniversity Of Pittsburgh Of The Commonwealth System Of Higher Education | Fabrication and parameter evaluation of a vertically aligned platinum wire aptasensor array for detection of cardiac biomarkers by impedance measurement |
WO2017062349A1 (en) * | 2015-10-05 | 2017-04-13 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Development and parameter assessment for vertically aligned platinum wire aptasensor arrays for impedimetric detection of cardiac biomarkers |
US11156609B2 (en) | 2015-10-05 | 2021-10-26 | University of Pittsburgh—of the Commonwealth System of Higher Education | Development and parameter assessment for vertically aligned platinum wire aptasensor arrays for impedimetric detection of cardiac biomarkers |
JP7085471B2 (en) | 2015-10-05 | 2022-06-16 | ユニバーシティ オブ ピッツバーグ-オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | Creation and parameter evaluation of vertically oriented platinum wire apter sensor arrays for detection by impedance measurements of cardiac biomarkers |
JP7417664B2 (en) | 2015-10-05 | 2024-01-18 | ユニバーシティ オブ ピッツバーグ-オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | Fabrication and parameter evaluation of a vertically oriented platinum wire aptasensor array for impedance-based detection of cardiac biomarkers |
Also Published As
Publication number | Publication date |
---|---|
WO2001061053A2 (en) | 2001-08-23 |
WO2001061053A3 (en) | 2002-03-14 |
WO2001061053A9 (en) | 2002-10-17 |
EP1257820A2 (en) | 2002-11-20 |
CA2404492A1 (en) | 2001-08-23 |
US6824669B1 (en) | 2004-11-30 |
AU2001238573A1 (en) | 2001-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050023155A1 (en) | Protein and peptide sensors using electrical detection methods | |
JP6013519B2 (en) | Microfluidic device based on integrated electrochemical immunoassay and its substrate | |
Kriz et al. | Peer reviewed: Molecular imprinting: New possibilities for sensor technology | |
AU776266B2 (en) | Method for fabricating micro-structures with various surface properties in multilayer body by plasma etching | |
JP4191608B2 (en) | Microfluidic devices and surface modification processes for solid phase affinity binding assays | |
US20060141469A1 (en) | Multi-layered electrochemical microfluidic sensor comprising reagent on porous layer | |
CA2393733A1 (en) | Methods and compositions relating to electrical detection of nucleic acid reactions | |
US20020090649A1 (en) | High density column and row addressable electrode arrays | |
JP2008534987A (en) | Improved method and apparatus for analyte enrichment and fractionation for chemical analysis including matrix-assisted laser desorption ionization (MALDI) mass spectrometry (MS) | |
US6133046A (en) | Microsystems for biological analyses, their use for detecting analytes, and method for producing them | |
JP2006505797A (en) | Sample dispensing device in electrospray mass spectrometer | |
JP2009501908A (en) | Microfluidic device and method for making and using the same | |
US20030138845A1 (en) | Protein and peptide sensors using electrical detection methods | |
US20030209432A1 (en) | Methods and compositions relating to electrical detection of nucleic acid reactions | |
EP2324353B1 (en) | Selectively functionalized transducer microarray | |
Díaz‐González et al. | Diagnostics using multiplexed electrochemical readout devices | |
AU2001236625A1 (en) | Detection and differentiation of bacteria using electrical detection methods | |
JP4189123B2 (en) | Bio-related substance detection method, chip device and device | |
WO2008019694A2 (en) | Bio surface acoustic wave (saw) resonator design for detection of a target analyte | |
Chandnani et al. | Technological advancement and current standing of microfluidic chip based devices for targeted analysis of biomarkers | |
Okuyama et al. | Numerical Modeling for Sensitive and Rapid Molecular Detection by Membrane-Based Immunosensors | |
US20220291211A1 (en) | Microfluidic microparticle-labeled impedance sensor array for enhancing bioassay sensitivity | |
KR100531787B1 (en) | Device and method for antigen detection using electrochemiluminescence type intercalators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MOTOROLA, INC., ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SAWYER, JAYMIE ROBIN;LI, CHANGMING;CHOONG, VI-EN;AND OTHERS;REEL/FRAME:013844/0672;SIGNING DATES FROM 20030123 TO 20030211 |
|
AS | Assignment |
Owner name: CLINICAL MICRO SENSORS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MOTOROLA, INC.;REEL/FRAME:017390/0679 Effective date: 20050720 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |